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And who am I, living in the middle of history, to tell the universe that it 
- or my observation of it - is temporary?”
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THE HEMATOPOIETIC SYSTEM
The hematopoietic system is capable of replenishing all mature blood cell types throughout 
a complete human lifespan. This is possible due to a strict hierarchical system in which 
mature blood cells are at the bottom and hematopoietic stem cells (HSCs) are at the very top 
(Figure 1). HSCs carry the lifelong capacity to self-renew as well as supply the system with 
progenitors that can differentiate into the various hematopoietic cell lineages.1,2
Figure 1. The hierarchy of normal hematopoiesis
The normal hematopoietic system knows a strict hierarchy with hematopoietic stem cells (HSCs) at the 
very top. HSCs can self-renew as well as supply the system with progenitors that can then differentiate 
into the various hematopoietic lineages. The scheme shows the different intermediate progenitor cell 
stages, as well as the fully differentiated cells of the distinct hematopoietic maturation lineages.
LT-HSC: long-term hematopoietic stem cell; ST-HSC: short-term HSC; MPP: multipotent progenitor; MkEP: early 
megakaryocyte erythrocyte progenitor; CMP: common myeloid progenitor; CLP: common lymphoid progenitor; GMP: 
granulocyte macrophage progenitor; MEP: megakaryocyte erythrocyte progenitor; NK cell: natural killer cell. 
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Figure 2. Schematic representation of murine hematopoietic development
The total duration of murine embryogenesis is 19-21 days. Defi nitive hematopoiesis begins in the Aorta-
Gonad-Mesonephros (AGM) system around the embryonic age of 8.5 days (E8.5). At E11.5 the liver has 
begun to replace the AGM system as the major hematopoietic organ and at E14.5, fetal hematopoiesis 
is at its peak in the liver, after which it starts to divert to the bone marrow (BM) and spleen. At E18 most 
hematopoietic progenitors are still located in the liver, where they gradually decrease through postnatal 
day 14 (P14). While the number of progenitors in liver, spleen and BM is about equal at P2, already at P5 
the majority of hematopoietic progenitors are found in the BM compartment.
E0.5 E1.5 E3.5 E8.5 E11.5 E14.5
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In this thesis we use murine hematopoiesis as a model. Primitive erythropoiesis starts 
at the embryonic age of 7 days (E7) by formation of blood islands in the visceral yolk-sac. 
Figure 2 illustrates the development of definitive hematopoiesis, starting around E8.5 in the 
Aorta-Gonad-Mesonephros (AGM) system.3 While yolk-sac derived progenitors are limited to 
mainly erythroid development, AGM derived progenitors are truly multi-potent and contribute 
to the eventual HSC pool. At E11.5 the liver has begun to replace the AGM system as the 
major hematopoietic organ and at E14.5, fetal hematopoiesis is at its peak in the liver, after 
which it starts to divert to the bone marrow (BM) and spleen.4 At E18 most hematopoietic 
progenitors are still located in the liver, where they gradually decrease through postnatal 
day 14 (P14). While the number of progenitors in liver, spleen and BM is about equal at P2, 
already at P5 the majority of hematopoietic progenitors are found in the BM compartment.5 
The spleen remains a hematopoietic organ throughout the murine life, but its role in adult 
mice is limited to erythropoiesis and some lymphopoiesis. In adult mice the majority or even 
all HSCs and progenitors reside in the BM.5
While human and murine embryogenesis are clearly distinct, development of 
definitive hematopoiesis is very similar. Much like in the mouse, in human embryos primitive 
hematopoiesis is initiated in the yolk sac and definitive hematopoiesis in the AGM system.6 
In contrast to murine hematopoiesis, the human fetal liver seems incapable of producing 
HSCs; it rather receives hematopoietic progenitors of AGM and yolk-sac origin that then 
proliferate and differentiate. In week 10-11 of human embryogenesis, hematopoiesis starts 
its shift to the BM compartment, which, unlike in mice, already operates as a major site of 
hematopoiesis before birth.7
HSCs undergo discrete developmental changes throughout life.8 The biggest change 
occurs with the transition from fetal to adult hematopoiesis. Early and mid- gestational 
hematopoiesis is characterized by a rapid expansion of undifferentiated HSCs9 and is 
meanwhile rich in erythroid progenitors, feeding the high demand of erythrocytes and oxygen 
transport required for embryonic growth and development.8 In adult hematopoiesis, lifelong 
production of blood cells depends on the delicate balance between HSC self-renewal and 
differentiation.10 In contrast to fetal hematopoiesis, most adult HSCs turn quiescent11 to 
ensure maintenance of the HSC pool. This switch sets in at E16.5 and is complete at around 
3 weeks after birth.8 As fetal HSCs markedly differ from adult HSCs with respect to cell cycle 
status11, proliferative capacity9 and differentiation potential12, it is perceivable that distinct 
mechanisms control cell homing and self-renewal during fetal and adult life, and indeed, 
multiple studies have shown that fetal HSCs differ from adult HSCs in gene expression13,14, 
marker expression15,16 and regulation13,17.
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ACUTE LEUKEMIA
Leukemia is characterized by blocked maturation and uncontrolled proliferation of HSCs or 
hematopoietic progenitors. These immature hematopoietic cells, also known as leukemic 
blasts, have lost their ability to differentiate and respond to normal cell regulating mechanisms 
such as signals of cell death. Leukemias are divided in acute and chronic forms and within 
these categories a myeloid, lymphoid and undifferentiated group are recognized, mainly 
depending on morphologic features of the malignant cells. Whereas chronic leukemias 
consist of more mature leukemic blasts and generally develop more slowly, acute leukemia 
is characterized by a comparatively rapid expansion of blasts that originate from highly 
immature progenitors. The studies in this thesis focus on acute leukemia. Acute leukemias 
have an incidence of 4.7 per 100,000 per year in the general population.18,19 Although acute 
leukemia accounts for <3% of all cancers, leukemia is the leading cause of cancer death 
in children and adults aged <39 years; and while acute myeloid leukemia (AML) is most 
common in adults, acute lymphoid leukemia (ALL) is around 5 times more common than AML 
in pediatric patients.20,21 When acute leukemias develop, the infiltration of leukemic blasts in 
the BM is often so severe that the formation of normal hematopoietic cells becomes highly 
impaired. This frequently leads to hematopoietic insufficiency with cytopenias (anemia, 
leukopenia, thrombocytopenia), causing patients to present with symptoms such as fatigue, 
easy bleeding and recurrent infections. In addition, patients may present with symptoms 
caused by accumulation of leukemic blasts in various tissues such as liver, spleen, skin, 
lymph nodes and the central nervous system. Without adequate treatment, acute leukemias 
progress and are often fatal within months or even weeks after diagnosis. 
There is significant heterogeneity in treatment response of patients with AML or ALL. 
This heterogeneity can in part be correlated to genetic aberrations present in leukemic cells. 
These genetic aberrations consist of single gene mutations and chromosomal abnormalities. 
Chromosomal abnormalities include loss or gain of chromosomal material (e.g. trisomies 
or chromosomal deletions), as well as structural abnormalities due to translocations. Within 
the wide spectrum of genetic aberrations in cancer, one can distinguish between drivers 
(genetic events that contribute to tumor progression) and passengers (genetic events 
that occur at a later stage of cancer development due to general chromosomal instability, 
but do not significantly contribute to tumor progression). This distinction is critical to the 
development of new therapies that directly target leukemogenic pathways. In this thesis we 
discuss two chromosomal translocations that are leukemia drivers. The first translocation 
concerns a rearrangement of the Mixed-Lineage Leukemia 1 (MLL1) gene at chromosome 
11q23.22,23 MLL translocations are found in about 10% of all patients with acute leukemia, 
but this percentage is significantly higher in infant patients where the frequency of MLL 
rearrangements is around 80%.21,24,25 In MLL translocations, the MLL1 N-terminus is fused 
to the C-terminus of one of its various fusion gene partners of which AF9 is one of the 
most common (MLL-AF9).26 The second group of translocations that will be discussed are 
those of the Nucleoporin 98 (NUP98) gene. NUP98 is part of the nuclear pore complexes 
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that span the nuclear envelope and mediate exchange of macromolecules between the 
nucleus and cytoplasm. In NUP98 translocations, similar to MLL1, the NUP98 N-terminal is 
fused to the C-terminal of a diverse group of fusion partner genes. Fusion partners include 
homeobox genes with a conserved DNA-binding domain, such as HOXA9 and HOXD13, 
and proteins with a histone “writer” or “reader” domain, such as NSD1, JARID1A and PHF23. 
The frequency of NUP98 rearrangements in adults with AML is only 1-2%.27 However, the 
frequency of NUP98 rearrangements is significantly greater in childhood AML, i.e. 6-10%.28-31 
Both NUP98- and MLL1- translocations are associated with an unfavorable prognosis24,28-31, 
warranting a research effort into the leukemogenic mechanisms of these fusions to identify 
novel therapeutic opportunities. 
EPIGENETIC DEREGULATION IN LEUKEMIA
The term “epigenetics” was derived from the Greek word “epi” meaning “upon” or “above” 
and first coined in 1940 by the British geneticist Conrad Waddington.32 The mechanism of 
epigenetics refers to heritable changes in gene transcription, caused by external factors that 
influence accessibility of the DNA or genome without actual changes in the DNA sequence 
(genetics). Since all cells in a multicellular organism contain essentially the same DNA, it 
is the cell type specific packaging of this DNA in chromatin that determines transcriptional 
output. Therefore, epigenetic regulatory mechanisms are instrumental in dictating cell 
identities and they have been implicated in fundamental biological processes such as 
development, stem cell differentiation and genome integrity.33 Epigenetic gene regulation 
is primarily achieved through DNA methylation and post-translational histone modification 
(Figure 3). DNA methylation occurs on CpG dinucleotides via the addition of a methyl group 
to the C5 position of cytosines, and DNA hypermethylation is generally associated with 
gene silencing.34 Histone proteins can be modified at specific amino acid residues by the 
binding of a variety of molecules including methyl, acetyl, phosphoryl or ubiquitin groups. 
The addition of these histone modifications is catalyzed by a class of enzymes known as 
chromatin “writers”. Chromatin “readers” bind histones that have been marked with specific 
modifications by writers. They may themselves possess additional chromatin modifying 
capacities, or alternatively recruit other proteins to modify the local chromatin environment. 
Finally, chromatin “erasers” catalyze the removal of histone modifications, thereby reversing 
their biochemical effects on the chromatin fiber. These epigenetic modifications control 
accessibility of the DNA and thereby control which parts of the genome are being transcribed 
at a given time. 
For several years it has been evident that deregulation of the epigenome is a common 
feature of various diseases, including cancer. The earliest observations of epigenetic 
abnormalities in cancer cells were alterations in patterns of DNA methylation and histone 
acetylation.35 However, until recently it was unclear whether epigenetic changes play a 
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causal role in cancer development or whether they merely correlate with the cancerous state. 
The availability and diminishing cost of whole genome sequencing has instigated a massive 
amount of cancer sequencing studies. These studies have been crucial in our understanding 
not only of the cancer genome but also epigenome. We now know that 25-30% of the 
identifi ed cancer driver mutations affect genes encoding chromatin regulatory proteins.36,37 
Some of the most common epigenetic regulator gene mutations in de novo AML are found 
in TET2, IDH1, IDH2, DNMT3A and ASXL1.38 A genome-wide pediatric sequencing study 
identifi ed different chromatin modifi ers such as EZH2, CREBBP, SETD2, MLL2 and NSD2 
to be mutated in ALL.39,40 Interestingly it seems that epigenetic regulator gene mutations are 
enriched in adults and patients of advanced age, compared to children with leukemia.38,41,42 
Together these fi ndings suggest that altered epigenetic states do not just correlate with 
cancer but likely drive disease pathogenesis. This notion has spurred a signifi cant research 
effort to understand how altered epigenetic states drive cancer cell phenotypes and how to 
therapeutically exploit these phenomena.43
methylated CpG
unmethylated CpG
histone acetyl
histone methyl
histone ubiquitin
histone phosphoryl
Nucleus
Nucleosome
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Leukemic blasts of patients with either an MLL1 or NUP98 translocation show 
elevated expression of MEIS1 and HOXA cluster genes.28,29,44-47 Studies in MLL-rearranged 
leukemia have shown that HOXA and MEIS1 are direct targets of MLL1 fusion proteins 
and that the expression of these genes is a crucial part of the leukemogenic program.47-50 
These MLL1 fusion targets are associated with aberrantly high levels of histone 3 lysine 79 
dimethylation (H3K79me2), a chromatin mark that was found to be regulated by the histone 
methyltransferase DOT1L.50,51 MLL-rearranged cells are highly dependent on Dot1l for 
leukemia initiation and maintenance48,52-54, a discovery that led to the development of small 
molecule inhibitors targeting DOT1L, one of which is currently undergoing a clinical phase I 
trial.55,56 Findings such as these indicate the importance of chromatin regulation in leukemia 
and beautifully illustrate how our evolving knowledge of epigenetic deregulation in cancer 
can lead to new therapeutic approaches. The current state of therapeutically targeting the 
cancer epigenome will be reviewed in Chapter 2.
MOF AND MLL1
In this thesis, we focus on the two chromatin-modifiers MLL1 and MOF, and their respective 
role in leukemogenesis. MLL1 is a large nuclear protein that contains a SET domain with 
H3K4 mono- di and tri-methyltransferase activity if bound to the WDR5/RBBP5/ASH2L/
DUMPY30 subcomplex.57-59 Mll1 loss is embryonically lethal60 and Mll1-deficient fetal and 
adult hematopoietic cells lack HSC and progenitor activity, illustrating that Mll1 is crucial for 
murine definitive hematopoiesis61,62.
MOF is a histone 4 lysine 16 (H4K16) acetyltransferase63-65 and is also crucial for murine 
embryogenesis65,66. Murine embryos with homozygous, constitutional loss of Mof do not 
develop beyond the blastocyst stage. MOF is a cell type-dependent regulator of chromatin 
state and controls various essential cellular processes such as DNA damage response67-71, 
cell cycle progression67,72 and embryonic stem cell self-renewal and pluripotency73. The role 
of MOF in tumorigenesis seems complex. Studies in breast carcinoma74, medulloblastoma74 
and ovarian cancer75 indicate that tumor progression is associated with downregulation of 
MOF and H4K16 acetylation (H4K16ac). On the other hand, studies in lung76,77 and oral78 
Figure 3. Epigenetic gene regulation is primarily achieved through DNA methylation and post-
translational histone modification
In order for all DNA to fit in a cell nucleus, the DNA double helix is wound around a cluster of 8 histone 
proteins known as nucleosomes. This complex of histones and DNA is referred to as chromatin. When 
the chromatin is compact, DNA cannot be translated. Various histone modifications contribute to 
compaction or opening of chromatin.
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carcinoma have associated high expression of MOF with carcinogenesis and suppression of 
MOF with cancer cell death. This suggests that MOF may be involved in tumorigenesis in a 
cell and tissue dependent manner. 
Both MOF and MLL1 function in larger protein complexes. MOF is part of the mammalian 
non-specific lethal (NSL) complex, containing various other proteins such as WDR5, HCF1, 
NSL1, NSL2, NSL3, MCRS2, PHF20 and OGT1.79,80 Three components of the NSL complex, 
WDR5, HCF1 and PHF20 are shared with the MLL1-core protein complex (Figure 4).79,80 
In addition, human MOF was shown to physically associate with MLL1 in a multi-protein 
complex that catalyzes both histone acetylation and methylation.81 These studies demonstrate 
potential physical and functional association between the NSL and MLL1 complexes. 
MOF and MLL1 link back to NUP98 rearranged leukemia through a couple of studies 
in Drosophila, beginning with a study that has shown that, while wild type, full-length 
NUP98 is localized at the nuclear envelope in the nuclear pore complex, truncated NUP98 
is nucleoplasmic localized and functions as a potential transcriptional activator with a 
preference for promoters of genes with high H3K4 methylation and H4K16 acetylation.82 A 
more recent Drosophila study has demonstrated that only nucleoplasm localized NUP98 can 
physically interact with the NSL and MLL1 complexes.83 We hypothesized that, since NUP98 
fusion proteins contain a truncated NUP98 portion, NUP98 fusions might be localized in 
the nucleoplasm rather than at the nuclear membrane and therefore may interact with the 
NSL and MLL1 complex. This hypothesis is the subject of experimental studies presented 
in Chapter 3.
The functional relation between MLL1 and MLL-AF9 has previously been studied where 
it was suggested that MLL1 might be involved in MLL-AF9 leukemogenesis.84 However, 
more recent work has shown that MLL1 H3K4 methyltransferase activity is not required for 
MLL-AF9 leukemogenesis.85 While MLL1 and MOF physically interact81, we hypothesized 
that it may be the histone acetyltransferase activity of MOF that is required for MLL-AF9 
leukemogenesis and that MLL1 merely functions as a scaffolding protein, recruiting MOF 
to the MLL-AF9 fusion complex. This question and our findings are addressed in Chapter 
4. Although the function of MLL1 in normal hematopoiesis has been well defined, the role 
of MOF in general hematopoiesis and hematopoietic development has not previously been 
studied. In Chapter 5 of this thesis we will depict the important regulatory role of MOF and its 
histone acetyltransferase activity in mammalian hematopoietic development.
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Figure 4. Physical association between the NSL and MLL1-core protein complex
The epigenetic regulators MOF and MLL1 function in larger protein complexes. MOF is part of the 
mammalian non-specifi c lethal (NSL) complex. Two components of the NSL complex, WDR5 and HCF1, 
are shared between the NSL and MLL1-core protein complex.
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ABSTRACT
The epigenome and underlying chromatin biology are key determinants of transcriptional 
output. Perturbations within the epigenome are thought to be a key feature of many, if not all 
cancers, and it is now clear that epigenetic changes are instrumental in cancer development. 
The inherent reversibility of these changes makes them attractive targets for therapeutic 
manipulation and a number of small molecules targeting chromatin-based mechanisms 
are currently in clinical trials. In this perspective we discuss how understanding the cancer 
epigenome is providing insights into disease pathogenesis and informing drug development. 
We also highlight additional opportunities to further unlock the therapeutic potential within the 
cancer epigenome.
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INTRODUCTION
Epigenetics refers to heritable traits that are not attributable to changes in DNA sequence. 
In more specific terms, it can be used to describe how chromatin-associated proteins and 
reversible chemical modifications of DNA and histone proteins maintain transcriptional 
programs by regulating chromatin structure (Strahl and Allis, 2000). Since all cells in a 
multicellular organism contain essentially the same DNA, the development of specialized 
cell types requires a tightly regulated process that leads to the expression of genes 
critical for a specific cell type; and repression of genes required for alternative cell fates. 
One important process by which cells regulate cell type specific gene expression is the 
packaging of DNA into chromatin in a fashion that modulates transcriptional output in a given 
cell type. Therefore, epigenetic regulatory mechanisms are instrumental in dictating cell 
identities and have been implicated in fundamental processes such as development, stem 
cell self-renewal, differentiation, genome integrity and proliferation (Tessarz and Kouzarides, 
2014). Epigenetic gene regulation is primarily achieved through the collaboration of multiple 
regulatory pathways; involving sequence specific DNA binding transcription factors, long 
non-coding RNAs (lncRNAs), ATP-dependent nucleosome remodeling, DNA methylation, 
introduction of histone variants, and post-translational modification (PTM) of histone proteins. 
Histone proteins can be modified at specific amino acid residues by diverse chemical 
moieties including methylation, acetylation, phosphorylation, ubiquitination and SUMOylation 
(Kouzarides, 2007). Identification of the chromatin regulatory proteins involved in mediating, 
removing and binding these modifications has expedited our understanding of the biology 
of many of these PTMs (Figure 1). Moreover, examining the genome-wide localization of 
histone PTMs, DNA methylation and chromatin regulatory proteins in a wide spectrum of 
biological contexts has allowed researchers to begin defining “epigenomic landscapes” and 
how these relate to cellular phenotypes (Bernstein et al., 2010). Combining these data with 
gene expression profiles has provided significant insights into the biological significance of 
many of these entities as they relate to gene expression (Brien and Bracken, 2009).
It has been appreciated for some time that deregulation of the epigenomic landscape 
is a common feature of a number of diseases, including cancer. Some of the earliest 
observed epigenetic abnormalities in cancer cells were alterations in the patterns of DNA 
methylation and histone acetylation (Feinberg and Vogelstein, 1983; Fraga et al., 2005; 
Greger et al., 1989; Sakai et al., 1991). Localized hypermethylation of gene promoter regions 
leading to transcriptional repression of tumor suppressor genes such as CDKN2A and RB1 
were subsequently found to be a common feature of many cancers (Baylin and Jones, 
2011). Moreover, DNA hypermethylation events also occur over broad sub-chromosomal 
domains encompassing multiple tumor suppressor genes (Coolen et al., 2010; Frigola 
et al., 2006). The chemotherapeutic agents azacitidine (5-azacytidine) and decitabine 
(5-aza-2’-deoxycytidine); when used at low doses were shown to irreversibly inhibit the 
enzymatic activity of the DNA methyltransferase enzyme DNMT1 and induce global 
hypomethylation. These drugs represent the first targeted epigenetic therapies and were FDA 
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approved in 2005 for the treatment of myelodysplastic syndrome (MDS) and are currently 
recommended as fi rst line treatments for high-risk MDS patients (Issa and Kantarjian, 2009). 
Global loss of histone acetylation is also a common feature of many cancers (Fraga et al., 
2005), and has been associated with unfavorable patient outcomes in certain cases (Seligson 
et al., 2005). Vorinostat (Suberoylanilide hydroxamic acid – SAHA) which inhibits the activity 
of histone deacetylase (HDAC) enzymes, leading to global increases in histone acetylation, 
was granted FDA approval for the treatment of advanced cutaneous T-cell lymphoma in 
2006 (Mann et al., 2007; Wagner et al., 2010). Since this initial success, the HDAC inhibitors 
romidepsin and panobinostat have been approved for use in cutaneous T-cell lymphoma 
and multiple myeloma, respectively (Khan and La Thangue, 2012; Laubach et al., 2015). 
Recently, studies that combine DNA methylation and HDAC inhibitors have been initiated; 
with several clinical trials currently ongoing examining the utility of these combinations in 
hematopoietic malignancies and solid tumors (Falkenberg and Johnstone, 2014). Moreover, 
pre-clinical studies have indicated that combination therapies involving HDAC inhibitors and 
some of the emerging epigenetic therapies may prove clinically benefi cial (Fiskus et al., 
Figure 1. Chromatin writers, readers and 
erasers in epigenetic gene regulation
The addition of histone post-translational 
modifi cations is catalyzed by a class of 
enzymes known as chromatin “writers”. The 
modifi cations established by these writers 
may affect gene transcription by altering 
electrostatic interactions within or between 
adjacent nucleosomes. Alternatively they 
may act as binding substrates for another 
class of chromatin regulators called 
chromatin “readers”. Chromatin readers 
employ characteristic binding domains, 
such as chromo-, bromo-, and PHD-fi nger 
domains to bind nucleosomes marked by 
specifi c modifi cations, or a combination 
of modifi cations. Chromatin readers may 
themselves possess additional chromatin 
modifying activities, or alternatively recruit 
additional proteins to modify the local 
chromatin environment. Finally, chromatin 
“erasers” catalyze the removal of histone 
modifi cations, thereby reversing their 
biochemical effects on the chromatin fi ber. 
“Reader”
Interpretation of chromatin 
modifications
“Writer”
Binding
pocket
“Eraser”
Nucleosome
Chromatin fiber
Removal of chromatin 
modifications
Addition of chromatin 
modifications
Enzyme 
active site
Enzyme 
active site
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2014; Mazur et al., 2015).
Until recently it was unclear whether epigenetic changes play a causal role in cancer 
development or whether they merely are a result of the cancerous state. However, recent 
cancer genome sequencing studies have shown that genes encoding chromatin regulatory 
proteins are among the most commonly mutated gene sets in cancer (Garraway and Lander, 
2013). In fact, 25-30% of the identified cancer driver mutations affect genes encoding 
chromatin regulatory proteins (Garraway and Lander, 2013; Vogelstein et al., 2013). These 
findings indicate that altered epigenetic states do not just correlate with cancer but likely 
drive disease pathogenesis. This has spurred a significant research effort to understand how 
altered epigenetic states drive cancer cell phenotypes and how to therapeutically exploit 
these phenomena. We have only begun to scratch the surface with regard to our mechanistic 
understanding of the cancer epigenome, but this limited knowledge has already delivered 
tangible successes with regard to our ability to therapeutically manipulate cancer promoting 
epigenetic states and cancer associated gene expression programs (Table 1) (Cai et al., 
2015).
 In this perspective we will discuss how our burgeoning understanding of the cancer 
epigenome and chromatin regulatory mechanisms are yielding significant insights into the 
mechanisms underlying disease development; and providing a rational means to identify 
drug targets for the treatment of certain cancers. This is a very exciting time in the field, with 
Table 1: Selection of targeted epigenetic therapies in use or under clinical investigation in cancer patients 
CHROMATIN WRITERS
Protein Biological function Cancer type Clinical Trial ReferencesSmall-molecule(s)
CHROMATIN READERS
CHROMATIN ERASERS
DOT1L H3K79 methylation AML, ALL EPZ-5676 NCT01684150
NCT02141828
Daigle et al., 2013
McCabe et al., 2012;
Knutson et al., 2013
Issa and Kantarjian
2009
Filippakopoulos et al.,
2010; Delmore et al.,
2011; Zuber et al.,
2011
Harris et al., 2012;
Schenk et al.; 2012
Mann et al., 2007;
Khan and La Thangue
2012
EZH2 H3K27 methylation Non-Hodgkin lymphoma,
SNF5-deficient MRTs
GSK2816126, 
EPZ-6438,
CP1-1205
NCT01897571
NCT02082977
NCT02395601
DNMT1 DNA Methylation 
(Hemi-methylated CpGs)
MDS, CMML FDA approved
BET-family Acetyl-lysine binding AML, MDS, lymphoma,
glioblastoma, NMC
multiple myeloma, 
Breast cancer, NSCLC,
Prostate cancer, 
Pancreatic cancer
OTX015, CPI-0610,
 
NCT01713582
NCT01949883
NCT02157636
NCT02158858
NCT02259114
NCT02296476
NCT02303782
LSD1 H3K4/K9 demethylation AML, MDS, SCLC GSK2879552,
Tranylcypromine
NCT02034123
NCT02177812
NCT02261779
NCT02273102
HDAC1/2/3
AML - Acute myeloid leukemia, ALL - Acute lymphoid leukemia, MRT - Malignant rhabdoid tumor, MDS - Myelodysplastic 
syndrome, CMML - Chronic myeloproliferative leukemia, NMC - NUT midline carcinoma, NSCLC - Non-small cell lung 
cancer, SCLC - Small cell lung cancer  
Lysine deacetylation Cuteanous T cell
lymphoma, Multiple
myeloma
Vorinstat,
Romidepsin,
Panobinostat
FDA approved
Azacitidine,
Decitabine
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a number of targeted epigenetic therapies in ongoing clinical trials. However, the relatively 
small number of drug targets identified to date is still a limiting factor and we will also discuss 
how a more comprehensive approach to studying the cancer epigenome will be necessary 
in order to truly harness the therapeutic potential therein. 
 
EXPLOITING ONCOGENIC CHROMATIN ACTIVITIES
Oncogenic chromatin writers
The histone methyltransferase (HMT) EZH2 is subject to recurrent gain-of-function mutations 
in B-cell lymphoma (Morin et al., 2011, 2010). EZH2 is a lysine methyltransferase and the 
catalytic subunit of the PRC2 complex; as part of this complex, EZH2 mediates the mono-, 
di- and tri-methylation of lysine 27 of histone H3 (H3K27me1/2/3) (Conway et al., 2015). EZH2 
primarily functions as a transcriptional repressor through deposition of H3K27me3 at the 
promoter regions of PRC2 target genes (Margueron and Reinberg, 2011). In addition, EZH2 
mediated H3K27me2 may also be important for transcriptional repression by maintaining 
the inactive state of intergenic enhancer elements (Ferrari et al., 2014; Lee et al., 2015). 
Heterozygous point mutations of EZH2 are found in 22% of patients with diffuse large B-cell 
lymphoma and 10% with follicular lymphoma. These mutations affect key residues within the 
active site of the catalytic Su(var)3-9, enhancer of zeste, trithorax (SET) domain (McCabe et 
al., 2012; Morin et al., 2010). In vitro analysis has shown that the preferred enzymatic activity 
of wild type EZH2 is the conversion of H3K27me0-to-me1 and H3K27me1-to-me2, while the 
enzyme is relatively inefficient at the final conversion step to H3K27me3. However, owing 
to alterations in substrate binding modality, the lymphoma associated EZH2 SET domain 
mutants exhibit enhanced ability to convert H3K27me2-to-me3 (Antonysamy et al., 2013; 
M. T. McCabe et al., 2012; Sneeringer et al., 2010; Wigle et al., 2011; Yap et al., 2011). This 
finding suggests that wild type and mutant EZH2 collaborate to push the kinetics of PRC2 
activity towards increased H3K27me3 production. Indeed, lymphoma cell lines containing 
EZH2 gain-of-function mutations exhibit globally increased levels of H3K27me3, with a 
concomitant decrease in H3K27me2 (McCabe et al., 2012; Yap et al., 2011). Chromatin 
immunoprecipitation coupled with next generation sequencing (ChIP-seq) for H3K27me3 in 
an in vivo mouse model of Ezh2-mutant lymphoma demonstrated that mutant EZH2 drives 
aberrant repression of genes required for cell cycle exit and appropriate differentiation of 
Germinal Center B-cells via accumulation of H3K27me3 at gene promoter regions (Béguelin 
et al., 2013). Taken together, these data support the idea that mutant EZH2 promotes 
lymphoma development through alterations in H3K27 methylation levels, leading to a block 
in Germinal Center B-cell differentiation and enhanced proliferation (Figure 2). 
This observation has made EZH2 enzymatic activity an attractive target for treatment 
of EZH2-mutant lymphomas. Several highly selective small molecule EZH2 SET domain 
inhibitors have been developed (Knutson et al., 2012; McCabe et al., 2012; Qi et al., 2012). 
Thesis_DG.Valerio_v3_homecomputer.indb   32 10/17/16   12:07 AM
33Targeting the Cancer Epigenome
CH
AP
TE
R 
2
Interestingly, these molecules were shown to reduce H3K27me3 levels to a similar degree 
in cells, regardless of their EZH2-mutational status (McCabe et al., 2012; Qi et al., 2012). 
However, EZH2-mutant cells are acutely sensitive to EZH2 inhibition both in vitro and in vivo, 
where EZH2 inhibition leads to up-regulation of repressed H3K27me3 marked genes and 
apoptotic cell death (Béguelin et al., 2013; McCabe et al., 2012). These data lend further 
support to the notion that aberrant H3K27me3 accumulation is essential for the survival 
of EZH2-mutant lymphoma cells. Based on these pre-clinical successes, some of these 
compounds have now entered phase I clinical trials for the treatment of relapsed refractory 
B-cell lymphoma, and advanced solid tumors (Figure 2, and discussed further below) - 
NCT02395601, NCT01897571, and NCT02082977 at www.clinicaltrials.gov.
The NSD2 gene (also known as MMSET or WHSC1) encodes an HMT, responsible for 
mediating di-methylation of H3K36 (H3K36me2). NSD2 primarily functions as a transcriptional 
activator by depositing intragenic H3K36me2 at active genes (Huang et al., 2013; Kuo et al., 
2011), although it may also function in transcriptional repression in limited contexts (Marango 
et al., 2008). NSD2 was initially discovered because of its involvement in a recurrent 
chromosomal translocation t(4;14), occurring in 20% of multiple myeloma (MM) cases (Chesi 
et al., 1998). This translocation places NSD2, and its neighboring gene FGFR3, under the 
control of the IgH locus Eµ enhancer, leading to increased expression of both genes, though 
NSD2 appears to be the oncogene in this setting (Keats et al., 2003; Santra et al., 2003). 
NSD2 is also subject to recurrent gain-of-function mutations in lymphoid malignancies, with 
the highest prevalence (14%) in pediatric acute lymphoblastic leukemia (ALL) patients 
carrying an ETV6-RUNX1 fusion (Jaffe et al., 2013; Oyer et al., 2014). These mutations 
result in a glutamic acid to lysine switch at position 1099 (E1099K) within the SET domain of 
NSD2, leading to increased enzymatic activity in vitro. Consistent with this, global levels of 
H3K36me2 are increased in cells harboring either an E1099K activating NSD2 mutation or a 
t(4;14) translocation (Huang et al., 2013; Jaffe et al., 2013). Moreover, H3K36me2 ChIP-seq 
in t(4;14) rearranged MM cells demonstrates that H3K36me2 marked domains undergo a 
broad expansion into intergenic space as a result of increased NSD2 expression (Kuo et 
al., 2011; Popovic et al., 2014). Consistent with the fact that higher order H3K36 methylation 
directly inhibits the enzymatic activity of the PRC2 complex (Schmitges et al., 2011; Yuan et 
al., 2011), this expansion of H3K36me2 is accompanied by global losses of H3K27me2/3 
(Jaffe et al., 2013). While the exact mechanism by which NSD2 drives malignancy remains 
unclear, the broad gain of H3K36me2 and loss of repressive H3K27 methylation may lead to 
an opening of the chromatin landscape, creating a more permissive or “stem cell-like” state 
which is more amenable to additional reprogramming by transcription factors (Nimura et al., 
2009). Consistent with this, expression profiling of t(4;14) MM cells revealed that these cells 
have increased expression of genes associated with self-renewal, and reduced expression of 
genes associated with mature B-cell functions (Huang et al., 2013; Kuo et al., 2011; Popovic 
et al., 2014). Interestingly, despite the global loss of H3K27 methylation, H3K27me3 is focally 
increased at certain gene promoters, many of which correlate with aberrantly repressed 
B-cell differentiation genes (Popovic et al., 2014). Together, these findings suggest that 
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NSD2 activation drives a broad rewiring of the epigenome, which may in turn block terminal 
differentiation thereby contributing to oncogenesis. 
Several studies have demonstrated that the activity of the NSD2 SET domain is essential 
for the observed chromatin/transcriptional changes and tumorigenicity in MM and lymphoma 
cells (Jaffe et al., 2013; Kuo et al., 2011). This supports the notion that the changes in 
H3K36me2 are instrumental for development of these cancers and suggests that targeting 
the NSD2 SET domain with a specific small-molecule would be an excellent therapeutic 
approach. However, to date no potent inhibitors of NSD2 have been published (Cain, 2013). 
In addition to targeting the NSD2 SET domain, recent studies have demonstrated that certain 
chromatin reading domains in NSD2 are essential for the oncogenic function of the protein 
(Huang et al., 2013; Popovic et al., 2014). For example, NSD2 protein fragments lacking 
functionality in the second, third or fourth PHD-finger domain or the second PWWP-domain 
have reduced transforming activity. These domains potentially mediate the interaction of 
NSD2 with chromatin, or with ancillary protein co-factors that are important for NSD2 function. 
It will be important to further elucidate the function of these domains; since they too may be 
viable drug targets for the treatment of NSD2 activated cancers.
Oncogenic chromatin readers
NUT midline carcinoma (NMC) is an aggressive form of squamous cell cancer that occurs in 
all age groups and NMC patients have a dismal average overall survival of just 6.7 months 
(French, 2014). This disease is characterized by translocations of the NUT gene to one of 
two bromodomain and extra terminal (BET) family genes, BRD4 or BRD3. Together these 
translocations account for approximately 80% of all NMC cases. Alternatively NUT may 
also be indirectly linked to BRD4, through fusion to the BRD4 associated protein NSD3 
(French et al., 2014; Shen et al., 2015). This propensity for linkage of NUT to BET family 
proteins suggests that their collaborative function is important for disease pathogenesis. 
The function of wild type NUT is unclear, though it has been reported to interact with the 
lysine acetyltransferases p300/CBP and enhance their activity (Reynoird et al., 2010). BET 
family proteins are acetyl-lysine readers, that promote transcription by interacting with, and 
recruiting the positive transcription elongation factor (P-TEFb) and Mediator complexes 
to chromatin (Jang et al., 2005; Jiang et al., 1998; Lovén et al., 2013; Yang et al., 2005). 
BRD-NUT fusion proteins bind chromatin in distinctive foci associated with elevated levels of 
histone acetylation (French et al., 2008). Recent ChIP experiments demonstrate that these 
foci correspond to broad “megadomains” of BRD-NUT binding, ranging from 100KB-1.4MB 
in size, typically delimited by topological chromatin domains (Alekseyenko et al., 2015). 
Moreover, these megadomains are also associated with elevated binding of pTEFb and 
Mediator components (Wang and You, 2015). Several genes within these megadomains 
such as MYC (Grayson et al., 2014), TP63 and MED24 (Alekseyenko et al., 2015) exhibit 
increased expression in a BRD-NUT dependent manner and are essential for maintaining the 
undifferentiated and highly proliferative state of NMC cells. Together these data suggest that 
BRD-NUT megadomains promote the expression of genes that drive NMC pathogenesis.
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Interestingly, the formation of these megadomains requires the function of both the 
BET bromodomains and the acetyltransferase activity of p300/CBP (Reynoird et al., 2010). 
This suggests a model wherein p300/CBP mediated histone acetylation generates a binding 
substrate for BET bromodomains, leading to spreading of BRD-NUT into the surrounding 
chromatin fiber (Alekseyenko et al., 2015; French, 2014). The fact that BET bromodomains 
are critical for this process has been therapeutically exploited using the small-molecule BET 
inhibitor JQ1 (Filippakopoulos et al., 2010). Treatment of NMC cell lines with JQ1 induces 
a rapid differentiation and proliferation arrest. Moreover, JQ1 treatment improves survival in 
murine xenograft models. Based on these pre-clinical successes, several derivatives of JQ1 
with improved pharmacodynamic properties are currently in clinical trials for the treatment 
of NMC and other cancers (discussed further below) - NCT01587703, NCT01713582, 
NCT01949883, NCT01987362, and NCT01943851 at www.clinicaltrials.gov.
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Figure 2. Targeting the oncogenic function of EZH2 in lymphoma and solid tumors
Heterozygous point mutations of the EZH2 SET domain in non-Hodgkin lymphomas leads to an enhanced 
accumulation of H3K27me3 on the promoters of PRC2 target genes in Germinal Center B-cells (upper 
panel). This causes aberrant silencing of these genes, many of which are required for terminal B-cell 
differentiation and cell cycle exit. Small-molecule inhibitors (right panels) of EZH2 enzymatic activity 
are currently in clinical trials for the treatment of lymphoma patients with activating EZH2 mutations. 
Moreover, these molecules are also in trials for the treatment of SNF5-deficient malignant rhabdoid 
tumors (MRTs) where SNF5-loss facilitates aberrant EZH2-mediated silencing of SNF5 target genes, 
such as the tumor suppressor CDKN2A (lower panel).
Thesis_DG.Valerio_v3_homecomputer.indb   35 10/17/16   12:07 AM
36 Chapter 2
EXPLOITING NON-ONCOGENE CHROMATIN DEPENDENCIES
Chromosomal rearrangements at 11q23 are associated with acute leukemia which led to 
the discovery of the MLL1 gene (Djabali et al., 1992; Gu et al., 1992; Tkachuk et al., 1992; 
Ziemin-van der Poel et al., 1991). MLL translocations are found in ~10% of patients with 
acute leukemia and are generally associated with an unfavorable prognosis (Krivtsov and 
Armstrong, 2007; Muntean and Hess, 2012). MLL rearrangements are more frequently 
present in infant and pediatric patients, with the highest frequency of 80% in infant ALL 
(Greaves, 1996). MLL1 is primarily thought to function as a transcriptional activator at least 
in part through tri-methylation of H3K4 (H3K4me3) at the promoters of active genes. In 
MLL-rearranged leukemia the N-terminus of MLL1 is fused to one of over 70 different fusion 
partners; however, MLL-AF4 t(4:11), MLL-AF9 t(9:11), MLL-ENL t(11;19), MLL-AF10 t(10;11) 
and MLL-ELL t(11;19) are the most common translocations, collectively accounting for the vast 
majority (>80%) of MLL1-rearrangements seen in patients (Krivtsov and Armstrong, 2007). 
MLL-rearranged leukemias exhibit a strikingly low rate of somatic mutation (Andersson et al., 
2015), supporting the notion that MLL1 fusions are the primary drivers of these leukemias. 
Despite the loss of the C-terminal SET domain of MLL1 in MLL1 fusions, genome-wide levels 
of H3K4me3 are not reduced in MLL1 fusion leukemia cells; suggesting that alternative H3K4 
methyltransferase(s) maintain H3K4 methylation in these cells (Bernt et al., 2011; Mishra et al., 
2014). Indeed recent evidence suggests that maintaining H3K4 methylation levels in MLL1 
fusion leukemia stem cells may be important for the leukemic potential of these cells (Wong 
et al., 2015). This highlights the importance of identifying the H3K4 methyltransferase(s) 
involved in maintaining H3K4 methylation levels in MLL1 fusion leukemia. Some of the first 
hints toward the mechanisms by which MLL1 fusion proteins mediate leukemogenesis 
came from the realization that a number of the most common MLL1 fusion partners exist in 
overlapping protein complexes whose functions are associated with transcriptional elongation 
(Deshpande et al., 2012). The HMT DOT1L, which mediates mono-, di- and tri-methylation 
of H3K79 (H3K79me1/2/3), is a component of several of these complexes and perturbations 
in normal H3K79me2 patterns are a feature of MLL-rearranged leukemia (Guenther et al., 
2008; Krivtsov et al., 2008). DOT1L-mediated deposition of H3K79me2 downstream of active 
gene promoters is believed to be important for efficient transcriptional elongation and active 
gene expression (Nguyen and Zhang, 2011). Subsequent studies demonstrated that the 
aberrant levels of H3K79me2 in MLL-rearranged leukemia accumulate specifically at MLL1 
fusion target genes, indicating that this phenomenon is likely driven by MLL1 fusion protein 
mediated recruitment of DOT1L to these sites (Bernt et al., 2011) (Figure 3). These genes 
include several key regulators of hematopoietic stem cell identity, such as Hoxa cluster genes 
and Meis1. It has recently been shown that a critical function of DOT1L mediated H3K79 
methylation is to inhibit repressive mechanisms that would otherwise silence MLL1 fusion 
driven gene expression (Chen et al., 2015). These data support the hypothesis that MLL1 
fusion proteins cause a block in hematopoietic cell differentiation by preventing repression 
of stem cell regulators.
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Genetic inactivation of Dotl1 in a mouse model of MLL-AF9 driven leukemia led to 
prolonged survival, demonstrating that DOT1L-mediated H3K79me2 is important for 
leukemogenesis (Bernt et al., 2011; Jo et al., 2011; Nguyen et al., 2011). Strikingly, Dot1l 
inactivation specifically results in downregulation of MLL-AF9 target genes, suggesting 
that inhibiting DOT1L may provide a specific means to target these leukemias. Parallel 
studies demonstrated that pharmacological inhibition of DOT1L enzymatic activity with a 
small-molecule inhibitor reduced H3K79me2 levels in vitro and in vivo, leading to reduced 
expression of MLL-AF9 target genes (Daigle et al., 2011) (Figure 3). These early successes 
lead to the development of an improved DOT1L inhibitor (Daigle et al., 2013), which is 
currently in ongoing clinical trials for the treatment of patients with MLL-rearranged leukemia 
- NCT02141828 and NCT01684150 at https://clinicaltrials.gov. 
Until the discovery of the first histone demethylase LSD1 (also known as KDM1A) 
histone demethylation was thought to be a passive process, accomplished through dilution 
of methylated histones during cell division. LSD1 is a member of the FAD-dependent 
monooxidase family of enzymes and is primarily responsible for mediating the demethylation 
of the mono- and di-methylated forms of H3K4 and H3K9 (H3K4me1/me2 and H3K9me1/me2) 
(Metzger et al., 2005; Shi et al., 2004). Interest in LSD1 as a potential therapeutic target 
in cancer was spurred by observations of increased LSD1 expression in several cancers 
including neuroblastoma (Schulte et al., 2009), prostate cancer (Kahl et al., 2006), bladder 
cancer (Kauffman et al., 2011), colorectal and lung cancer (Hayami et al., 2011; Mohammad 
et al., 2015) and certain hematopoietic cancers (Harris et al., 2012). Significantly, recent 
studies using both genetic inactivation and pharmacologic inhibition of LSD1 in the context 
of AML have provided evidence for a functional link between LSD1 and leukemia (Harris 
et al., 2012; Schenk et al., 2012). Moreover, LSD1 inhibition can sensitize AML cells to 
all-trans -retinoic acid (ATRA) induced differentiation, and combining LSD1 inhibition with 
ATRA treatment reduces engraftment of primary AML patient samples in xenograft models 
(Schenk et al., 2012). Interestingly, LSD1 inhibition is not associated with global increases in 
either H3K4me1/2 or H3K9me1/2 levels across the genome; and the underlying epigenetic 
mechanism(s) of how LSD1 inhibition affects leukemia cell phenotypes is still unclear. 
This is confounded by the fact that focal decreases, as well as increases in H3K4me2 are 
apparent in LSD1 inhibitor treated leukemia cells (Harris et al., 2012; Schenk et al., 2012). 
LSD1 inhibition has also recently been shown to have clinical efficacy in small cell lung 
cancer (SCLC) (Mohammad et al., 2015). As with AML, LSD1 inhibition in the setting of 
SCLC does not have a global effect on H3K4me1/2 levels. Moreover, LSD1 inhibition results 
in generally non-overlapping transcriptional changes in sensitive cell lines. As such, a clear 
mechanistic understanding of the role of LSD1 in sustaining leukemia and lung cancer cells 
is currently lacking. However, despite the lack of a clear mechanistic understanding of the 
role of LSD1 in leukemia and SCLC these pre-clinical successes have lead to LSD1 inhibitors 
entering clinical trials for the treatment of these diseases – NCT02273102, NCT02177812, 
NCT02261779 and NCT02034123 at https://clinicaltrials.gov. 
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EXPLOITING TRANSCRIPTIONAL ADDICTIONS
A number of recent studies have demonstrated that several chromatin regulatory proteins, 
namely BRD4, CDK7 and CDK9, all of which play general roles in transcriptional activation, 
are specifically required for cancer cell survival in certain contexts (ChIPumuro et al., 2014; 
Christensen et al., 2014; Dawson et al., 2011; Delmore et al., 2011; Kwiatkowski et al., 2014; 
Wang et al., 2015; Zuber et al., 2011). As mentioned above, BRD4 binds acetylated histones 
and modulates the localization and function of transcriptional complexes such as pTEFb 
and Mediator. CDK7 and CDK9 are cyclin-dependent kinases and components of the TFIIH 
and pTEFb complexes, respectively. Within these complexes CDK7 and CDK9 promote 
transcription by phosphorylating RNA polymerase II (RNAPII), thereby enabling active 
transcriptional initiation and elongation (Larochelle et al., 2012; Zhou et al., 2012). Given the 
general role of BRD4, CDK7 and CDK9 in facilitating transcription, the fact that cancer cells 
show a greater dependency on these proteins is somewhat surprising, but there is growing 
evidence that cancer cells may be significantly addicted to high rates of transcription (Lin et 
al., 2012). Interestingly, an overarching theme emerging from these studies is that inhibiting 
these proteins leads to preferential downregulation of super-enhancer associated genes 
(ChIPumuro et al., 2014; Kwiatkowski et al., 2014; Lovén et al., 2013; Shi and Vakoc, 2014; 
Wang et al., 2015). Super-enhancers are clusters of enhancer elements that activate the 
expression of genes required for cell identity; and in cancer cells, super-enhancers also drive 
the expression of key oncogenes (Lovén et al., 2013). ChIP-seq studies have demonstrated 
that BRD4 and CDK7 are preferentially bound at super-enhancers (ChIPumuro et al., 2014; 
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Figure 3. Targeting MLL-rearranged leukemia through co-opted DOT1L activity
Studies have demonstrated that MLL1 fusion proteins, such as MLL-AF9, recruit aberrant chromatin 
activity in the form of DOT1L mediated H3K79me2 to the promoter of MLL1 fusion target genes in 
primitive hematopoietic cells. DOT1L activity is essntial for the expression of MLL1 fusion target genes 
such as HOXA9 and MEIS1, and this requirement has been exploited through the development of small-
molecule inhibitors of DOT1L enzymatic activity (right panel). DOT1L inhibitors are currently in clinical 
trials for the treatment of MLL-rearranged leukemia. 
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Lovén et al., 2013), and recent work indicates that mutations in enhancer elements, or 
oncogenic transcription factors may drive the formation of super-enhancers in tumor cells 
(Mansour et al., 2014; Oldridge et al., 2015). Taken together, these findings suggest that 
inhibiting certain components of the general transcriptional machinery provides a means to 
target transcriptional addictions to oncogenic transcription factors such as MYC (Shi and 
Vakoc, 2014), MYCN (ChIPumuro et al., 2014), TAL1 (Kwiatkowski et al., 2014) and others 
(Christensen et al., 2014). A critical next step will be to understand how these addictions 
develop and to determine which specific components of the transcriptional machinery are 
required in which cancer types.
EXPLOITING CHROMATIN BASED MECHANISMS OF ACQUIRED 
DRUG RESISTANCE
A significant clinical challenge in cancer treatment is the emergence of therapeutic 
resistance. Rewiring of signaling programs and epigenomic changes are increasingly being 
recognized as mechanisms of acquired drug resistance (Brown et al., 2014; Holohan et al., 
2013; Sharma et al., 2010). For example, breast cancers with activated PI3K and ERBB2 
signaling are typically treated with kinase inhibitors targeting these pathways. However, 
resistance often emerges owing to upregulation of alternative receptor tyrosine kinase (RTK) 
genes which compensate for the inhibited enzyme (Azuma et al., 2011; Britschgi et al., 2012; 
Chandarlapaty et al., 2011; Rexer et al., 2011). Combination therapies targeting multiple 
RTKs can in some instances circumvent resistance, but the multitude of upregulated RTKs 
limits the effectiveness of this approach. Recent work has demonstrated that combining PI3K 
or ERBB2 inhibitors with BET bromodomain inhibition re-sensitizes previously resistant breast 
cancer cells to kinase inhibition (Stratikopoulos et al., 2015; Stuhlmiller et al., 2015). The 
effectiveness of adding BET inhibitors in this context can be explained by increased BRD4 
binding at the promoter/enhancer regions of transcriptionally activated RTKs in response 
to PI3K inhibition, suggesting that BRD4 facilitates the upregulation of alternative RTKs 
(Stratikopoulos et al., 2015). Moreover, BRD4 also appears to be important for transcriptional 
activation of the downstream target genes of these RTKs (Stuhlmiller et al., 2015), further 
explaining the utility of BET inhibitors in this setting. BRD4 inhibition may also have utility 
in prostate cancers resistant to androgen receptor (AR) inhibition. Sustained AR signaling 
is a primary driver of castration-resistant prostate cancer, and inhibition of AR signaling is 
used as a therapeutic approach in this subset of patients. Unfortunately, these patients often 
develop resistance to AR inhibitors and invariably succumb to disease (Watson et al., 2015). 
BRD4 directly interacts with the N-terminus of the AR in a bromodomain dependent manner, 
and AR signaling-positive prostate cancer cells are exquisitely sensitive to BET inhibition 
(Asangani et al., 2014). BRD4 and AR colocalize on chromatin and BET inhibition leads to 
a robust downregulation of AR target genes, suggesting that BET inhibition might be an 
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approach to circumvent acquired resistance to AR inhibitors. Another example of resistance 
mediated by epigenetic changes concerns patients with T-cell acute lymphoblastic leukemia 
(T-ALL) driven by activating mutations in NOTCH1. Small molecule y-secretase inhibitors 
(GSI) block NOTCH1 signaling in T-ALL lymphoblasts, but response to these inhibitors is only 
transient, suggesting that resistance limits their clinical efficacy (Palomero and Ferrando, 
2009). GSI-resistant cells exhibit increased BRD4 binding on chromatin compared to GSI-
naive cells, and maintain MYC expression via alternative enhancer usage at the MYC locus, 
independent of NOTCH1 (Knoechel et al., 2014; Yashiro-Ohtani et al., 2014). This renders GSI 
resistant cells markedly more sensitive to JQ1 treatment, and in vivo GSI-JQ1 combination 
therapy is significantly more effective against primary human T-ALL than treatment with 
either single agent (Knoechel et al., 2014). These findings demonstrate that acquired drug 
resistance may in fact be commonly driven by epigenetic changes, which may be addressed 
by incorporating epigenetic modulators in combination therapies. 
A number of recent studies have identified mechanisms of acquired resistance to 
novel epigenetic therapies. For example, resistance to the BET bromodomain inhibitors 
JQ1 and I-BET in MLL-AF9 AML cells is mediated in part by alternative enhancer usage 
at the MYC locus; which maintains expression levels of MYC in resistant cell lines (Fong 
et al., 2015; Rathert et al., 2015). Interestingly, this appears to be downstream of the WNT 
signaling pathway and inhibition of WNT signaling may provide a means to circumvent 
resistance in this setting (Fong et al., 2015). Significantly, a distinct mechanism of BET 
inhibitor resistance has been described in triple-negative breast cancer cells (Shu et al., 
2016). In this setting, resistant cells accumulate increased levels of phosphorylated BRD4, 
which appears to be crucial for the acquisition of resistance. Despite being bound by 
JQ1 phosphorylated BRD4 remains on chromatin indicating that the association of BRD4 
with chromatin in this context is bromodomain independent. It will be important to further 
characterize the underlying mechanism(s) involved in this resistance phenotype; particularly 
in the context of the signaling pathway(s) driving BRD4 phosphorylation since modulation 
of these pathways may re-sensitize cells to BET inhibition. Taken together, these studies 
demonstrate that non-overlapping, and perhaps context dependent mechanisms can 
contribute to acquired resistance to a single epigenetic therapy; illustrating the need to study 
resistance mechanisms in multiple cancer models. Resistance to EZH2 inhibitors has also 
recently been described in EZH2 gain-of-function lymphoma cells (Gibaja et al., 2015). This 
resistance was shown to be mediated by the acquisition of distinct mutations in the mutant 
(Y661D) and wildtype (Y111L) EZH2 alleles, respectively. These mutations render the PRC2 
complex insensitive to treatment with EZH2 inhibitors, potentially by reducing the ability of 
these compounds to bind EZH2 (Gibaja et al., 2015). Studying the underlying mechanisms 
of acquired resistance to epigenetic therapies is of the utmost importance as it will be 
essential for our ability to circumvent these clinical barriers. Moreover, understanding these 
mechanisms may also provide a means of predicting therapeutic responses based on the 
identification of biomarkers of resistance or sensitivity.
Thesis_DG.Valerio_v3_homecomputer.indb   40 10/17/16   12:07 AM
41Targeting the Cancer Epigenome
CH
AP
TE
R 
2
IDENTIFYING ADDITIONAL THERAPEUTIC OPPORTUNITIES 
WITHIN THE CANCER EPIGENOME
The majority of somatic mutations affecting chromatin regulatory proteins in cancer are loss-
of-function mutations leading to a reduction, or complete loss of chromatin modifying activities 
(Garraway and Lander, 2013). However, our ability to intervene therapeutically in this context 
is currently limited since it is often unclear what mechanisms are driving oncogenesis. The 
demonstration of “epigenetic antagonism” between the SWI/SNF and PRC2 complexes in 
cancer cells provides an interesting concept to consider in this context (Knutson et al., 2013; 
Wilson et al., 2010). The SWI/SNF complex is an ATP-dependent chromatin-remodeling 
complex that primarily functions in transcriptional activation. SWI/SNF activity plays important 
tumor suppressive roles in vivo and many SWI/SNF components are inactivated in cancer 
(Kadoch and Crabtree, 2015; Kadoch et al., 2013). In Drosophila melanogaster SWI/SNF 
genes were discovered as antagonists of PRC2 mediated gene repression (Kennison and 
Tamkun, 1988; Tamkun et al., 1992). This antagonism is conserved in mammals where SWI/
SNF components directly oppose PRC2 mediated gene repression (Kia et al., 2008). In 
cancer, loss of the SWI/SNF component SNF5 (also known as SMARCB1 or BAF47) leads 
to elevated levels of H3K27me3 genome-wide, suggesting that SNF5-deficient cancers 
may rely on EZH2-mediated H3K27me3 to drive tumorigenesis. Roberts and colleagues 
demonstrated that this is indeed the case as concurrent loss of Ezh2 and Snf5 is not 
compatible with cancer development (Wilson et al., 2010). This finding has been exploited 
therapeutically using EZH2 SET domain inhibitors to treat SNF5-deficient rhabdoid tumors, 
which are markedly more sensitive to this treatment than SNF5 wild type cancers (Knutson et 
al., 2013) (Figure 2). Moreover, EZH2 inhibitor treatment of non-small cell lung cancer cells 
with mutations in the SWI/SNF component BRG1 (also known as SMARCA4) sensitizes these 
cells to chemotherapy, an effect that was not apparent in BRG1 wild type cells (Fillmore et 
al., 2015). These are significant observations given the fact that approximately 20% of all 
cancers contain inactivating mutations in SWI/SNF components (Kadoch et al., 2013); and 
suggest that EZH2 inhibitors may have broad clinical utility outside of merely an EZH2 gain-
of-function context. Following these observations, EZH2 inhibitors are now entering clinical 
trials for the treatment of SNF5-deficient tumors - NCT02601937 and NCT02601937 https://
clinicaltrials.gov. 
The central tenet that has emerged here is how loss of a single chromatin modifying 
activity may facilitate an increase in another, or perhaps multiple, functionally antagonistic 
activities which themselves promote oncogenesis (Figure 4). This highlights the need to expand 
our understanding of the interconnectedness of the epigenome, and how loss (and gain) of 
a single activity in cancer cells impacts the epigenome at large. This knowledge will shed 
light on mechanisms of disease pathogenesis and allow us to identify additional therapeutic 
opportunities. Recent advancements in sensitivity and accuracy of mass spectrometry and 
the introduction of quantitative labeling techniques such as SILAC and iTRAQ is now allowing 
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for the molecular characterization of global epigenetic signatures (Britton et al., 2011). 
The use of these quantitative techniques has already identified antagonistic relationships 
involving cancer relevant histone methylation at H3K27 and H3K36 (Jaffe et al., 2013; Pasini 
et al., 2010; Yuan et al., 2011). For example, loss of PRC2 mediated H3K27 methylation 
due to mutation or deletion of PRC2 components in certain hematopoietic malignancies, 
malignant peripheral nerve sheath tumors (MPNSTs), melanomas and glioblastomas; leads 
to global increases in H3K27 acetylation (H3K27ac) and H3K36me1/2/3 (De Raedt et al., 
2014; Ernst et al., 2010; Jaffe et al., 2013; Lee et al., 2014; Nikoloski et al., 2010; Ntziachristos 
et al., 2012; Zhang et al., 2012, 2014). The functional role of increased H3K36 methylation 
in a PRC2-deficient context has yet to be addressed; however, ChIP-seq studies have 
demonstrated that the increases in H3K27ac typically occur at previously silenced gene 
enhancer elements, potentially leading to inappropriate enhancer activity and transcriptional 
activation of associated genes (Ferrari et al., 2014). Consistent with this, transcriptional 
profiling of PRC2-deficient MPNST and T-ALL cells demonstrates that these cancers have 
characteristic expression signatures involving aberrant activation of PRC2 target genes with 
associated increases in H3K27ac and H3K9ac (Lee et al., 2014; Ntziachristos et al., 2012). 
Figure 4. Defining the epigenomic changes in cancer
The alteration of a single chromatin modifying activity in cancer cells is known to have profound 
effects on the landscape of additional related chromatin modifications and other chromatin regulators. 
These alterations are likely instrumental in disease pathogenesis; however until recently our ability 
to systematically annotate such changes has been limited. The use of unbiased quantitative mass 
spectrometry techniques holds great promise for the annotation of chromatin dynamics in response to 
cancer promoting alterations in epigenetic pathways. This may facilitate the identification of additional 
therapeutic targets within the cancer epigenome.
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Re-introduction of PRC2 activity into PRC2-deficient MPNST cells leads to silencing of these 
aberrantly active genes, which is associated with loss of H3K27ac and cell growth arrest. 
Taken together, these findings suggest that increases in H3K27ac in response to PRC2-
loss may be instrumental in driving oncogenic gene expression programs. This implicates 
H3K27ac as a potential therapeutic target for the treatment of PRC2-deficient cancers. The 
use of quantitative mass spectrometry to define global epigenomic changes in cancer cells 
will yield significant mechanistic insights into the role of altered epigenomic states in cancer 
development (Creech et al., 2014; Stunnenberg and Vermeulen, 2011) (Figure 4). Moreover, 
this will provide a rationale for therapeutically targeting such modifications.
PERSPECTIVES
The manipulation of cancer-promoting epigenetic states holds significant potential for the 
development of new cancer therapies. However, our understanding of the epigenomic 
alterations that promote oncogenesis and their influences on chromatin-based mechanisms 
are still limited. Additional effort is needed to deliver on this therapeutic promise. Unbiased 
analyses of the epigenomic changes in cancer cells will provide significant insights into the 
chromatin alterations that are instrumental in disease pathogenesis. Additionally, the use of 
chromatin-focused genomic screening techniques, particularly those utilizing the CRISPR/
Cas9-mediated genome editing technology, are already facilitating the identification of 
epigenetic dependencies in cancer cells (Shi et al., 2015; Zuber et al., 2011). Application of 
these approaches will be important for the identification of additional therapeutic targets within 
the cancer epigenome. Moreover, their use in the context of drug resistance will facilitate the 
annotation of mechanisms related to drug sensitivity (Chen et al., 2015) and thereby aid 
the rational design of treatment regimens to circumvent the emergence of drug resistant 
cells. Structure based drug design towards the development of small-molecule therapeutics 
is often hampered by difficulties producing high-resolution structures for target molecules 
using traditional methods such as X-ray crystallography. However, recent advancements 
in cryogenic-electron microscopy (cryo-EM) techniques are revolutionizing the structural 
biology field and may well soon help alleviate this bottleneck (Nogales, 2016). Moreover, 
novel approaches to drug design such as the use of phthalimide conjugates to mediate 
proteosomal degradation of target proteins may overcome several limitations of conventional 
small-molecules (Winter et al., 2015). The mechanistic dissection of altered epigenomic 
states in cancer cells will undoubtedly accelerate the development of clinical strategies to 
manipulate these phenomena. In the next 10 years we will surely see the identification of new 
context-specific drug targets, complimented by the development of novel small-molecule 
therapeutics. As the field matures, this interface of basic and clinical research will hopefully 
allow us to thoroughly exploit the therapeutic potential of the cancer epigenome and provide 
curative options for cancer patients.
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HIGHLIGHTS
• NUP98 fusions interact with MLL1 and NSL histone-modifying complexes.
• NUP98 fusions and MLL1 colocalize at Hoxa and Hoxb cluster gene loci.
• Mll1 is required for NUP98-HOXA9-induced leukemogenesis in vitro and in vivo.
• Mll1-dependent gene expression signatures resemble human NUP98-NSD1 AML. 
ABSTRACT
The Nucleoporin 98 gene (NUP98) is fused to a variety of partner genes in an array of 
hematopoietic malignancies via chromosomal translocations involving 11p15. Here we 
demonstrate that NUP98 fusion proteins encoded by these translocations, including 
NUP98-HOXA9 (NHA9), NUP98-HOXD13 (NHD13), NUP98-NSD1, NUP98-PHF23, and 
NUP98-TOP1 physically interact with mixed lineage leukemia 1 (MLL1) and the non-specific 
lethal (NSL) histone-modifying complexes. We identified the target genes to which NHA9 
and MLL1 bind in NHA9 transformed cells, and found significant colocalization of these 
proteins. Furthermore, Mll1 is required for the colony formation of NHA9 cells in vitro and the 
maintenance of NHA9 leukemia in vivo. Inactivation of Mll1 led to decreased expression of 
genes where NHA9 and MLL1 were colocalized and reversed a gene expression signature 
found in NUP98-rearranged human leukemias. Our data reveal a molecular mechanism for 
Mll1 function in NUP98-fusion driven leukemogenesis and suggest that targeting the MLL1/
NSL complexes might be a novel approach to target this disease.
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INTRODUCTION
The nuclear pore complexes (NPCs) span the nuclear envelope and mediate the exchange 
of macromolecules between the nucleus and cytoplasm, including the movement of small 
molecules and the selective, facilitated transport of large proteins and RNAs (Tran et al., 2006; 
D’Anfelo et al., 2008). The proteins that make up the nuclear pore complex are known as 
nucleoporins. The 98 kD nucleoporin (NUP98), a component of NPCs, is generated through 
a biogenesis pathway that involves synthesis and proteolytic cleavage of a 186 kD precursor 
protein (Fontoura et al., 1999). NUP98 was initially identified as a docking protein for cytosol-
mediated docking of transport substrates (Radu et al., 1995). The NH3-terminus of the 
NUP98 protein contains 38 nontandem repeats that possess the amino acids phenylalanine 
(F), leucine (L) and glycine (G) in various orders including FG, FXFG, or GLFG (where X is 
any amino acid). This repeat region provides docking sites for a family of nuclear transport 
signal receptor proteins known as importins, exportins and transportins (Griffis et al., 2002). 
The Gle2-binding sequence (GLEBS) at the amino terminal of NUP98 is responsible for 
the binding of Ribonucleic Acid Export 1 (REA1, the mammalian homologue of the mRNA 
export protein Gle2p) (Fontoura et al., 1999; Radu et al., 1995). The C-terminal part of NUP98 
encodes the RNA binding domain (RBD) and nuclear localization signal (NLS). NUP98 is 
mainly localized to the nuclear envelope within the NPC (Radu et al., 1995), however a small 
fraction of NUP98 has been detected within the nucleus in cells from Xenopus Laevis (Radu 
et al., 1995) or human (Iwamoto et al., 2013), indicating potential dynamic movement of 
NUP98 between the nuclear interior and the nuclear pore complex (Griffis et al., 2002). The 
GLFG domain of NUP98 is required for the nucleoplasmic localization of NUP98 (Enninga 
et al., 2002; Powers et al., 1997). Recent studies (Kalverda et al., 2010) in Drosophila show 
that nucleoplasmic localized Nup98 functions as a potential transcriptional activator with 
a preference for promoters of genes with high H3K4 methylation and H4K16 acetylation 
involved in development, cell signaling, and cell cycle regulation. Another study in Drosophila 
demonstrated that nucleoplasm localized Nup98, but not nuclear envelop localized, NPC-
associated full-length Nup98, physically interact with the non-specific lethal (NSL) and 
trithorax (Trx)/mixed lineage leukemia (MLL) complexes (Pascual-Garcia et al., 2014). 
Similar to the Drosophila NSL complex, the human NSL complex contains the histone 
acetyltransferase (HAT) males absent on the first (MOF), and multiple other components 
including NSL1, NSL2, NSL3, MCRS2, plant homeodomain-linked finger-containing proteins 
PHF20, O-linked N-acetylglucosamine transferase isoform 1 (OGT1), host cell factor 1 
(HCF1), and the tryptophan-aspartate (WD) repeat domain 5 (WDR5) (Prestel et al., 2010; 
Raja et al., 2010; Cai et al., 2010). Two components of the human NSL complex WDR5 and 
HCF1 are shared among members of the mixed-lineage leukemia/set-domain containing 
(MLL/SET) family of histone 3 lysine 4 (H3K4) methyltransferase complexes (Raja et al., 2010; 
Cai et al., 2010). MLL1 (also known as KMT2A) is a histone methyltransferase (Milne at al., 
2002). Human MOF has been shown to physically associate with MLL1 in a multi-protein 
complex that catalyzes both histone acetylation and methylation (Dou et al., 2005). These 
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previous studies demonstrate potential physical association and functional links between the 
NSL and MLL1 complexes, but the extent to which the MLL1 and NSL complexes represent 
one large regulatory complex or multiple complexes composed of various components 
remains unclear. 
NUP98 translocations have been detected in patients with various hematopoietic 
disorders, such as myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) 
in blast crisis, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). 
Although the frequency of NUP98 rearrangements in unselected adult patients with AML is 
rare (around1% to 2%), the frequency of NUP98 rearrangements in patients with an 11p15 
abnormality is 35% (Gough et al., 2011). However, the frequency of NUP98-rearrangements 
is greater in childhood AML with between 6-10% of cases harboring this translocation (Bisio 
et al., 2014). Adults and children with AMLs carrying a NUP98 translocation have a relatively 
poor prognosis (Hollink et al., 2011; de Rooij et al., 2013; Chou et al, 2009). All the NUP98 
translocations produce gene rearrangements that encode fusion proteins which possess a 
common NH3-terminus which invariably contains the nucleoporin FG/GLFG repeat motifs 
and GLEBS domain fused in-frame with various COOH-terminal fusion partners. Therefore, 
the RBD and NLS at the C-terminal portion of NUP98 are replaced by the C-terminus of 
the fusion partner. The various NUP98 fusion partners, include homeobox genes with the 
conserved DNA-binding domain, such as HOXA9 and HOXD13, and proteins with a histone 
“writer” or “reader” domain, such as nuclear receptor binding SET domain protein 1 (NSD1), 
jumonji/ARID domain-containing protein 1A (JARID1A) and PHD finger protein 23 (PHF23). 
Studies using mouse models expressing NUP98 fusions including NUP98-HOXA9, NUP98-
HOXD13, NUP98-Topoisomerase I (NUP98-TOP1), NUP98-NSD1, NUP98-JARID1A and 
NUP98-PHF23 confirmed their leukemogenic potential (Kroon et al., 2001; Pinearlt et al., 
2003; Gurevich et al., 2004, Wang et al., 2007, Wang et al., 2009; Gough et al., 2014). 
NUP98-rearranged leukemias show elevated HOXA and HOXB cluster genes and mouse 
model systems have recapitulated this high-level expression independent of whether the 
leukemias are derived from mouse or human bone marrow (BM) (Kroon et al., 2001; Pinearlt 
et al., 2003; Wang et al., 2007, Wang et al., 2009; Gough et al., 2014; Takeda et al., 2006; 
Chung et al., 2006; Hollink et al., 2011; de Rooij et al., 2013 and Shiba et al., 2013). However, 
the molecular mechanisms of NUP98-fusion mediated leukemogenesis and elevated HOX 
gene expression in this leukemia are unclear. 
In this study, we demonstrate that the NUP98 fusions NUP98-HOXA9 (NHA9), NUP98-
HOXD13 (NHD13), NUP98-NSD1, NUP98-PHF23 and NUP98-TOP1 physically interact with 
the MLL1 and NSL complexes. Genome-wide chromatin immunoprecipitation followed by 
next generation sequencing (ChIP-seq) illustrated that NUP98-HOXA9 and MLL1 colocalize 
on chromatin and are found associated with Hox gene promoter regions. We further 
demonstrate the dependence of the NUP98-fusion driven gene expression signature and 
leukemia maintenance on Mll1 in vitro and in vivo and that inactivation of Mll1 reverses a gene 
expression program found in NUP98-rearranged human leukemia. Together, our data show 
a functional interaction between NUP98 fusions and the NSL/MLL1 complexes that reveals 
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a crucial role for Mll1 in the epigenetic regulation of HOX gene expression in NUP98-fusion 
driven leukemia. 
RESULTS
NUP98 fusions and the N-terminus of NUP98 localize to the nucleus
A schematic of wild type (WT) NUP98 is shown in Figure 1A. The first GLFG domain (GLFG-1) 
contains a total of 17 FG/GLFG repeats; while the second GLFG domain (GLFG-2) contains 
21 FG/GLFG repeats. For NHA9 and NHD13 fusions, the HOXA9 or the HOXD13 portion of the 
fusion protein still processes the helix-turn-helix (homeobox) DNA-binding domain. To assess 
the subcellular localization of NUP98 and NUP98 fusions, we overexpressed Human influenza 
hemagglutinin (HA)-tagged WT full-length NUP98, HA-tagged NHA9 and NHD13 fusion 
proteins, and HA-tagged NH3-terminal portion of WT NUP98 (N-NUP98, 1-469 amino acids of 
the N-terminal NUP98 preserved in NUP98 fusions) in 293T cells by transient transfection. To 
confirm the expression of NUP98 proteins, Western blot analysis was performed using whole 
cell lysates from transiently transfected 293T cells. Indeed, we detected expression of the 
appropriately sized N-NUP98, full-length NUP98, NHA9, and NHD13 fusion proteins (Figure 
1B). To determine whether HA-tagged NUP98 or NUP98 fusions associate with NPCs, cells 
were double stained for HA and NUP214, a component of NPCs, mainly localized at the 
nuclear envelop. Immunofluorescence showed that the full-length NUP98 protein is primarily 
localized to the nuclear envelope with a distinct staining around the rim of the nucleus, and 
displayed highly overlapping immunolabeling patterns to NUP214 at the nuclear rim (Figure 
1C). However, the NUP98 fusion proteins (NHA9 and NHD13) do not colocalize with NUP214 
signal at the nuclear envelope, and are predominantly located in the nucleoplasm with 
multiple punctate foci (Figure 1C). In contrast to full-length NUP98, the N-NUP98 protein, 
which contains all 38 FG/GLFG repeats, failed to form the typical rim structure at the nuclear 
envelope and showed more defined FG/GLFG body staining throughout the nucleus (Figure 
1C). These data suggest that the C-terminal sequence of full-length NUP98 is required for its 
subcellular localization at the nuclear envelope within the NPCs as previously demonstrated 
(Griffis et al., 2002). Our data further demonstrate that N-NUP98 exhibits a similar intranuclear 
localization as the NUP98 fusions NHA9 and NHD13, which is distinct from full-length NUP98. 
This suggests that the NH3-terminus of NUP98 is necessary for the intranuclear localization of 
NUP98 fusions, and loss of the COOH-terminus of NUP98 frees NUP98 and NUP98 fusions 
from the nuclear envelope.
To define how individual domains of the retained NH3-terminal NUP98 affect the 
nuclear localization pattern of NUP98 fusion proteins, we generated a series of Flag-Avi-
tagged NHA9 mutants. Figure 1D shows the various NHA9 mutants with either deletion of the 
GLFG-1 domain (2-156, NHA9-GLFG-1 del), deletion of the GLEBS domain (157-213, NHA9-
GLEBS del), deletion of the GLFG-2 domain (214-469, NHA9-GLFG-2 del) or deletion of both 
the GLFG-1 and GLFG-2 domain (all 38 FG/GLFG repeats deleted, NHA9-(GLFG-1+2) del). 
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Figure 1. The subcellular localization and expression of NUP98 and NUP98 fusions
(A) Schematic representation of WT full-length NUP98, NUP98-HOXA9 (NHA9), NUP98-HOXD13 (NHD13) 
and N-NUP98. Fusion break points are indicated with arrows. GLFG, glycine-leucine-phenylalanine-
glycine; GLEBS, GLE2-binding sequence; bd, binding domain; NLS, nuclear localization signal. 
(B) Western blot analysis of whole cell lysates from transfected 293T cells detected by anti-HA and anti-
beta Tubulin antibodies. One representative experiment of three is shown.
(C) Immunofl uorescence staining of 293T cells transfected with the HA-tagged full-length NUP98, NHA9, 
NHD13 and N-NUP98 vectors. Cells were fi xed, permeabilized and stained with an anti-HA and an anti-
NUP214 antibody for double-immunofl uorescence analysis by confocal microscopy. HA was labeled 
with Alexa Fluor 568-conjugated secondary antibody (red), and the NUP214 was labeled with Alexa 
Fluor 488-conjugated secondary antibody (green). Nuclei were counterstained with (DAPI, blue).
(D) Schematic of the various NHA9 mutant constructs used in this study. Arrow indicates break point.
(E) Western blot analysis of whole cell lysates from transfected 293T cells detected by anti-Flag and 
anti-beta Tubulin antibodies. One representative experiment of three is shown.
(F) Immunofl uorescence staining of 293T cells transfected with Flag-Avi-tagged NHA9 and NHA9 mutant 
vectors. Cells were fi xed, permeabilized and stained with an anti-Flag and an anti-NUP214 antibody 
for double-immunofl uorescence analysis by confocal microscopy. Flag was labeled with Alexa Fluor 
568-conjugated secondary antibody (red), and the NUP214 was labeled with Alexa Fluor 488-conjugated 
secondary antibody (green). Nuclei were counterstained with DAPI (blue).
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The expression of these mutant NHA9 proteins in transiently transfected 293Ts was detected 
by Western blot (Figure 1E) and the subcellular distribution of the proteins was examined 
by immunofl uorescence staining using anti-Flag and anti-NUP214 antibodies (Figure 1F). 
The NHA9-GLEBS del mutant showed similar intranuclear localization to intact NHA9 with 
multiple punctate foci, whereas the NHA9-(GLFG1+2) del mutant with no FG/GLFG repeats 
localized diffusely throughout the nucleus. The NHA9-GLFG-1 del and the NHA9-GLFG-2 del 
displayed fewer punctated nuclear foci compared to WT NHA9 overexpressing cells. These 
data confi rm that the FG/GLFG repeats, and not the GLEBS domain, are required for NUP98 
fusion proteins to form punctated, intranuclear localized foci.
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NUP98 fusions interact with MLL1 and NSL histone-modifying complexes
The physical and functional interaction between Nup98 and histone-modifying complexes 
NSL and Trx, found in Drosophila (Pascual-Garcia et al., 2014), suggests that the intranuclear 
localized and FG/GLFG repeats containing NUP98 leukemic fusion proteins might also 
interact with the NSL and MLL1 complex. To test this hypothesis, we generated 293T cell lines 
that stably express bacterial BirA biotin ligase and a COOH-terminal Flag-Avi-tagged NUP98 
fusion protein consisting of the NHA9 fusion protein, the NHD13 fusion protein or N-NUP98. 
Whole cell lysates were prepared from each cell line and subjected to biotin-mediated affinity 
purification with streptavidin magnetic beads. The eluted proteins from the streptavidin 
beads were fractionated by SDS-PAGE and analyzed by Western blotting for the presence 
of NSL/MLL1 protein complex members. As shown in Figure 2A, the known NSL/MLL1 
complex components were detected by anti-MOF, anti-PHF20, anti-OGT1, anti-HCF1, anti-
WDR5 and anti-MLL1 antibodies in streptavidin bead eluates from Flag-Avi-tagged NHA9, 
NHD13 and N-NUP98 expressing cells, but not from control cells with BirA expression only. 
Moreover, proteins such as CXXC1 (a unique component of the SETD1 complex) and EZH2 
(the catalytic subunit of the Polycomb repressive complex 2), which are not found in the 
NSL/MLL1 complexes, were not detected in the eluted protein from streptavidin beads after 
biotin-mediated affinity purification. To test the interaction in a different system, we generated 
U937 cell lines that stably express bacterial BirA biotin ligase and a COOH-terminal Flag-Avi-
tagged NHA9 or NHD13 fusion protein (Figure S1A). As shown in Figure S1B, the interaction 
between NUP98 fusion proteins and the NSL/MLL1 complex was also detected in U937 cells, 
a human leukemic monocyte cell line. 
Considering that most NUP98 fusion proteins possess a similar NH3-terminal portion of 
NUP98, we explored whether other NUP98 fusion proteins also interact with the NSL/MLL1 
complex. Consistent with our data above, three other NUP98 fusions, NUP98-NSD1, NUP98-
PHF23 and NUP98-TOP1 also interacted with NSL/MLL1 complex proteins including MOF, 
PHF20, OGT1, HCF1, WDR5 and MLL1n (Figure 2B). Our results demonstrate that NUP98 
fusions, such as NHA9, NHD13, NUP98-NSD1, NUP98-PHF23 and NUP98-TOP1, physically 
interact with the NSL/MLL1 complex. These data suggest that the common NH3-terminus of 
NUP98 mediates binding of NUP98 fusions to the NSL/MLL1 complex, and further implicate 
a potential role for the NSL/MLL1 complex in NUP98-fusion driven leukemia.
To further assess the specificity of these interactions, we determined whether full-
length NUP98 interacts with the NSL/MLL1 complex. 293T cells were transfected with vectors 
expressing Flag-tagged full-length NUP98 and NHD13, and proteins were immunoprecipitated 
using an anti-Flag antibody. The NHD13 fusion again showed interaction with NSL/MLL1 
complex members such as MOF, PHF20, HCF1 and WDR5 (Figure 2B). However, none 
of these NSL/MLL1 complex proteins were detected in immunoprecipitates from the cells 
expressing WT full-length NUP98 (Figure 2C). These data indicate that nuclear envelope 
associated full-length NUP98 is not available for the interaction with the NSL/MLL1 complex, 
which occurs inside the nuclear interior, suggesting that the intranuclear localized GLFG 
repeat-rich portion of NUP98 fusions may be essential for their interaction with the complex. 
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To further elucidate the NUP98 fusion domains responsible for the interaction with the 
NSL/MLL1 complex, we performed biotin-mediated affinity purification on 293T cell lysates 
expressing BirA biotin ligase and Flag-Avi-tagged NHA9 or one of the NHA9 mutant proteins. 
Removal of the first 17 FG/GLFG repeats (NHA9-GLFG-1 del) or the GLEBS domain (NHA9-
GLEBS del) of the NUP98 moiety did not affect binding of NHA9 to NSL/MLL1 complex 
members (Figure 2D). However, upon deletion of the 21 FG/GLFG repeats (NHA9-GLFG-2 
del), the interaction with MLL1 was significantly reduced (Figure 2D). The interaction of 
NHA9 with NSL/MLL1 complex was completely abolished by deletion of both GLFG domains 
with 38 FG/GLFG repeats (NHA9-(GLFG1+2) del) (Figure 2D). These data demonstrate that 
the FG/GLFG repeat motifs rather than the GLEBS domain of NHA9 are required for the 
interaction between NHA9 and the NSL/MLL1 complex. 
NUP98 fusion proteins bind to chromatin to drive gene expression
The importance of the NSL and MLL1 complexes in chromatin regulation and transcriptional 
activation raises the question of how recruitment of the NSL/MLL1 complexes by NUP98 
fusions might affect the expression of NUP98 fusion target genes in leukemia. However, 
direct binding targets of NUP98 fusion proteins have not been identified. To define these 
targets, we immortalized mouse BM lineage-negative (Lin-), SCA1+, cKIT+ (LSK) cells by 
enforced expression of NHA9 or NHD13 through retroviral transduction with vectors 
carrying C-terminally Flag-Avi-tagged NHA9 or NHD13, and BirA ligase (Figure S2A). These 
immortalized cells form dense, round, blast-like colonies in a colony-forming unit (CFU) 
assay in vitro (Figure S2B) and can be maintained in liquid medium for long-term culture 
(data not shown). Using these immortalized cells with the expression of Flag-Avi-tagged 
NUP98 fusions and BirA, the genome-wide direct binding targets of NHA9 and NHD13 were 
Figure 2. NUP98 fusions interact with MLL1 and the NSL histone-modifying complex
(A) Immunoprecipitation (IP) with streptavidin magnetic beads for NHA9, NHD13, N-NUP98 and the 
various NSL/MLL1 complex members. The Flag-Avi-tagged NHA9, NHD13 and N-NUP98 were stably 
expressed in 293T cells with co-expression of the BirA biotin ligase. Whole cell lysates were prepared 
and subjected to IP using streptavidin magnetic beads. Cell lysates (Input) and proteins eluted from the 
streptavidin beads (IP) were separated by SDS–PAGE and analyzed by Western blotting with anti-Flag, 
anti-MOF, anti-PHF20, anti-OGT1, anti-HCF1, anti-WDR5, anti-MLL1n, anti-CXXC1, anti-EZH2 and anti-
beta Tubulin antibodies. 
(B) Co-IP was performed on lysates from Flag-tagged NUP98-NSD1 (left), NUP98-PHF23 (middle) and 
NUP98-TOP1 (right) transfected 293T cells with an anti-Flag antibody, and analyzed by Western blotting. 
(C) Immunoblots of Co-IP on lysates from Flag-tagged full-length NUP98 (WT NUP98) or NHD13 
transfected 293T cells with an anti-Flag antibody. 
(D) Co-IP was performed on lysates from Flag-Avi-tagged NHA9 or NHA9-mutant transfected 293T cells 
with co-expression of the BirA biotin ligase, and analyzed by Western blotting. Data are representative 
of three individual experiments.
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identified through the metabolic labeling of NHA9 or NHD13 with biotin, followed by biotin-
mediated chromatin affinity purification coupled with high throughput sequencing using 
streptavidin beads. 
After calling peaks genome wide, 6514 NHD13-bound and 2872 NHA9-bound regions 
were defined. Interestingly, 10% of the NHA9 peaks (274 genes) and 15% of the NHD13 
peaks (995 genes) were detected at promoter regions; similar percentage (29%) of the 
NHA9 peaks (833 genes) and NHD13 peaks (1896 genes) map to the gene body region 
(containing introns, exons, untranslated regions and transcription termination sites); while 
the majority of identified NHA9 peaks (61%, 1745) and NHD13 peaks (56%, 3623) present at 
intergenic regions (Figure 3A). Relative to the background distribution of all such annotated 
sites in the mouse genome, NUP98 fusion bound regions showed a marked enrichment 
for promoters (enriched 9.61 fold and 15.27 fold over background for NHA9 and NHD13, 
respectively) compared to that at gene body and intergenetic regions (~1 for both NHA9 
and NHD13) (Figure S2C). Next, we asked whether the two NUP98 fusions (NHA9 and 
NHD13) bind to any loci in common. A pairwise comparison between the NHA9 and NHD13 
enrichment at all binding loci revealed 191 overlapping binding sites at promoter regions 
(p=1.24e-207, hypergeometric test), 599 overlapping genes in the gene body regions (p=0) 
and 1129 overlapping targets at intergenic regions (p=0) (Figure 3A). This significant overlap 
in binding targets between NHA9 and NHD13 (hereafter simply referred to as NUP98-HOX) 
suggests that NUP98-HOX fusions likely use the same transcriptional program to drive 
leukemia development. Given that HOX genes are activated in both MLL-AF9 and NUP98 
fusion leukemia, we then compared the NHA9 and NHD13 ChIP-seq data with previously 
reported MLL-AF9 ChIP-seq data (Bernt et al., 2011). As MLL-AF9 has been shown to act on 
promoters and NUP98-HOX fusion binding sites are enriched at such regions (Figure S2C), 
we focused our further analyses on the NUP98 fusion targets at the promoter region. 17 
NUP98-HOX fusion binding targets overlapped with MLL-AF9 target genes at their promoter 
regions (Figure 3B, 3C), including genes with a known important function in MLL-AF9 
leukemia, such as Hoxa3, Hoxa7, Hoxa9, Meis1, Jmjd1c, Mir196b and less well-defined 
targets, such as Baz2b and Cdk17 (Figure 3B), suggesting that Hoxa cluster genes and 
Meis1 may also be important to the NUP98-fusion driven leukemogenic gene expression 
program. Interestingly, at promoters, NHA9 and NHD13 have unique binding targets such 
as Hoxb cluster genes, which are not bound by MLL-AF9 (Figure 3C). To further examine 
whether the NUP98-HOX direct binding targets defined here are functionally important 
in murine and human cells expressing these fusion proteins, we compared the ChIP-seq 
results to published gene expression profiling datasets. Gene set enrichment analysis 
(GSEA) revealed a highly significant enrichment of the NHD13 promoter region binding 
targets in the upregulated gene sets from murine Lin-SCA1+(LS) BM cells transduced with 
NHD13 (Palmqvist et al., 2007) (Figure 3D, NES 1.60; FDR-q=0.08%). Moreover, 10 of the 
182 genes whose expression increased ≥2 fold in human cord blood CD34+ cells within 3 
days of NHA9 expression (Takeda et al. 2007) were also direct targets in our system thus 
showing significant enrichment (p=5.74e-06, hypergeometric test) (Figure 3E). Among these 
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10 genes, Hoxa7, Hoxa9 and Pbx3 were significantly upregulated in the before mentioned 
NHD13 transduced murine LS BM cells (Palmqvist et al., 2007). There was no overlap 
between the 30 downregulated genes in human cord blood NHA9 transduced cells (Takeda 
et al., 2006) and the 274 NHA9 promoter targets as defined in Figure 3A. These results show 
that NUP98-HOX binding is associated with elevated expression of target genes in mouse 
and human cells, and Hoxa7, Hoxa9 and Pbx3 are among the common activated targets of 
NUP98-HOX fusions. Given the essential role of Hoxa7, Hoxa9 and Meis1 genes in MLL-AF9 
leukemia (Ayton et al., 2003; Martin et al., 2003; Kumar et al., 2009), our results suggest that 
the binding of NUP98-HOX fusions to the Hox gene locus to activate Hox gene expression 
may contribute to NUP98-HOX fusion leukemia transformation. 
To determine whether our findings for NUP98-HOX fusions hold true for other NUP98 
fusions with fusion partners other than homeobox genes, we immortalized mouse BM LSKs 
by retroviral transduction with vectors carrying Flag-Avi-tagged NUP98-TOP1 and BirA 
ligase (Figure S2A and B). Biotin-mediated ChIP-seq was performed to define the direct 
binding targets of NUP98-TOP1. Genome-wide analysis revealed NUP98-TOP1 occupation 
at 833 promoter regions, 1588 gene body regions and 3476 intergenic regions (Figure S2D). 
ChIP-qPCR confirmed the significant enrichment of NUP98-TOP1 at promoter regions of 
Hoxa7, Hoxa9, Hoxb5, Evi1 and Meis1 (Figure S2E), though the enrichment of NUP98-TOP1 
at the Hoxb5 promoter region was less than that of NHA9 (Figure S2F). NUP98-TOP1 
binding sites largely overlap with the common NUP98-HOX targets at promoter regions (183 
overlapping genes including Hoxa cluster genes, Hoxb cluster genes, Eya1, Pbx3 and Meis1, 
p=1.27e-269, hypergeometric test), gene body regions (571 overlapping targets, p=0) and 
intergenic regions (1067 overlapping sites, p=0) (Figure S2G), indicating that NUP98 fusion 
proteins with distinct fusion partners share common target genes. 
To further dissect the contribution of the NUP98 portion to the DNA binding properties 
of NUP98 fusion proteins, we retrovirally overexpressed Flag-Avi-tagged N-NUP98, and BirA 
ligase in mouse BM LSKs (S2A) to perform a Biotin-mediated ChIP-seq. Genome-wide peak 
detection analysis identified a total of 1296 N-NUP98 binding targets, significantly fewer than 
for all NUP98 fusions (NHD13, NHA9 and NUP98-TOP1). Among the N-NUP98 target loci, 
227 sites were located at promoter regions, 343 sites at gene body regions and 726 binding 
sites at intergenic regions (Figure S2H). Interestingly, the 227 N-NUP98 targets at promoter 
regions included Hoxa7, Hoxa9, Hoxb5, Pbx3, Evi1 and Meis1. ChIP-qPCR validated the 
significant enrichment of N-NUP98 at these promoter regions (Figure S2I). We then compared 
the annotated N-NUP98 targets to the common targets between NUP98-TOP1 and NUP98-
HOX fusions defined in Figure S2G (NUP98 fusions) and found an overlap at 67 promoter 
regions (p=1.69e-93, hypergeometric test), 226 gene body regions (p=2.34e-302) and 310 
intergenic regions (p=1.33E-239)(Figure S2J). The significant overlap in binding targets 
between N-NUP98 and NUP98 fusions, and the colocalization of N-NUP98 and NUP98 
fusions at Hoxa, Hoxb and Meis1 loci, as illustrated by genome browser tracks (Figure S2K), 
suggests that the NUP98 moiety of NUP98 fusion proteins contributes to the binding of 
NUP98 fusions at these target genes. 
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Figure 3. Genome-wide binding of NUP98 fusions in immortalized mouse bone marrow cells and 
functional correlation of their target genes in mouse and human cells
(A) ChIP-seq experiments were performed using immortalized mouse BM cells by enforced expression 
of NHA9 or NHD13 through retroviral transduction of LSKs with vectors carrying C-terminal Flag-Avi-
tagged NHA9 or NHD13, and BirA ligase. Mapping of NHA9 and NHD13 ChIP-seq data identified 
binding sites to different genomic regions (promoter, gene body or intergenic) as shown in the bar 
graph. The Venn diagrams illustrate overlapped targets (yellow) between NHA9 (blue) and NHD13 (red) 
among different genomic regions with a p-value calculated by hypergeometric test. 
(B) Venn diagram for overlap of NHA9 (red), NHD13 (blue) and previously published MLL-AF9 (green) 
binding sites at promoter regions. 
(C) Genome browser tracks representing the shared binding sites of NHA9, NHD13 and MLL-AF9 at the 
Hoxa cluster loci, the Meis1 locus, and the unique binding of NHA9 and NHD13 at the Hoxb cluster loci. 
(D) Gene set enrichment analysis (GSEA) illustrates enrichment of NHD13 promoter region binding 
targets in a previously published gene expression microarray dataset from murine LS BM cells 
transduced with NHD13. NES, normalized enrichment score; FDR, false discovery rate. 
(E) Venn diagram showing the overlap between NHA9 promoter targets (red) and the upregulated genes 
in a previously published gene expression microarray dataset from NHA9 transduced human CD34+ 
cord blood cells (gray).
Colocalization of NHA9 and MLL1 at Hoxa and Hoxb cluster gene loci
Our data show an interaction between NUP98 fusions and the NSL/MLL1 complexes, as well 
as the association of NUP98 fusions (NHA9, NHD13, and NUP98-TOP1) with the Hoxa and 
Hoxb cluster gene loci. MLL1 has been shown to directly regulate HOX gene expression (Yu 
et al., 1995; Milne et al., 2002; Ayton et al., 2003; Hsieh et al., 2003; Ernst et al., 2004; Hess et 
al., 2004; Milne et al., 2005). To test whether NUP98 fusions and MLL1 were recruited to the 
same regions of Hox gene clusters, MLL1 ChIP-seq analysis was carried out on murine NHA9 
cells using an antibody that recognizes the NH3-terminus of MLL1. ChIP-seq results revealed 
MLL1 binding sites distributed across all chromosomes. Analysis of all bound genomic loci 
indicated that 937 MLL1 binding sites mapped to promoter regions, while 4132 MLL1 peaks 
were bound to the gene bodies (Figure 4A). We then compared MLL1 and NHA9 binding 
regions and found a significant overlap at promoters (37 genes, p=3.7e-14, hypergeometric 
test) and gene bodies (520 genes, p=1.45e-204) (Figure 4B). The 37 overlapping promoter 
region targets include Hoxa3, Hoxa7, Hoxa9, Hoxb4, Hoxb5, Meis1, Eya1 and Pbx3 loci. 
To further confirm the co-occupancy of NHA9 and MLL1 at Hoxa gene loci, we performed 
sequential ChIP for NHA9 followed by MLL1 (data not shown), and found that the Hoxa9 
locus is bound by both NHA9 and MLL1. The overlap in binding sites between MLL1 and 
NHA9 shows that NHA9 and MLL1 colocalize on chromatin and supports our earlier finding 
that NHA9 interacts with MLL1 and the extended NSL/MLL1 complexes.
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Given that that MOF and MLL1 are both part of the NSL/MLL1 complexes and work in 
concert to modify H4K16ac and H3K4me3 at promoters (Dou et al., 2005), we further tested 
whether H3K4me3 and H4K16ac modifications are associated with NHA9-bound regions in 
murine NHA9 cells by anti-H3K4me3 and anti-H4K16ac ChIP-seq. The distribution patterns 
of H3K4me3 (Figure 4C) and H4K16ac (Figure 4D), shown as the average profile around 
TSSs (±1.5Kb), indicate high enrichment of H3K4me3 and H4K16ac in regions of chromatin 
where NHA9 and MLL1 are found (Figure 4C and 4D). Among a total of ~34,000 transcripts, 
most of the NHA9-bound promoter targets (blue dots) and co-bound promoter targets of 
NHA9 and MLL1 (red dots) showed a positive correlation between H3K4me3 and H4K16ac 
level by scatter plot analysis (Figure 4E). The presence of both H3K4me3 and H4K16ac 
marks at NHA9 promoter region binding targets is in line with the coordinated roles of 
MOF-mediated H4K16 acetylation and MLL1/SET-mediated H3K4 methylation. Importantly, 
specific individual peaks of H3K4me3 and H4K16ac overlapped with NHA9 and MLL1 binding 
targets, such as Hoxa cluster genes, Hoxb cluster genes, Pbx3 and Meis1, suggesting a 
tight association between NHA9 and these modifications (Figure 4F). We repeated the MLL1 
ChIP-seq experiment using an anti-NH3-terminus MLL1 antibody (MO435) (Liu et al., 2014). 
This additional experiment confirmed the colocalization of MLL1 with NHA9, H3K4me3 and 
H4K16ac at NHA9 target gene loci (Figure S2L). Together our findings demonstrate that 
NHA9 and MLL1 are recruited to the same Hox loci, and this recruitment is associated with 
chromatin modifications of active gene expression, supporting the notion that the association 
between NUP98 fusions and the NSL/MLL1 complexes is important for NUP98-fusion driven 
leukemogenic gene expression. 
Figure 4. Colocalization of NHA9 and MLL1 at Hoxa and Hoxb cluster gene loci
(A) MLL1 ChIP-seq was performed using an anti-MLL1n antibody in murine transformed NHA9 LSKs. 
The bar graph indicates the number of MLL1-bound targets defined to promoter and gene body regions. 
(B) Venn diagram shows the overlap between NHA9 (red) and MLL1 (purple) binding targets at promoter 
(left) and gene body regions (right) with a p-value calculated using the hypergeometric test. 
(C) ChIP-seq experiments for H3K4me3 were performed in murine NHA9 transformed cells. Shown are 
the average binding profiles of H3K4me3 at a region of ±1.5 kb around the annotated TSSs of NHA9-
bound (red), MLL1-bound (purple) and NHA9/MLL1 co-bound targets (turquoise). Tag densities were 
normalized to the input (gray). 
(D) ChIP-seq experiments for H4K16ac were performed in murine NHA9 transformed cells. Average 
binding profiles of H4K16ac are shown. 
(E) Genome-wide representation of the relation between H3K4me3 and H4K16ac in NHA9 cells at NHA9 
promoter targets (blue) and NHA9/MLL1 co-bound promoter targets (dark red) compared to all ~34000 
transcripts (gray). The x and y-axis represent binding read numbers per Kb.
(F) Genome browser tracks of genomic regions showing colocalization of NHA9, MLL1, H3K4me3 and 
H4K16ac at four representative, well-known MLL1 targets; Hoxa cluster genes, Hoxb cluster genes, 
Pbx3 and Meis1.
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Mll1 is required for NHA9 driven leukemogenesis in vitro and in vivo
To test the function of Mll1 in NHA9 driven leukemia, we first assessed the impact of Mll1 
deletion on colony formation from NHA9 transduced mouse BM cells. LSKs were purified 
from the BM of a well described Mll1 conditional knockout model where Cre-recombinase is 
driven by the estrogen receptor (ERT2-cre;Mll1f/f, ERT2-cre;Mll1f/+ and Mll1f/f) (Jude et al., 2007; 
Artinger et al., 2013), and cells were transduced with NHA9 retrovirus (Figure 5A). After 
immortalization with NHA9, cells were treated with 4-hydroxyl tamoxifen (4-OHT) for 48 hours 
to induce excision of the Mll1 gene and either plated in a semi-solid medium or kept in liquid 
culture. The induced excision of floxed Mll1 was confirmed by genomic PCR (Figure S3A). 
Loss of Mll1 dramatically reduced the number of colonies formed by NHA9 transformed 
ERT2-cre;Mll1f/f (Mll1-/-NHA9) BM cells compared to those from the NHA9 transformed Mll1f/f 
(Mll1+/+NHA9) control (Figure 5B, 5C) and reduced cell growth in liquid culture (Figure S3B). 
The heterozygous loss of one Mll1 allele in NHA9 transformed ERT2-cre;Mll1f/+ (Mll1+/-NHA9) 
cells also showed a modest reduction of colony number in CFU assay (Figure 5B, 5C) and 
cell growth in liquid culture (Figure S3B), suggesting a potential gene dosage effect of Mll1 
on the clonogenic capacity and cell growth of NHA9 cells. Moreover, the Mll1-/-NHA9 cells 
failed to form compact and hypercellular blast colonies, which were seen in about 50% of 
colonies formed in Mll1+/-NHA9 and Mll1+/+NHA9 cells (Figure 5D, 5E). Finally, Mll1-/-NHA9 
cells displayed a significant degree of granulocytic differentiation on Wright-Giemsa–stained 
cytospin preparations compared to the characteristic blast-like morphology with a high 
nucleus to cytoplasmic ratio and the absence of granular cytosolic structures observed in 
Mll1+/-NHA9 and Mll1+/+NHA9 cells (Figure 5F). These results indicate that Mll1 is required for 
maintenance of NHA9 transformed cells in vitro. 
Mice transplanted with BM cells expressing NHA9 through retroviral transduction 
develop AML with a long latency (Kroon et al., 2001). To determine the effect of Mll1 loss 
on NHA9 driven leukemogenesis in vivo, we decided to use a mouse model where co-
expression of NHA9 and Meis1a induces rapid AML development based on the rationale 
that NHA9 function should still be required in this model since Meis1 cannot transform 
mouse BM by itself (Kroon et al., 2001). NHA9 transformed ERT2-cre;Mll1f/f, ERT2-cre and 
Mll1f/f BM LSKs were transduced with a retrovirus encoding Meis1a-YFP, and sorted based 
on the expression of GFP (NHA9) and YFP (Meis1a) by flow cytometry (FACS) (Figure 
S3C). The transduced GFP+YFP+ BM cells of individual genotypes were transplanted into 
lethally irradiated C57BL/6 mice with 0.2x106 helper cells (Figure 5A). Peripheral white blood 
cell (WBC) count and GFP+YFP+ percentage in peripheral blood (PB) were monitored. 15 
days after transplantation, the primary mice transplanted with NHA9-Meis1a cells showed 
comparable GFP+YFP+ percentage in PB by FACS analysis (79.7% in mice with ERT2-
cre;Mll1f/f cells, 80.6% in mice with ERT2-cre cells, and 86.2% in mice with Mll1f/f cells, Figure 
5G). Next, 4-OHT was administered by oral gavage to examine the impact of Mll1 excision 
on the initiation of NHA9-Meis1a-induced AML. Homozygous deletion of Mll1 resulted in 
significant reduction of the GFP+YFP+ percentage in the PB, 7 and 14 days post induction 
of Cre-recombinase (39.6% and 30.7% respectively, Figure 5G, p < 0.01). This significant 
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Figure 5. Mll1 loss in a murine NHA9 driven leukemia model leads to differentiation, decrease in 
tumor load and prolonged survival
(A) Schematic for in vitro and in vivo Mll1 knockout experiments.
(B) Day 7 of methylcellulose colony-forming (CFU) assay of NHA9 in vitro transformed ERT2-cre;Mll1f/f, 
ERT2-cre;Mll1f/+ or wild type (Mll1+/+) LSKs plated after 48 hours of tamoxifen (4-OHT) treatment. 
Representative petri dishes are shown.
(C) Bar graph indicates mean number of colonies per 35mm dish after 7 days. 1000 cells were plated 
per dish. Data are representative of four individual experiments.
(D) Shown is the mean percentage of blast versus non-blast colonies relative to all colonies counted per 
dish, per genotype.
(E) Representative images of colonies at day 7 of CFU assay. 
(F) Representative images of Wright-Giemsa–stained cytospin preparations of cells harvested at day 7 
of CFU assay.
(G) ERT2-cre;Mll1f/f, ERT2-cre or Mll1f/f LSKs were retrovirally transduced with GFP-NUP98-HOXA9 and 
YFP-Meis1a, sorted for double positive cells and injected into lethally irradiated C57Bl/6 mice (n=8 per 
group). Mice were treated with 4-OHT at day 15 post transplant to excise Mll1. Plotted is the GFP+YFP+% 
of live cells in PB of mice before 4-OHT treatment and at two different time-points post treatment. A dot 
represents a single mouse in the experiment.
(H) Survival curve of mice in primary leukemia experiment. Mice were treated with 4-OHT at day 15 after 
transplant. Data are representative of three individual experiments.
(I) Primary ERT2-cre;Mll1f/f NHA9-Meis1a mouse leukemia BM cells were injected into sub-lethally 
irradiated C57Bl/6 mice. Half of the mice (n=10) were treated with 4-OHT at day 7 after transplant to 
excise Mll1 (p-value calculated by log-rank test).
* p < 0.05, ** p < 0.01. Error bars represent SD of mean.
a. Log-rank test p-value comparing survival for ERT2-cre;Mll1f/f to Mll1f/f 
b. Log-rank test p-value comparing survival for ERT2-cre;Mll1f/f to ERT2-cre
c. Log-rank test p-value comparing survival for ERT2-cre;Mll1f/f to ERT2-cre;Mll1f/f without 4OHT treatment
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reduction was not observed in mice transplanted with either ERT2-cre or Mll1f/f NHA9-
Meis1a cells. The primary recipient mice were followed until they succumbed to leukemia. 
Consistent with a previous report (Kroon et al., 2001), the mice transplanted with NHA9 and 
Meis1a co-transduced BM cells rapidly developed AML. Diseased mice were characterized 
by extremely elevated peripheral nucleated cell counts, anemia (data not shown), and 
splenomegaly (Figure S3D). At time of death, FACS analysis demonstrated more than 90% 
GFP+YFP+ cells in the PB (Figure S3E), BM and spleen (data not shown) of leukemic mice. 
The majority of GFP+YFP+ cells in BM, spleen and PB expressed the myeloid cell markers 
CD11b (MAC1) or GR1, indicating a myeloid leukemia phenotype (Figure S3F). Mice 
transplanted with ERT2-cre;Mll1f/f NHA9-Meis1a cells and treated with 4-OHT, developed AML 
with a median survival of 43 days, compared to the mice transplanted with ERT2-cre NHA9-
Meis1a cells, Mll1f/f NHA9-Meis1a cells, or ERT2-cre;Mll1f/f NHA9-Meis1a cells without 4-OHT 
treatment, developing AML with a median survival of 30.5 days, 29 days and 29.5 days 
respectively (Figure 5H). These data demonstrate that homozygous loss of Mll1 leads to 
prolonged survival in an NHA9-Meis1a primary leukemia model. At time of death, GFP+YFP+ 
BM cells of ERT2-cre;Mll1f/f NHA9-Meis1a, 4-OHT+ mice were no longer completely excised 
(Figure S3G), indicating that the leukemias that eventually form are caused by cells that have 
escaped Mll1 deletion. Together, these results show that Mll1 is essential for the initiation of 
NHA9 driven leukemia. 
NHA9-Meis1a–induced acute leukemia was also transplantable into secondary recipient 
mice. To test whether Mll1 is required for the maintenance of NHA9 driven AML, 10,000 
primary leukemia cells harvested from the BM of unexcised ERT2-cre;Mll1f/f NHA9/Meis1a 
leukemic mice were injected into sub-lethally irradiated C57BL/6 recipients. The excision 
of Mll1 was induced by treatment with 4-OHT after 7 days of transplantation. Loss of Mll1 
revealed a significant increase in survival compared to the secondary AML that developed 
in untreated mice, with a median latency of 30 versus 16 days respectively (Figure 5I, 
p < 0.0001). Similar to the primary leukemia experiment, the leukemias that formed in the 
ERT2-cre;Mll1f/f NHA9-Meis1a 4-OHT+ mice were no longer fully excised (data not shown). 
These data show that Mll1 is essential for the maintenance of NHA9 driven AML. 
To further evaluate the role of Mll1 in other NUP98 fusion leukemias, we carried out 
analogous in vitro experiments for a diverse set of NUP98 fusions. Consistent with our 
observations for NHA9, 4-OHT–induced homozygous deletion of Mll1 in NHD13 (Figure 
S4A-D), NUP98-JARID1A (Figure S4E-H) or NUP98-TOP1 (Figure S4I-L) transformed cells, 
led to a significant reduction in CFU assay colony number and increased granulocytic 
differentiation. These results demonstrate that Mll1 is indispensable for the maintenance of 
NUP98 fusion transformed cells in vitro, suggesting that the requirement of Mll1 may be a 
shared feature for most, if not all, NUP98-fusion driven leukemia.
We next compared the Mll1 dependence of NUP98 fusions to the previously reported 
Mll1 dependence of MLL-AF9 (Thiel et al., 2010). We found that the deletion of Mll1 had a 
much more dramatic effect on colony formation in NUP98-fusion transformed cells than in 
cells transformed with MLL-AF9, both in CFU assays and liquid culture (Figure S5A-G). The 
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overexpression of Hoxa9 and Meis1 has been shown to transform mouse BM cells in vitro 
and induce AML in vivo (Kroon et al., 1998). We confirmed that the loss of Mll1 does not 
inhibit colony formation of BM LSKs transfomed by Hoxa9/Meis1, as described before (Thiel 
et al., 2010) (Figure S5H-L). In addition, loss of Mll1 did not affect Hoxa9/Meis1 induced in 
vivo leukemogenesis (Figure S5M-N). These results demonstrate that the deletion of Mll1 in 
NUP98-fusion transformed cells had a much more profound effect than did Mll1 deletion in 
cells transformed with MLL-AF9, and had no effect on cells transformed with Hoxa9/Meis1, 
indicating the specificity of Mll1 dependence in NUP98 fusion leukemia.
Mll1-dependent gene expression signatures resemble human NUP98-NSD1 AML 
To identify Mll1-dependent genes involved in the maintenance of NHA9 transformed BM 
cells, we performed gene expression analysis after Mll1 deletion by RNA sequencing 
(RNA-seq). ERT2-cre;Mll1f/f NHA9 cells were treated with 4-OHT for 48 hours to induce 
Mll1 excision, and harvested for RNA extraction another 3 days later. Mll1f/f NHA9 vehicle 
treated BM cells were used as a control. Assessment of normalized gene expression 
differences between control and Mll1-deficient NHA9 cells revealed an Mll1-dependent gene 
expression signature. GSEA showed positive enrichment for gene signatures associated 
with hematopoietic cell differentiation (Figure 6A, left panel, NES 1.749, FDR-q 0.002), and 
negative enrichment for hematopoietic stem cell and progenitor gene signatures in Mll1-
deficient NHA9 cells (Figure 6A, right panel, NES -1.938, FDR-q <0.001). These data fit with 
the increased myeloid differentiation phenotype observed in Mll1-/-NHA9 cells. Interestingly, 
GSEA also demonstrated a significant negative enrichment of genes directly co-bound by 
NHA9 and MLL1 (Figure 6B, NES -1.493, FDR-q 0.026) in the Mll1 knockout cells. Changes in 
expression of NHA9 and MLL1 co-bound targets were assessed in more detail by checking 
the log2 fold change between Mll1-/-NHA9 and Mll1+/+NHA9 cells, confirming that these co-
bound targets, such as Hoxa cluster, Hoxb cluster, Eya1 and Meis1, were among the most 
strongly decreased genes upon Mll1 deletion in NHA9 BM cells (Figure 6C, p < 0.001). We 
validated the decreased expression of Hoxa genes, Hoxb genes and Meis1 by qRT-PCR at 
various time-points after Mll1 deletion (Figure 6D and Figure S6A). These data indicate that 
Mll1 is required to sustain expression of oncogenic programs targeted by NHA9. Of note, 
reduction of Hoxa9, Hoxa10, Hoxb6 and Meis1 gene expression was also detected in NHD13 
(Figure S6B) and NUP98-JARID1A (Figure S6C) cells upon homozygous Mll1 deletion. The 
Mll1 dependent transcriptome in MLL-AF9 cells has previously been characterized (Cao 
et al., 2014). However, in our hands, MLL-AF9 transformed cells only show minimal to no 
changes of Hoxa7, Hoxa9, Hoxa10 and Meis1 gene expression upon Mll1 loss (Figure S5G), 
once more suggesting a unique dependency of NUP98 fusions on Mll1. 
To examine the potential clinical relevance of the Mll1-dependent gene expression 
signature found in NHA9 cells, we first compared this gene signature to the microarray 
dataset of human cord blood CD34+ cells retrovirally infected with NHA9 or t(8;21) 
(AML1-ETO) (Abdul-Nabi et al., 2010). GSEA exhibits enrichment of NHA9/MLL1 co-bound 
promoter targets (Figure 6E, left panel, NES 1.302, FDR-q 0.169), and enrichment of the Mll1-
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dependent gene expression signature (Figure 6E, right panel, NES1.214, FDR-q 0.166) in the 
upregulated genes from human CD34+ NHA9 vs AML1-ETO cells. We further compared our 
RNA-seq data to published human microarray data from pediatric de novo AML patients with 
a NUP98-NSD1 translocation versus a t(8;21) rearrangement, which showed high expression 
of HOXA and B cluster genes in AML with NUP98-NSD1 translocations (Hollink et al., 2011). 
GSEA analysis on this dataset illustrates significant enrichment of NHA9/MLL1 co-bound 
promoter targets (Figure 6F left panel, NES 1.771, FDR-q 0.004), and enrichment of the Mll1-
dependent gene expression signature (Figure 6F right panel, NES 1.413, FDR-q 0.091) in 
NUP98-NSD1 vs AML1-ETO AML patient gene expression data. These findings demonstrate 
a strong similarity between the Mll1-dependent gene expression signature in our murine 
NHA9 AML model and the expression profile of human NUP98 fusion AML, indicating that 
our findings in murine AML models can be extended to human leukemia, and suggesting that 
Mll1 is likely an important determinant of human NUP98-fusion driven AML.
Figure 6. Mll1-dependent gene expression signature in NHA9 transformed mouse LSKs resembles 
human NUP98-NSD1 leukemia
(A) GSEA with a differential expression analysis ranked list comparing RNA-seq data from ERT2-cre;Mll1f/f 
NHA9 cells at day 3 post tamoxifen (4-OHT) treatment (Mll1-/-) to ERT2-cre;Mll1f/f treated with vehicle 
control (Mll1f/f). Enrichment was assessed for genes that are either upregulated in mature hematopoietic 
populations (left) or in hematopoietic progenitors and stem cells (right) derived from mouse BM and fetal 
liver compartments.
(B) A gene set was created using the list of NHA9/MLL1 co-bound promoter targets from the ChIP-seq 
analysis using NHA9 in vitro transformed LSKs. GSEA was generated using the RNA-seq differential 
expression analysis comparing Mll1-/- to Mll1f/f NHA9 cells. 
(C) Bar graphs indicate log2 fold change in gene expression as measured by RNA-seq when comparing 
Mll1-/- to Mll1f/f NHA9 cells.
(D) NHA9 in vitro transformed ERT2-cre;Mll1f/f LSKs were plated in liquid culture following 48 hours of 
4-OHT or vehicle (ETOH) treatment. Cells were replated and harvested every 3 days. Bar graphs illustrate 
relative expression levels (RT-qPCR) as mean log fold change compared to vehicle control treated cells. 
The x-axis indicates cells harvested at various time-points post treatment. Data are representative of 
three individual experiments.
(E) A gene set was created using the NHA9/MLL1 co-bound promoter targets (left). Another Mll1-
dependent gene set was created using the list of significantly downregulated genes when comparing 
ERT2-cre;Mll1f/f cells at day 3 post 4-OHT (Mll1-/-) treatment to ERT2-cre;Mll1f/f treated with vehicle control 
(Mll1f/f) with LFC < -1 and adjusted p < 0.05 (right). Enrichment of these Mll1-dependent gene sets in 
previously published human gene expression microarray data from NHA9 versus AML1-ETO transfected 
human CD34+ cord blood cells (GSE57194) was assessed. 
(F) Same Mll1-dependent gene sets as in Figure 6E were used to assess enrichment in previously 
published human gene expression microarray data from pediatric de novo AML patients with a NUP98-
NSD1 translocation versus patients with an AML1-ETO rearrangement (GSE17855).
NES, normalized enrichment score; FDR, false discovery rate.
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Hoxa9 and Meis1 overexpression rescues NHA9 driven leukemia from Mll1 dependence
The significant downregulation of Hoxa9 and Meis1 in Mll1-/-NHA9 BM cells (Figure 6D) 
suggests an important role of Hoxa9 and Meis1 in NHA9 induced leukemia. To test whether 
the overexpression of Hoxa9/Meis1 can rescue NHA9 cells from their dependence on Mll1, 
NHA9 transduced ERT2-cre;Mll1f/f, ERT2-cre;Mll1f/+ and Mll1f/f BM cells were transduced with 
a Hoxa9/Meis1-expressing retrovirus and selected by hygromycin (Figure 7A). Following 
deletion of Mll1, cells were plated in methylcellulose for a CFU assay. Consistent with the 
prior results, deletion of Mll1 in NHA9 cells reduced the colony number compared to those of 
Mll1+/+NHA9 BM cells (Figure 7B). The overexpression of Hoxa9/Meis1 had no effect on the 
colony formation of Mll1-/-NHA9 cells in the first plating assay (Figure 7B), but restored the 
clonogenic capacity of Mll1-/-NHA9 cells in the second round of the replating assay (Figure 
7B). Strikingly, at the 1st and 2nd plating, more than 80% of the colonies formed in Hoxa9/
Meis1 overexpressed Mll1-/-NHA9 cells exhibited a typical dense, round blast colony shape 
(Figure 7C, 7D) and displayed blast morphology in Wright-Giemsa–stained cytospins (Figure 
7E). This is significantly different from the differentiation seen in Mll1-/-NHA9 cells (Figure 7C, 
p < 0.01). As a control, effective Mll1 excision was observed by PCR in 4-OHT treated cells 
(Figure 7F). These data show that upregulation of Hoxa9 and Meis1 by Mll1 in NHA9 cells 
contributes to the maintenance of NHA9 transformed cell proliferation in vitro. To further 
examine whether Hoxa9/Meis1 overexpression rescues the leukemogenicity of NHA9 cells 
from Mll1 dependence, NHA9 transformed ERT2-cre;Mll1f/f BM LSKs overexpressing Hoxa9 
and Meis1, were transplanted into lethally irradiated C57BL/6 mice (Figure 7A). After 4-OHT 
induced Mll1 deletion, mice transplanted with Mll1-/-NHA9 + Hoxa9/Meis1 cells displayed 
a significant increase in leukemia burden as measured by percentage of GFP+YFP+ cells 
in PB (Figure 7G), compared to the non-rescue Mll1-/-NHA9 control. In addition Mll1-/-
NHA9 + Hoxa9/Meis1 mice had a significantly shortened overall survival (Figure 7H). PCR 
analysis confirmed that both floxed Mll1 alleles were excised at time of death in the 4-OHT 
treated ERT2-cre;Mll1f/f NHA9 + Hoxa9/Meis1 mice (Figure 7I). These results illustrate that 
the upregulation of Hoxa9 and Meis1 by Mll1 contributes to NHA9 driven leukemia. The 
overexpression of Hoxa9 or Meis1 alone did not rescue the impaired clonogenic capacity of 
Mll1-/-NHA9 cells (data not shown), suggesting that the interplay between Hoxa9 and Meis1 
is required for NHA9 induced leukemia.
Gene expression analysis demonstrated the downregulation of Hoxb cluster genes 
in NHA9 cells upon Mll1 loss. To determine whether the Mll1 dependence in NHA9 is 
not only Hoxa, but also Hoxb gene reliant, analogous in vitro rescue experiments were 
performed using NHA9 transformed ERT2-cre;Mll1f/f cells. The overexpression of Hoxb6 alone 
or in combination with Meis1, could rescue the clonogenic defect of Mll1-/-NHA9 cells in a 
serial CFU replating assay (Figure S7A-B), and inhibited Mll1-loss induced differentiation 
(Figure S7C-D). Together these data provide strong evidence that NUP98 fusion proteins 
drive leukemogenesis, at least in part through dysregulation of both Hoxa and Hoxb gene 
expression by Mll1. 
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Figure 7. Hoxa9 and Meis1 overexpression rescues murine NHA9 driven leukemia from Mll1 
dependence
(A) Schematic for in vitro and in vivo Mll1 knockout rescue experiments.
(B) Day 7 of CFU assay of NHA9 in vitro transformed ERT2-cre;Mll1f/f, ERT2-cre;Mll1f/+ or Mll1+/+ LSKs, 
plated after 48 hours of tamoxifen (4-OHT) treatment. Samples stating “+rescue” were infected with 
virus containing Hoxa9 and Meis1 and selected by hygromycine treatment, prior to excision. Bar graphs 
display mean number of colonies per 35mm dish. 1000 cells were plated per dish. Day 7 of the 1st plating 
(left) and 2nd plating (right). Data are representative of three individual experiments.
(C) Shown is the mean percentage of blast versus non-blast colonies relative to all colonies counted per 
dish, per sample after the 1st plating.
(D) Representative images of colonies formed at day 7 of the 1st plating. 
(E) Representative images of Wright-Giemsa–stained cytospin preparations of cells harvested at day 7 
of the 1st plating.
(F) PCR analysis illustrates excision throughout the duration of a colony-forming experiment. 
Representative gel images are shown.
(G) ERT2-cre;Mll1f/f, ERT2-cre or Mll1f/f LSKs were retrovirally transduced with NHA9 and Meis1a or both 
Meis1a and Hoxa9 (“+rescue”). Cells were then sorted and injected into lethally irradiated C57Bl/6 mice. 
Mice were treated with 4-OHT at day 15 post transplant to excise Mll1. Plotted is the GFP+YFP+% of live 
cells in PB of mice before 4-OHT treatment and 14 days post treatment. A dot represents a single mouse 
in the experiment.
(H) Survival curve. Mice were treated with 4-OHT at day 15 after transplant.
(I) PCR analysis illustrates Mll1 excision in the murine BM of ERT2-cre;Mll1f/f + Hoxa9/Meis1 recipient mice 
at time of death. Representative gel images are shown.
* p < 0.05, ** p < 0.01. Error bars represent SD of mean.
a. Log-rank test p-value comparing survival for ERT2-cre;Mll1f/f to Mll1f/f 
b. Log-rank test p-value comparing survival for ERT2-cre;Mll1f/f to ERT2-cre;Mll1f/f + Hoxa9/Meis1
c. Log-rank test p-value comparing survival for ERT2-cre;Mll1f/f to non 4OHT-treated
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DISCUSSION
NUP98 fusion proteins are generated by the fusion of the NH3-terminus of NUP98 to the 
COOH-terminus of various proteins, some of which possess DNA or chromatin binding 
domains, and many of which are proteins of unknown function (Gough et al., 2011). These 
findings raise the question how NUP98 fusion proteins with such drastically different fusion 
partners drive leukemogenesis. We identified a novel interaction between NUP98 fusions and 
the NSL and MLL1 complexes, both of which contain histone-modifying enzymes. We show 
that a portion of the NH3-terminus of NUP98 with GLFG repeats, which is preserved in all 
NUP98 fusion proteins, interacts with the NSL/MLL1 complexes. In addition, we demonstrate 
that Mll1 is critical for the ability of NUP98 fusions to drive leukemogenic gene expression 
and maintain leukemogenic transformation. Of note, we found that the HOXA9 portion of the 
NHA9 protein or the HOXD13 portion of the NHD13 protein alone, do not interact with the 
NSL/MLL1 complexes (data not shown), providing further support for the NH3-terminus of 
NUP98 as the critical interaction site for NSL/MLL1. The intranuclear localization of NUP98 
fusion proteins and N-NUP98 indicates that this interaction occurs in the nuclear interior and 
away from the nuclear pores. The FG/GLFG repeats containing domains, but not the GLEBS 
domain, are required for the NUP98 fusion proteins to form punctated nuclear foci and 
interact with the NSL/MLL1 complexes, suggesting that the FG/GLFG repeats in the NUP98-
moiety may be involved in the binding to the NSL/MLL1 complexes. A study in Drosophila 
demonstrates a component of the NSL complex, MBD-R2, is required for the recruitment of 
Nup98 to chromatin (Pascual-Garcia et al., 2014). These data suggest that the association 
of NUP98 fusions with NSL/MLL1 complexes may be through the direct binding of the 
NUP98 fusion FG/GLFG repeats to PHF20 (the human homologue of Drosophila MBD-R2). 
However the specific site of FG/GLFG repeats mediating the binding with PHF20 remains to 
be determined. 
NUP98 fusion proteins with distinct fusion partners share common target genes, 
suggesting that the shared NUP98 moiety of these fusion proteins may contribute to the DNA 
binding properties of NUP98 fusions. The significant overlap in binding targets between 
N-NUP98 and NUP98 fusions further support this hypothesis. Since N-NUP98 does not 
contain any recognizable DNA-binding or chromatin-binding motif itself, the recruitment 
of N-NUP98 to these specific gene loci is likely due to the interaction between N-NUP98 
and other proteins or protein complexes with DNA or chromatin binding capacity, including 
the NSL/MLL1 complex. Our results suggest that this NUP98 moiety-mediated recruitment 
of NUP98 fusions to certain regions of the chromatin by the interaction with NSL/MLL1 
complexes may be a shared general pathogenic mechanism of NUP98 fusions in AML. This 
would help to explain how NUP98 fusions bind to Hox gene loci. As an example, HOXA9 
itself does not bind to Hox genes (Huang et al., 2012), but NHA9 does, suggesting that the 
recruitment of NHA9 to Hox gene loci is not via the homeobox domain of the HOXA9 protein 
retained in NHA9 fusion protein. 
The colocalization of NHA9 and MLL1 at Hox cluster gene loci, as revealed by ChIP-
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seq, not only supports the identified interaction between NHA9 and NSL/MLL1 complexes, 
but also indicates that NHA9 utilizes this interaction to be recruited to chromatin, at least 
to part of the NHA9 binding targets, including Hox gene loci. A recent publication showed 
chromatin-prebound CRM1 influences localization of the NHA9 fusion to induce expression 
of Hox cluster genes (Oka et al., 2015). However, CRM1 targets are generally associated with 
H3K27me3 repressive modifications, thus the mechanisms of CRM1 activity are unclear. Of 
note, this study was performed in murine embryonic stem (ES) cells, in which the chromatin 
modifications associated with HOX loci are quite different from those in other cell types. For 
example, in ES cells, HOX cluster genes are bivalent for both H3K4me3 and H3K27me3, a 
phenomenon that is not seen in hematopoietic stem cells. Therefore, these findings in ES 
cells need to be interpreted with the cellular context in mind. 
The colocalization of MLL1 and NHA9 at Hoxa and Hoxb gene promoters demonstrated 
here, and the direct regulation of Hox genes by Mll1 (Yu et al., 1995; Milne et al., 2002; 
Ayton et al., 2003; Hsieh et al., 2003; Ernst et al., 2004; Hess et al., 2004; Milne et al., 2005), 
prompted us to explore whether NUP98 fusions co-opt mechanisms used during normal 
development in order to drive leukemogenesis. In vitro and in vivo functional assays showed 
that Mll1 is crucial for the growth and block in differentiation of NHA9 transformed cells, 
and for the initiation and maintenance of NHA9 driven AML. Therefore, both growth and 
differentiation may represent mechanisms by which Mll1 influences NHA9 leukemogenesis. 
These findings were further supported by transcriptome analyses which show a significant 
enrichment of MLL1 and NHA9 co-bound targets among the genes downregulated in the 
absence of Mll1, and rescue experiments which show the overexpression of Hoxa9/Meis1 
restored the in vitro transformation defects and in vivo leukemogenicity of NHA9 Mll1 deficient 
cells. Together these results demonstrate that Mll1 controls NHA9 induced leukemogenesis 
by maintaining the expression of Hox genes and other stem cell associated genes to 
support the maintenance of leukemic cells. Furthermore, we have established the in vitro 
dependence on Mll1 for other NUP98 fusions such as NHD13, NUP98-JARID1A and NUP98-
TOP1, suggesting a more general role for Mll1 in NUP98-fusion driven leukemia. Previous 
studies show that NUP98-HOX fusions promote self-renewal and aberrant gene expression 
to a significantly greater extent than NUP98 fusions with non-homeobox partners (Saw et 
al., 2013), suggesting that the COOH-terminal fusion partner may influence the oncogenic 
potency of NUP98 fusions. Whether and how Mll1 differentially affects this aspect of NUP98 
fusions remains to be explored. 
The role of endogenous Mll1 in other AML subtypes, such as MLL1-fusion driven leukemia 
has previously been reported (Milne et al., 2010; Thiel et al., 2010), but the NUP98-fusion 
dependence on Mll1 appears to be even more absolute than for MLL-AF9. These data are 
of particular interest given the recent publication showing that the histone methyltransferase 
activity of MLL1 is dispensable for MLL-AF9 leukemogenesis (Mishra et al., 2014). Therefore 
our findings indicate a specific, and more dramatic requirement for MLL1 in NUP98-fusion 
driven leukemia. It is noteworthy that the NHA9 and MLL1 co-bound Hoxb gene targets, 
which play a critical role in hematopoietic stem cell self-renewal (Sauvageau et al., 1995; 
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Bijl et al., 2006), are not bound by MLL-AF9. The deletion of Mll1 in NHA9 cells resulted in 
significant downregulation of not only Hoxa, but also Hoxb cluster genes, including Hoxb5, 
Hoxb6, Hoxb7 and Hoxb8. However, the Hoxb cluster genes are not activated in MLL-AF9 
leukemia cells, and as expected, Mll1 deficient MLL-AF9 cells did not show any change 
in Hoxb gene expression (Cao et al., 2014). This differential Hox gene expression pattern 
between NHA9 and MLL-AF9 leukemia might explain part of the more dramatic dependency 
of NUP98 fusion leukemia on Mll1. The capability of Hoxb6 alone to rescue the clonogenic 
capacity of Mll1-/-NHA9 cells further supports the idea that this unique Hoxb gene expression 
pattern is dependent on Mll1 and functionally important for NUP98-fusion driven leukemia.
In this study, we focus our attention on the role of Mll1 in HOX gene regulation and 
leukemogenesis driven by NUP98 fusions. However, there is likely some contribution from 
the NSL complex components, such as MOF, to NUP98-fusion driven leukemia. The MOF-
containing NSL complex, an evolutionary conserved complex in Drosophila and mammals, is 
important for genome-wide H4K16 acetylation and associated with transcriptional activation 
(Prestel et al., 2010; Raja et al., 2010; Cai et al., 2010). MOF (MYST1), a member of the 
MYST (Moz-Ybf2/Sas3-Sas2-Tip60) family of histone acetyltransferases (HATs), is a global 
regulator of H4K16 acetylation in mammalian cells (Prestel et al., 2010; Raja et al., 2010; 
Cai et al., 2010). Human MOF has been shown to physically associate with MLL1 in a multi-
protein complex that catalyzes both histone acetylation and methylation (Dou et al., 2005). 
Indeed, we found enrichment of H4K16ac marks on NHA9 binding targets at promoters, 
suggesting the activation of these genes may in part be regulated by the HAT activity of MOF 
via its interaction with the NUP98 fusion. It will be interesting to further examine whether and 
how MOF affects the oncogenic program of NUP98-fusion driven leukemia. If so, targeting 
MOF may be used as a novel therapeutic approach. 
In conclusion, our findings support an emerging model that various fusion oncoproteins 
hijack histone modifying complexes to drive leukemogenic transformation. We demonstrate 
that NUP98 fusion proteins interact with the NSL/MLL1 complexes via its common 
NH3-terminus to drive its oncogenesis. The discovery of this common leukemogenic 
pathway for NUP98 fusion proteins, provides a rationale for the search of potential common 
therapeutic approaches in the treatment of leukemia patients carrying various NUP98 
rearrangements. The role of Mll1 in NUP98 fusion AML as established here, suggests that 
inhibition of the function of MLL1 or its interaction with menin, as recently proposed by others 
(Borkin et al., 2015), may be an effective treatment for patients with NUP98 fusion leukemia. 
Further studies will determine whether modulation of MOF HAT activity or interruption of the 
association between NUP98 fusions and the NSL/MLL1 complexes with small molecules 
would represent a novel approach in treating poor prognosis pediatric AMLs with NUP98 
fusions.
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EXPERIMENTAL PROCEDURES
Mice
The generation of the Mll1 conditional knockout mouse has been described previously 
(Jude et al., 2007). Mll1f/f mice were crossed to ERT2-cre mice to generate ERT2-cre; Mll1f/f 
mice; and ERT2-cre was maintained as a heterozygous allele. Genotyping strategies were 
described previously (Jude et al., 2007). Wild type C57BL/6 mice were purchased from 
Taconic, Hudson, NY. All animal experiments described in this study were approved by and 
adhered to the guidelines of the Memorial Sloan-Kettering Cancer Center Animal Care and 
Use Committee.
Plasmids and constructs
NUP98-HOXA9 and full-length NUP98 cDNAs with NH3-terminal HA tags in an MSCV-IRES-
GFP vector were provided by Dr. Nabeel R. Yaseen (Ghannam et al., 2004); NUP98-HOXD13 
cDNA by Dr. Peter Aplan, NUP98-PHF23 and NUP98-JARID1A in MSCV-IRES-puro by 
Dr. David Allis (Wang et al., 2009); and NUP98-TOP1 in MSCV-IRES-GFP and Meis1a in 
MSCV-IRES-YFP by Dr. Keith Humphries (Gurevich et al., 2004; Pineault et al., 2003). NH3-
terminal HA-tagged NUP98-HOXD13 and HA-tagged N-NUP98 (1-469 amino acids of the 
NH3-terminal NUP98) were constructed by PCR, checked by sequencing, and subcloned 
into the XhoI and EcoRI site of MSCV-IRES-GFP. NH3-terminal Flag-tagged WT NUP98 
and NUP98-HOXD13 were amplified by PCR and subcloned into the XhoI and EcoRI site 
of MSCV-IRES-GFP. C-terminal Flag-Avi-tagged NUP98-HOXA9, NUP98-HOXD13, NUP98-
TOP1 and N-NUP98 were constructed by PCR and subcloned into the HpaI site of the 
MSCV-IRES-puro plasmid. The MSCV-Hoxa9-Meis1-IRES-hygromycin, MSCV-Hoxa9-IRES-
puro, MSCV-BirA-YFP, MSCV-MLL-AF9-IRES-GFP and NUP98-NSD1 plasmid have been 
previously described (Bernt et al., 2011; Deshpande et al., 2014). The Hoxb6 plasmid was 
purchased from GE Dharmacon (CO, clone ID: 4223365) and subcloned into the HpaI site 
of an MSCV-IRES-miCD2 plasmid. The pCL-Eco plasmid was used for retroviral packaging. 
The COOH-terminal Flag-Avi-tagged NHA9 mutants NHA9-GLFG-1 del (deletion of the first 
GLFG domain, 2-156 residues), NHA9-GLEBS del (deletion of the GLEBS domain, 157-213 
residues), NHA9-GLFG-2 del (deletion of the second GLFG domain, 214-469 residues) and 
NHA9-(GLFG-1+2) del (deletion of both GLFG domains), were generated using the Q5® 
Site-Directed Mutagenesis Kit (New England BioLabs, Ipswich, MA). The mutant constructs 
were verified by sequencing. 
Cell culture
293T cells were cultured in DMEM, supplemented with heat inactivated 10% fetal bovine 
serum and 50 U/mL penicillin/streptomycin (all Thermo Fisher Scientific, Waltham, MA). In vitro 
transformed NUP98-HOXA9, NUP98-HOXD13, NUP98-JARID1A, NUP98-TOP1, MLL-AF9 or 
Hoxa9/Meis1 mouse LSKs were cultured in IMDM, supplemented with heat inactivated 10% 
fetal bovine serum, 50 U/mL penicillin/streptomycin (all Thermo Fisher Scientific, Waltham, 
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MA) and murine IL3 (10 ng/mL), IL6 (10 ng/mL) and SCF (20 ng/mL)(all PeproTech, Rocky 
Hill, NJ). Methylcellulose M3234 (Stemcell Technologies, Vancouver, BC, Canada).
Isolation of murine LSKs for in vitro transformation
WT, Mll1f/f ERT2-Cre, Mll1f/+ ERT2-Cre and Mll1f/f mice were sacrificed, and BM cell suspensions 
were prepared by crushing bones in a mortar after removal of muscle and connective 
tissues. Lineage depletion was performed by labeling BM cells with purified, biotinylated 
monoclonal antibodies to CD3e, CD11b (MAC1), CD45R (B220), Ly6G (GR1) and TER119 
(Biotin mouse lineage panel, BD, San Jose, CA). Lin+ cells were in majority removed by 
magnetic bead depletion with streptavidin conjugated MicroBeads over an LD column (both 
Miltenyi Biotech, San Diego, CA). LSKs were then obtained by staining lineage depleted 
(Lin-) cells with Streptavidin APC/Cy7, (Biolegend, San Diego, CA), CD117 (cKIT) APC and 
Ly6A/E (SCA1) PE/Cy7 (both eBioscience, San Diego, CA), and sorting the LSK population.
Data Analysis and Statistical Methods
Microsoft Excel and GraphPad Prism software were used for statistical analysis. Statistical 
significance between 2 groups was determined by unpaired 2-tailed Student’s t-test. The 
Kaplan-Meier method was used to plot survival curves for murine leukemic transplant data, 
and the log-rank test was used to evaluate statistical differences. The hypergeometric test 
was performed in R to calculate the statistical significance of overlapped targets. A p-value 
less than 0.05 was considered significant.
RNA-seq raw reads were aligned to NCBI37/mm9 and normalized using STAR. 
Differential expression data were obtained using the DEseq algorithm. These analyses were 
done through the platform from Basepair (New York City, NY). DEseq output tables are 
attached as supplemental tables. Gene set enrichment analyses (GSEAs) were performed 
using the Broad Institute web platform by pre-ranking the RNA-seq list based on log2 fold 
change. The NUP98-NSD1 and AML1-ETO pediatric AML gene expression data were 
obtained from the GEO GSE17855 dataset (Hollink et al., 2011). The NUP98-HOXA9 and 
AML1-ETO human cord blood gene expression data were obtained from the GEO GSE57194 
dataset (Abdul-Nabi et al., 2010).
The ChIP-seq analysis was performed using pipelines on Basepair software (http://
www.basepair.io). The fastq files were trimmed to remove adapter and low quality 
sequences using trim_galore and then aligned to the UCSC genome assembly mm9 using 
Bowtie (version 2.1.0) (Langmead et al., 2010). Duplicate reads were removed using Picard 
MarkDuplicates. To detect peaks, the software MACS (version 1.4) (Zhang et al., 2008) was 
applied using default parameters unless otherwise stated. For NUP98-HOXA9, NUP98-
HOXD13, H3K4me3 and H4K16ac peak detection, the p-value cutoff was set to 10-5, for 
MLL1 peak calling the p-value cutoff was set to 10-3. Peaks were annotated to genomic 
features (Promoter, Gene body, Intergenic) using custom scripts at Basepair, based on the 
UCSC database for mm9. The integrative analysis of histone modification levels and gene 
expression was performed using iCanPlot (http://www.icanplot.org) (Sinha et al., 2010).
Thesis_DG.Valerio_v3_homecomputer.indb   89 10/17/16   12:07 AM
90 Chapter 3
ACCESSION NUMBERS
RNA-seq and ChIP-seq data have been deposited at the NCBI Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov.ezp-prod1.hul.harvard.edu/geo/) with accession codes 
GSE75997 (Expression changes after loss of Mll1 in murine NHA9 transformed cells), 
GSE76001 (NUP98-HOXA9, NUP98-HOXD13, MLL1, H3K4me3 and H4K16ac ChIP-seq 
data), GSE83221 (MLL1 ChIP-seq data with Hsieh lab antibody MO435, NUP98-TOP1 and 
N-NUP98 ChIP-seq data).
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Figure S1, related to Figure 2. NHA9 and NHD13 interact with MLL1 and the NSL histone-modifying 
complex in U937 cells
(A) U937 cells were retrovirally transduced with an MSCV-IRES-BirA-YFP retrovirus, and YFP+ cells were 
sorted by FACS, 48 hours post-transduction (top plot). These sorted cells were then transduced with 
Flag-Avi-tagged NHA9 or NHD13 in an MSCV-IRES-GFP vector and GFP+YFP+ cells were sorted (middle 
and lower plot). 
(B) Whole cell lysates were prepared from U937 cells with stable expression of the Flag-Avi-tagged 
NHA9 or NHD13 and BirA biotin ligase and subjected to IP using streptavidin magnetic beads. Cell 
lysates (Input) and proteins eluted from the streptavidin beads (IP) were separated by SDS–PAGE and 
analyzed by Western blotting with anti-Flag, anti-MOF, anti-PHF20, anti-OGT1, anti-HCF1, anti-WDR5, 
anti-MLL1n, anti-CXXC1 and anti-beta Tubulin antibodies. 
Thesis_DG.Valerio_v3_homecomputer.indb   99 10/17/16   12:07 AM
100 Chapter 3
A B
Y
FP
 (B
irA
)
GFP (NUP98-fusions and N-NUP98)
NHA9 NHD13
C
0
2
4
6
8
10
12
14
16
E
nr
ic
hm
en
t r
el
at
iv
e 
to
ge
no
m
ic
 b
ac
kg
ro
un
d 
(fo
ld
 c
ha
ng
e)
Promoter Gene body Intergenic
NUP98-HOXA9
NUP98-HOXD13
9.6
15.3
0.9 0.90.9 0.8
0 102 103 104 105
0
102
103
104
105
2.75 93.7
3.330.267
0 102 103 104 105
0
102
103
104
105
0 0
86.713.3
0 102 103 104 105
0
102
103
104
105
3.97e-3 0.0417
98.41.55
0 102 103 104 105
0
102
103
104
105
0.0106 0.0466
96.23.72
0 102 103 104 105
0
102
103
104
105
1.32 94.4
3.191.09
0 102 103 104 105
0
102
103
104
105
0.248 96.9
1.471.41
0 102 103 104 105
0
102
103
104
105
4.06e-3 0.14
98.41.45
0 102 103 104 105
0
102
103
104
105
1.75 97.3
0.8430.116
NUP98-TOP1 N-NUP98
NHA9
+ BirA
NHD13
+ BirA
NUP98-TOP1
+ BirA
N-NUP98
+ BirA
100 μm 100 μm 100 μm
100 μm 100 μm 100 μm
NHA9 NHD13 NUP98-TOP1
NHA9
+ BirA
NHD13
+ BirA
NUP98-TOP1
+ BirA
E
G
D
4000
3500
3000
2500
2000
1500
1000
500
0
Prom
oter
Gen
e bo
dy
Inter
geni
c
833
1588
3476
N
um
be
r o
f t
ar
ge
ts
 (N
U
P
98
-T
O
P
1)
Gene body Intergenic
p=1.27e-269
650 183 8
p=0 p=0
Promoter
1017 571 28 2409 1067 62
NUP98-TOP1
NUP98-HOX
H
NUP98-TOP1
NUP98-TOP1+ Bira
Ac
tb
0.5
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
**
*
*
*
So
x1
7
Ho
xa
7
Ho
xa
9
Ho
xb
5
Ev
i1
Me
is1
NUP98-HOXA9
NUP98-HOXA9+ Bira
0.5
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
*
**
*
*
Ac
tb
So
x1
7
Ho
xa
7
Ho
xa
9
Ho
xb
5
Ev
i1
Me
is1
F
800
700
600
500
400
300
200
100
0
227
343
726
N
um
be
r o
f t
ar
ge
ts
 (N
-N
U
P
98
)
Prom
oter
Gen
e bo
dy
Inter
geni
c
Thesis_DG.Valerio_v3_homecomputer.indb   100 10/17/16   12:07 AM
101MLL1 in NUP98 Fusion Leukemia
C
H
A
PT
ER
 3
Hoxa3 Hoxa7 Hoxa9
757
I J
N-NUP98
NUP98-fusions
Gene body Intergenic
p=1.69e-93 p=2.34e-302 p=1.33e-239
Promoter
160 67 116 117 226 345 416 310
N-NUP98
N-NUP98 + Bira
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
*
* *
*
*
Ac
tb
So
x1
7
Ho
xa
7
Ho
xa
9
Ho
xb
5
Ev
i1
Me
is1
K
NHA9
MLL1
H3K4me3
H4K16ac
Meis1
Meis1
Pbx3
Pbx3
Hoxb
Hoxb5 Hoxb4
Hoxa
Hoxa3 Hoxa7 Hoxa9
L
NHD13
NHA9
N-NUP98
NUP98-TOP1
Hoxa
Hoxb5 Hoxb4
Hoxb
Meis1
Meis1
NHA9
MLL1
H3K4me3
H4K16ac
Figure S2, related to Figure 3 and 4. NHA9, NHD13, NUP98-TOP1, N-NUP98 and MLL1 ChIP and 
ChIP-seq
(A) Purified mouse BM LSKs were retrovirally transduced with Flag-Avi-tagged NHA9, NHD13, 
NUP98-TOP1 or N-NUP98 in an MSCV-IRES-GFP vector, and GFP+ cells were sorted by FACS, 48 hours 
post transduction. FACS sorting strategy is shown in the top plots. The sorted cells were then transduced 
with an MSCV-IRES-YFP retrovirus and GFP+YFP+ cells were sorted (lower two plots). 
(B) Representative images of colonies formed at day 7 of CFU assay of NHA9, NHD13 and NUP98-TOP1 
immortalized mouse LSKs with or without BirA expression.
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(C) The percentage of promoters, gene bodies, and intergenic sites bound by the fusion proteins was 
compared to the background distribution for all such sites, based on genome annotations compiled from 
RefSeq for mm9.
(D) Biotin-mediated chromatin affinity purification coupled with high throughput sequencing experiments 
(ChIP-seq) were performed using NUP98-TOP1 Flag-Avi-tagged immortalized mouse BM LSKs. Bar 
graph indicates the number of NUP98-TOP1-bound targets at promoter, gene body or intergenic 
regions.
(E, F, I) ChIP-seq experiments were performed using mouse BM cells by enforced expression of NHA9, 
NUP98-TOP1 or N-NUP98 through retroviral transduction of LSKs with vectors carrying Flag-Avi-tagged 
NHA9, NUP98-TOP1 or N-NUP98, and BirA ligase. Enrichment of the indicated NUP98 fusion at specific 
gene loci by RT-qPCR is shown (n=3 independent experiments).
(G) The Venn diagrams illustrate overlap in NUP98-TOP1 targets and common NUP98-HOX fusion 
targets with a p-value calculated using the hypergeometric test. 
(H) ChIP-seq experiment using N-NUP98 Flag-Avi-tagged immortalized mouse BM LSKs. Bar graph 
indicates the number of N-NUP98-bound targets at promoter, gene body or intergenic regions.
(J) The Venn diagrams illustrate overlap in N-NUP98 targets and common NUP98 fusion targets with a 
p-value calculated using the hypergeometric test. 
(K) Genome browser tracks representing the shared binding sites of NHA9 , NHD13 , NUP98-TOP1 and 
N-NUP98 at Hoxa loci (left), Hoxb loci (middle) and the Meis1 locus (right). 
(L) Genome browser tracks of genomic regions showing colocalization of NHA9, MLL1, H3K4me3 and 
H4K16ac at four representative MLL1 targets; Hoxa genes (left), Hoxb genes (middle left), Pbx3 (middle 
right) and Meis1 (right). An anti-N terminus MLL antibody (MO435) was used to perform this ChIP-seq 
experiment. 
* p < 0.05. Error bars represent SE of mean.
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Figure S3, related to Figure 5. Mll1 loss in a murine NHA9 driven leukemia model leads to 
differentiation, decrease in tumor load and prolonged survival
(A) NHA9 in vitro transformed ERT2-cre;Mll1f/f, ERT2-cre;Mll1f/+ or wild type (Mll1+/+) LSKs were plated in 
methylcellulose after 48 hours of 4-OHT treatment. PCR analysis illustrates Mll1 excision throughout the 
duration of the 7-day colony forming experiment. Representative gel images are shown.
(B) NHA9 in vitro transformed ERT2-cre;Mll1f/f, ERT2-cre;Mll1f/+ or Mll1+/+ LSKs were plated in liquid culture 
after 48 hours of 4-OHT treatment. Cells were replated and harvested every 3 days. The graph 
illustrates total number of viable cells over time, extrapolated from the number of cells plated and the 
number of cells in culture at replating. Cell growth between day 0 and day 3 has been excluded from 
the calculation, since unspecific death due to Cre expression and 4-OHT treatment skews the data. 
Asterisks represent the p-value of a t-test comparing Mll1-/- to either Mll1+/+ (dark blue) or Mll1+/- 
(turquoise). Data are representative of three individual experiments.
(C) Flow cytometry plots illustrate the sort strategy for ERT2-cre;Mll1f/f, ERT2-cre;Mll1f/+ or Mll1f/f LSKs 
retrovirally transduced with GFP-NUP98-HOXA9 and YFP-Meis1a. Double positive (GFP+YFP+) cells 
were sorted and used for in vivo experiments.
(D) The spleen weight of AML mice at time of death. A dot represents a single mouse.
(E) The percentage of GFP+YFP+ cells in PB of primary mice transplanted with ERT2-cre;Mll1f/f, 
ERT2-cre;Mll1f/+ or Mll1f/f NHA9-Meis1a cells at time of death. A dot represents a single mouse.
(F) Representative flow cytometry plots illustrate the expression of myeloid markers (Mac-1 and Gr-1) 
on GFP+YFP+ mouse BM, spleen and PB cells at time mice succumbed to AML.
(G) PCR analysis illustrates Mll1 excision in murine BM at time of death. Representative images shown.
** p < 0.01, *** p < 0.001. Error bars represent SD of mean.
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Figure S4, related to Figure 5. Mll1 loss leads to differentiation, impaired colony formation and 
downregulation of target genes in various NUP98-fusion driven leukemia models
(A) Day 7 of the 1st plating (left) and 2nd plating (right) of a CFU assay of NHD13 in vitro transformed 
ERT2-cre;Mll1f/f, ERT2-cre;Mll1f/+ or wild type (Mll1+/+) LSKs, plated after 48 hours of tamoxifen (4-OHT) 
treatment. Bar graphs display mean number of colonies per 35mm dish. 1500 cells were plated per 
dish. Data are representative of two individual experiments.
(B) Shown is the mean percentage of blast versus non-blast colonies relative to all colonies counted per 
dish, per sample, after the 1st plating.
(C) Representative images of colonies formed at day 7 of the 1st plating. 
(D) Representative images of Wright-Giemsa–stained cytospin preparations of cells harvested at day 7 
of the 1st plating.
(E) Day 7 of the 1st plating (left) and 2nd plating (right) of a CFU assay of NUP98-JARID1A in vitro 
transformed ERT2-cre;Mll1f/f, ERT2-cre;Mll1f/+ or Mll1+/+ LSKs, plated after 48 hours of 4-OHT treatment. 
Bar graphs display mean number of colonies per 35mm dish. 3000 cells were plated per dish. Data are 
representative of two individual experiments.
(F) Shown is the mean percentage of blast versus non-blast colonies relative to all colonies counted per 
dish, per sample, after the 1st plating.
(G) Representative images of colonies formed at day 7 of the 1st plating. 
(H) Representative images of Wright-Giemsa–stained cytospin preparations of cells harvested at day 7 
of the 1st plating.
(I) Day 7 of the 1st plating (left) and 2nd plating (right) of a CFU assay of NUP98-TOP1 in vitro transformed 
ERT2-cre;Mll1f/f or Mll1+/+ LSKs, plated after 48 hours of 4-OHT or vehicle control (ETOH) treatment. Bar 
graphs display mean number of colonies per 35mm dish. 1500 cells were plated per dish. Data are 
representative of two individual experiments.
(J) Shown is the mean percentage of blast versus non-blast colonies relative to all colonies counted per 
dish, per sample, after the 1st plating.
(K) Representative images of colonies formed at day 7 of the 1st plating. 
(L) Representative images of Wright-Giemsa–stained cytospin preparations of cells harvested at day 7 
of the 1st plating.
** p < 0.01. Error bars represent SD of mean.
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Figure S5, related to Figure 5. Deletion of Mll1 in MLL-AF9 or Hoxa9/Meis1 transformed LSKs does 
not affect proliferation, colony forming potential or in vivo leukemogenesis
(A) Day 7 of CFU assay of MLL-AF9 in vitro transformed ERT2-cre;Mll1f/f or wild type (Mll1+/+) LSKs plated 
after 48 hours of tamoxifen (4-OHT) treatment. Representative petri dishes are shown. 
(B) Bar graph indicates mean number of colonies per 35mm dish after 7 days. 1000 cells were plated 
per dish. Data are representative of two individual experiments.
(C) Shown is the mean percentage of blast versus non-blast colonies relative to all colonies counted per 
dish, per cell type.
(D) Colonies at day 7 of CFU assay. Representative images are shown.
(E) MLL-AF9 in vitro transformed ERT2-cre;Mll1f/f or Mll1+/+ LSKs were plated in liquid culture after 48 
hours of 4-OHT treatment. Cells were replated and harvested every 3 to 4 days. The graph illustrates 
total number of viable cells over time, extrapolated from the number of cells plated and the number of 
cells in culture at replating. Cell growth between day 0 and 3 has been excluded from the calculation, 
since unspecific death due to 4-OHT treatment skews the data. Data are representative of two individual 
experiments.
(F) PCR analysis illustrates Mll1 excision throughout the duration of a 7-day colony forming experiment. 
Representative gel images are shown.
(G) Bar graphs illustrate relative expression levels (RT-qPCR) as mean log fold change compared to 
4-OHT treated Mll1+/+ cells.
Error bars represent SD of mean.
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Figure S5, continued
(H) Day 7 of CFU assay of Hoxa9/Meis1 in vitro transformed ERT2-cre;Mll1f/f, ERT2-cre or Mll1f/f  LSKs 
plated after 48 hours of 4-OHT treatment. Representative petri dishes are shown. 
(I) Bar graph indicates mean number of colonies per 35mm dish after 7 days. 500 cells were plated per 
dish. Data are representative of two individual experiments.
(J) Shown is the mean percentage of blast versus non-blast colonies relative to all colonies counted per 
dish, per cell type.
(K) Colonies at day 7 of CFU assay. Representative images are shown.
(L) PCR analysis illustrates Mll1 excision throughout the duration of the colony forming experiment. 
Representative gel images are shown.
(M) ERT2-cre;Mll1f/f, ERT2-cre or Mll1f/f LSKs were retrovirally transduced with Hygro-Hoxa9/Meis1, 
selected and injected into lethally irradiated C57Bl/6 mice (n=6 per group). Mice were treated with 
4-OHT at day 11 post transplant to excise Mll1. The survival curve is shown. Data are representative of 
two individual experiments.
(N) PCR analysis illustrates Mll1 excision in murine BM at time of death. Representative gel images are 
shown.
Error bars represent SD of mean.
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Figure S6, related to Figure 6. Mll1 regulates Hoxa and Hoxb expression in NHA9 transformed 
murine LSKs
(A) NHA9 in vitro transformed ERT2-cre;Mll1f/f LSKs were plated in liquid culture following 48 hours of 
tamoxifen (4-OHT) or vehicle (ETOH) treatment. Cells were replated and harvested every 3 days. Bar 
graphs illustrate relative expression levels (RT-qPCR) as mean log fold change compared to vehicle 
control treated cells. The x-axis indicates cells harvested at various time-points post treatment. Data are 
representative of three individual experiments.
(B) NHD13 in vitro transformed ERT2-cre;Mll1f/f LSKs were plated in methylcellulose following 48 hours of 
4-OHT or vehicle treatment. Cells were replated and harvested after 7 days. Bar graphs illustrate relative 
expression levels (RT-qPCR) as mean log fold change compared to vehicle control treated cells. The 
x-axis indicates cells harvested at various time-points post treatment.
(C) Bar graphs illustrate relative expression levels as mean log fold change compared to vehicle control 
treated NUP98-JARID1A transformed cells.
* p < 0.05, ** p < 0.01. Error bars represent SD of mean.
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Figure S7, related to Figure 7. Hoxb6 overexpression rescues NHA9 transformed cells from Mll1 
dependence
(A) Day 7 of the 1st plating (left) and 2nd plating (right) of a CFU assay with NHA9 in vitro transformed 
ERT2-cre;Mll1f/f, ERT2-cre;Mll1f/+ or wild type (Mll1+/+) LSKs, plated after 48 hours of tamoxifen (4-OHT) 
treatment. Samples stating “+rescue” were transduced with Hoxb6 and sorted prior to excision. Bar 
graphs display mean number of colonies per 35mm dish. 1000 cells were plated per dish. Data are 
representative of two individual experiments.
(B) Samples stating “+rescue” were transduced with Hoxb6 and Meis1 and sorted prior to excision. Bar 
graphs display mean number of colonies per 35mm dish at day 7 of the 1st plating (left) and 2nd plating 
(right) of a CFU assay. 1000 cells were plated per dish. Data are representative of two individual     
experiments.
(C) Representative images of colonies formed at day 7 of the 1st plating.
(D) Representative images of Wright-Giemsa–stained cytospin preparations of cells harvested at day 7 
of the 1st plating.
** p < 0.01. Error bars represent SD of mean.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Indirect immunofluorescence
293T cells were seeded in 12-well plates and subsequently transfected with the HA-tagged 
NUP98, NUP98-HOXA9, and N-NUP98 MSCV-IRES-GFP vectors. After 24 hours, cells were 
washed with PBS, fixed with 4% paraformaldehyde, and permeabilized with PBS–0.2% Triton 
X-100 for 5 minutes at room temperature. Fixed cells were blocked with 2% bovine serum 
albumin (Sigma, St. Louis, MO) in PBS at room temperature for 1 hour, then incubated with 
either anti-HA antibody (HA.11, Covance, Dedham, MA) and anti-NUP214 antibody (Abcam, 
Cambridge, MA) or anti-Flag M2 antibody (F1804, Sigma, St. Louis, MO) and anti-NUP214 
antibody (Abcam, Cambridge, MA) overnight at 4°C, followed by a 50-minute incubation 
with Alexa Fluor 568-conjugated donkey anti-mouse secondary antibody and Alexa Fluor 
488-conjugated goat anti-rabbit secondary antibody. Coverslips were then mounted with 
ProLong Diamond Antifade Mountant with DAPI mounting medium (P36962, Thermo Fisher 
Scientific, Waltham, MA), and images were captured using a laser confocal microscope 
(Leica TCS SP5-II, Leica Microsystems CMS GmbH, Mannheim, Germany).
Co-immunoprecipitation (Co-IP) and Western blotting 
To generate cell lines with stable expression of BirA and NUP98 fusions, 293T or U937 cells 
were infected with BirA IRES-YFP virus, and sorted for YFP positive cells 48 hours after 
infection. YFP positive 293T or U937 cells were then transfected with C-terminal Flag-Avi-
tagged NUP98-HOXA9, NUP98-HOXD13, or N-NUP98 MSCV-puro vectors and selected in 
liquid culture with puromycin (Sigma, St. Louis, MO) 2.5 ug/mL for 7 days. Single YFP+ cells 
were sorted into 96 well plates (one YFP+ cell/well), and maintained in culture with 2.5 ug/mL 
puromycin for 2 weeks. The cells with high expression of the NUP98 fusions, as identified by 
Western, were used for IP experiments. 
293T cells with stable expression of NUP98 fusions or 293T cells 48 hours post transient 
transfection with NUP98 and NUP98 fusion vectors were lysed in 1X cell lysis buffer (20 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium 
pyrophosphate, 1 mM β-glycerophosphate, 1 mM Na3VO4, 1 µg/ml leupeptin) (#9803, Cell 
Signaling, Danvers, MA). Dynabeads M-280 Streptavidin (11205D, Thermo Fisher Scientific, 
Waltham, MA) or anti-Flag M2 Affinity Gel (A2220, Sigma-Aldrich, St. Louis, MO) were added 
into the lysates and samples were incubated overnight at 4°C. Next, protein complexes were 
washed 5 times with 1 mL lysis buffer. After the final wash, 2X SDS sample was added, and 
the beads were heated to 100°C for 5 minutes and analyzed by SDS-PAGE. 
Western blotting was done following standard procedures using a 4-12% Bis-Tris 
Gel (Nupage, Invitrogen, Carlsbad, CA, USA) and transferred onto PVDF membranes. For 
assessment of HA-tagged or Flag-tagged proteins by Western blot, the anti-HA antibody 
(HA.11, Covance, Dedham, MA) or anti-Flag M2 antibody (F1804, Sigma, St. Louis, MO) 
was used. For detecting NSL/MLL1 complex components the following antibodies were 
used: anti-PHF20 (ab157192), anti-HCF1 (ab137618), anti-WDR5 (ab178410), anti-beta 
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Tubulin (TUBB) (ab6046) and anti-CXXC1 (ab56035) from Abcam (Cambridge, MA); anti-
MOF (A300-993A) and anti-MLL1n (A300-086A) from Bethyl Labs (Montgomery, TX); anti-
OGT1(MBS274885) from MyBioSource (San Diego, CA ); and anti-EZH2 antibody (07-689) 
from EMD Millipore (Billerica, MA). The sheep anti-mouse IgG (NA931V) or the anti-rabbit 
IgG (NA934V) ECL horseradish peroxidase linked whole antibody from GE healthcare (Little 
Chalfont Buckinghamshire, UK) was used as the secondary antibody.
In vitro experiments with murine NUP98 fusion, MLL-AF9 or Hoxa9/Meis1 cells
For studying the impact of Mll1 deletion on LSKs transformed by NUP98 fusions, Hoxa9/
Meis1 or MLL-AF9, LSKs were retrovirally transduced with MSCV-NUP98-HOXA9-IRES-
GFP, MSCV-NUP98-HOXD13-IRES-GFP, MSCV-NUP98-TOP1-IRES-GFP, MSCV-NUP98-
JARID1A-IRES-puro, MSCV-Hoxa9-Meis1-IRES-hygro or MSCV-MLL-AF9-IRES-GFP, sorted 
for GFP or selected with hygromycin (Calbiochem, San Diego, CA) or puromycin (Sigma, 
St. Louis, MO), and grown out for several weeks to obtain highly proliferative transformed 
cultures. Subsequently, cells were treated with 300nM tamoxifen (4-OHT, Sigma-Aldrich, 
Carlsbad, CA) for 48 hours and then either plated in methylcellulose for colony-forming 
assays or in supplemented IMDM for liquid culture. Colonies were scored every 7 days using 
the Eclipse TS100 inverted microscope (Nikon, Tokyo, Japan). Since almost all colonies 
were either compact and hypercellular (blast-like) or small and diffuse (consistent with 
differentiation), colonies were classified into these two categories. Cells from pooled colony 
aggregates were then assessed for Mll1 excision, used for cytospins, and replated to test 
replating capacity. For liquid proliferation assays, cells were plated in triplicate in a 96-well 
flat bottom non-treated cell culture plate (Falcon, Corning Life Sciences, Corning, NY). Cells 
were counted every 3 or 4 days on a FACS CANTOII (BD) with DAPI viability stain (Thermo 
Fisher Scientific, Waltham, MA). Cells were then harvested for gene expression assays and 
replated up and till 15 days after 4-OHT treatments.
For the Hoxa9, Hoxb6 and Meis1 rescue experiments, NUP98-HOXA9 in vitro 
transformed cells were infected with retrovirus containing MSCV-Hoxa9-Meis1-IRES-
hygromycin, MSCV-Hoxa9-IRES-miCD2, MSCV-Hoxb6-IRES-miCD2 and/or MSCV-Meis1-
IRES-YFP. Cells were selected in liquid culture with hygromycin (Calbiochem, San Diego, 
CA) 50ug/mL for 10 days or sorted for hCD2 positivity. Effects of Mll1 excision were assessed 
as described above.
In vivo experiments
For primary NHA9 AML experiments, Mll1f/f ERT2-cre, Mll1f/+ ERT2-cre, ERT2-cre and Mll1f/f mouse 
LSKs were harvested and infected with MSCV-NUP98-HOXA9-IRES-GFP. After 2 weeks of 
cell culture, cells were infected with MSCV-Meis1a-IRES-YFP and sorted for GFP/YFP double 
positive cells after 4 days. In case of the Hoxa9/Meis1 in vivo rescue experiment, cells were 
also infected with MSCV-Hoxa9-IRES-miCD2 and sorted. Cells were cultured for a total 
of 3-4 weeks before injection of 1,250,000-2,300,000 GFP+YFP+ cells with 200,000 helper 
cells into lethally irradiated (2 x 500 cGy), 6-8 week old C57BL/6 female recipients. Mice 
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were euthanized at time of clinical symptoms of disease, coincided by leukocytosis. At time 
of death, bone marrow, spleen and peripheral blood were assessed for GFP and various 
immunophenotypic markers by flow cytometry on a FACS CANTOII (BD, San Jose, CA). Cell 
surface marks used were: CD117 APC/Cy7 (cKIT), Ly-6G PE (GR1), CD3e pacific blue (all 
Biolegend, San Diego, CA), CD45R PE/Cy7 (B220), Ly6A/E PE/Cy7 (SCA1), CD11b APC 
(MAC1) (all eBioscience, San Diego, CA). For primary Mll1 excision experiments, mice were 
treated by oral gavage with 1 dose of 8mg 4-OHT (Toronto Research Chemicals, Toronto, 
Canada) dissolved in corn oil (Sigma-Aldrich, Carlsbad, CA). 
For secondary transplant experiments, viable frozen bone marrow cells from primary 
leukemic, untreated mice were thawed and 10,000 cells injected into sub-lethally irradiated 
(1 x 500 cGy) 7-week-old C57BL/6 female recipients. Mice were treated by oral gavage with 
1 dose of 8mg 4-OHT dissolved in corn oil, 7 days post transplant.
For primary Hoxa9/Meis1 AML experiments, Mll1f/f ERT2-cre, ERT2-cre and Mll1f/f mouse 
Lin-/cKIT+ BM cells were harvested, infected with MSCV-Hoxa9-Meis1-IRES-hygro and 
selected with hygromycine as described. After 2 weeks of culture, 2,000,000 cells were 
injected into sub-lethally irradiated (1 x 600 cGy), 7-week-old C57BL/6 female recipients. 
Mice were treated by oral gavage with 1 dose of 8mg 4-OHT dissolved in corn oil, 15 days 
post transplant.
Cytospins and microscopic imaging
Cytospins were generated by spinning 50,000-100,000 cells onto glass slides (500 rpm for 
10 minutes) using the Shandon Cytospin 4 cytofuge (Thermo Fisher Scientific, Waltham, MA). 
Colony-forming assay dishes were imaged with the Gelcount (Oxford Optronix, Oxfordshire, 
UK). Pictures of individual colonies were taken using the Nikon Eclipse TE2000-E and 
pictures of Wright-Giemsa stained cytospin preparations were made using the Nikon Eclipse 
E800 microscope (both Nikon, Tokyo, Japan).
RNA extraction, real-time PCR and RNA sequencing 
Trizol (Invitrogen, Carlsbad, CA) was used to extract RNA from viable cells. After this step, 
inventoried taqman gene expression assays (Invitrogen, Carlsbad, CA) were used for real-time 
quantitative PCR. Assays used were: Meis1 (Mm00487664_m1), Hoxb5 (Mm00439368_m1), 
Hoxb6 (Mm00433970_m1), Hoxb7 (Mm00650702_m1), Hoxb8 (Mm00439368_m1) and 
Hoxa10 (Mm00433966_m1). For Hoxa9, SYBR Green primers were designed in the 5’-end 
of the gene to avoid picking up HOXA9 expression from the NUP98-HOXA9 fusion. Primers 
were 5’-TGGCATTAAACCTGAACCGC-3’ and 5’-GGACAAAGTGTGAGTGTCAAGC-3’. For 
Mll1, a custom-made taqman assay was used as described by Jude et al. (Jude et al., 2007). 
PCR master mixes were used (SYBR Green and Taqman, both Applied Biosystems, Grand 
Island, NY) and real-time PCR was performed on the ViiA 6 Real-Time PCR System (Applied 
Biosystems, Grand Island, NY). Further assay details can be provided on request. 
RNA for RNA sequencing was QCed on the Agilent Bioanalyzer 2100 platform (Agilent, 
Santa Clara, CA) and Poly-A tail selection was performed. Sequencing was done using the 
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Illumina Next-Gen Sequencing HiSeq platform (Illumina, San Diego, CA) with 30-45 million 
50bp, paired-end reads. 
Chromatin immunoprecipitation (ChIP-qPCR and ChIP-seq)
For ChIP of NUP98-HOXA9, NUP98-HOXD13, NUP98-TOP1 and N-NUP98, C-terminal Flag-
Avi-tagged NUP98-HOXA9, NUP98-HOXD13, NUP98-TOP1 or N-NUP98 were cloned into 
the MSCV-IRES-GFP retroviral vector. Ecotropic retrovirus was produced as described 
above. Retroviruses containing BirA were produced similarly using an MSCV-based vector 
with an YFP selection cassette. WT BM LSKs were isolated and co-transduced with both 
retroviruses as described above. After transduction for 2 to 4 days, GFP+YFP+ cells were 
sorted and maintained in liquid culture.
ChIP was performed similarly as described (Krivtsov et al., 2008). Briefly, cells were 
fixed in PBS 1% formalin (v/v) with gentle rotation for 10 minutes at room temperature. Fixation 
was stopped by the addition of glycine (125 mM final concentration). Fixed cells were 
washed twice in ice-cold PBS, resuspended in SDS lysis buffer (1% SDS, 10mM EDTA, 50 
mM Tris-HCl, pH 8.1). Chromatin was sheared by sonication to about 100-500bp fragments 
using bioruptor (diagenode, Denville, NJ) and diluted ten fold with dilution buffer (0.01% 
SDS, 1.1% Triton-X100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.1,167 mM NaCl). Antibodies 
against specific histone modifications, MLL1n (A300-086A, Bethyl Labs, Montgomery, TX) 
or Dynabeads M-280 Streptavidin (11205D, Thermo Fisher Scientific, Waltham, MA) were 
used to precipitate DNA fragments associated with modified histones, MLL1 or biotinylated 
NUP98 fusions (NUP98-HOXA9 or NUP98-HOXD13) respectively. Precipitates were washed 
sequentially with ice cold low salt wash (0.1% SDS, 1% Triton-X-100, 2mM EDTA, 20mM Tris-
HCl, pH8.1, 150mM NaCl), high salt wash (0.1% SDS, 1% Triton-X-100, 2mM EDTA, 20mM 
Tris-HCl, pH 8.1, 500mM NaCl), LiCl wash (0.25M LiCl, 1% IGEPAL CA-630, 1% deoxycholic 
acid, 1mM EDTA, 10mM Tris-HCl, pH 8.1) and TE wash (1mM EDTA, 10mM Tris-HCl, pH 
8.1) and eluted in elution buffer (1% SDS, 0.1 M NaHCO3). For biotinylated NHA9, NHD13, 
NUP98-TOP1 and N-NUP98 ChIP, a 2% SDS wash was conducted in addition to the washes 
described above and all washes were carried out at room temperature. All buffers except 
for the elution buffer were supplemented with protease inhibitor (Complete mini protease 
inhibitor cocktail tablets, Roche, Indianapolis, IN). Eluted DNA fragments were analyzed by 
quantitative PCR using promoter specific primers as listed. The anti-N terminus MLL antibody 
(MO435) , generated by a synthetic peptide of MLL amino acids 752–949 as immunogen in 
Dr. James J. Hsieh lab as described previously (Liu et al., 2014), was used to perform an 
additional ChIP-seq experiment. 
ChIP for H3K4me3 (ab8580, Abcam, Cambridge, MA) and H4K16ac (39167, Active 
Motif, Carlsbad, CA) in murine NUP98-HOXA9 transformed cells was performed as described 
above. For ChIP sequencing, ChIP DNA libraries were made following Illumina ChIP-seq 
library preparation kit and subjected to Solexa sequencing.
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Primers for ChIP-RT-q-PCR
Hoxa7 FW  5’-CTCTTCTGTTTCCCATCCTGGT-3’
Hoxa7 RV  5’-GGCAATATCCGGGATCCACT-3’
Hoxa9 FW  5’-GGAATAGGAGGAAAAAACAGAAGAGG-3’
Hoxa9 RV  5’-TGTATGAACCGCTCTGGTATCCTT-3’
Hoxa10 FW  5’-CCTTTTTGGTCGACTCGCTC-3’
Hoxa10 RV  5’-CAACACCAGCCTCGCCTCT-3’
Meis1 FW  5’-TCACCACGTTGACAACCTCG-3’
Meis1 RV  5’-GCTTTCTGCCACTCCAGCTG-3’
Hoxb5 FW  5’- CTCATTCCACCTGCAAACCT-3’
Hoxb5 RV  5’- CTTTCCACCAAGACCCAGAA-3’
Evi1 FW   5’-CTCACACCCCTGAAAGCAAT-3’
Evi1 RV   5’-CTGAGCACAAGGGTGTGTGT-3’
Sox17 FW  5’-GAGAGGTTGCACCAGAGAGG-3’
Sox17 RV  5’-GCGGCCGGTACTTGTAGTT-3’
Actin FW  5’-GGGAACCAGACGCTACGATC-3’
Actin RV   5’-TTGGACAAAGACCCAGAGGC-3’
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ABSTRACT
Given the recent interest in targeting chromatin-based mechanisms in acute myeloid 
leukemia, we conducted a chromatin regulator-focused RNAi screen to identify novel 
druggable targets in MLL-rearranged leukemia. In this screen we found hairpins targeting 
the Mof gene to be among the most potent suppressors of cell growth. MOF is an H4K16 
acetyltransferase and member of the MYST family of histone acetyltransferases (HATs). Using 
a conditional Mof knockout model, we studied the role of MOF in MLL-AF9 leukemogenesis 
and found that Mof inactivation led to reduced tumor burden and prolonged survival 
in an MLL-AF9 mouse model. RNA sequencing of Mof-deficient cells showed significant 
downregulation of genes within DNA damage repair pathways, and Mof-deficient MLL-AF9 
cells indeed contained significantly more yH2AX foci. In addition, we found a loss of global 
H4K16 acetylation (H4K16ac) upon Mof deletion. We performed rescue experiments using 
MOF mutants that lack HAT activity and found that MOF enzymatic activity is indispensable 
for MLL-AF9 leukemia maintenance. Finally, MG149, a MYST protein HAT inhibitor, had a 
strong anti-proliferative effect on murine, as well as human MLL-AF9 leukemia cell lines. 
These results indicate that MOF HAT activity is required for MLL-AF9 leukemia maintenance 
with loss of MOF HAT activity leading to elevated DNA damage. Based on our findings, we 
believe that small molecule inhibition of MOF HAT activity may prove to be a novel approach 
for the treatment of patients with MLL-rearranged leukemia.
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INTRODUCTION
Chromosomal rearrangements at 11q23 are associated with the development of acute 
leukemia and led to the discovery of the Mixed-Lineage Leukemia 1 (MLL1) gene.1,2 MLL 
translocations are found in about 10% of all patients with acute leukemia and are generally 
associated with an unfavorable prognosis.3 MLL translocations are more frequently present 
in infant and pediatric patients with the highest frequency (80%) in infant acute lymphoblastic 
leukemia (ALL).4,5 
It is evident that chromatin modifications, including DNA methylation and histone 
modifications, enforce oncogenic gene expression programs and substantially contribute to 
the initiation and maintenance of leukemia cells.6,7 Epigenomic studies utilizing in vivo and 
in vitro models of MLL-rearranged leukemia have revealed that direct targets of MLL1 fusion 
proteins such as HOXA cluster genes are associated with aberrantly high levels of histone 3 
lysine 79 dimethylation (H3K79me2).8,9 DOT1L was found to be the key regulator of H3K79me2 
and MLL-rearranged cells were shown to be highly dependent on Dot1l for leukemia initiation 
and maintenance.10-13 This discovery led to the development of small molecule inhibitors 
targeting DOT1L, one of which is currently undergoing early phase trials.14,15 Similarly, MLL-
rearranged leukemia maintenance was shown to be critically dependent upon expression of 
Bromodomain Containing 4 (Brd4).16,17 BRD4 is a well-known member of the bromodomain 
family, a family of epigenetic ‘‘readers’’, important for recognizing posttranslational chromatin 
modifications and recruiting downstream effector proteins to specific loci to activate gene 
expression programs.18 Multiple bromodomain inhibitors are currently under investigation in 
early phase clinical trials.18
Findings such as these indicate the importance of chromatin regulation in leukemia. 
In order to identify novel druggable epigenetic targets in MLL-rearranged leukemia, we 
conducted a chromatin regulator-focused RNAi screen in murine MLL-AF9 leukemia cells 
and found hairpins targeting (K)Lysine Acetyltransferase 8 (Kat8, also known as Mof) and 
the previously identified target Brd416, to be the most potent suppressors of cell growth. MOF 
is a histone 4 lysine 16 (H4K16) acetyltransferase and member of the MYST family of lysine 
acetyltransferases. The MYST family is named for its founding members MOZ, YBF2, SAS2 
and TIP60, proteins that all contain a MYST region with a canonical acetyl coenzyme A (CoA) 
binding site and C2HC-type zinc finger motif.19 MOF is one of the best-characterized MYST-
family proteins and was shown to be crucial for murine embryogenesis. MOF functions as 
a cell-type dependent regulator of chromatin state and controls various cellular processes 
such as T-cell differentiation20, DNA damage response21-25, cell cycle progression21,26 and 
embryonic stem cell self-renewal and pluripotency27.
The role of MOF in tumorigenesis seems complex. Studies in breast carcinoma28, 
medulloblastoma28 and ovarian cancer29 suggest that tumor progression is associated with 
downregulation of MOF and H4K16 acetylation (H4K16ac). On the other hand, studies in 
lung30,31 and oral32 carcinoma have associated high expression of MOF with carcinogenesis 
and suppression of MOF with cancer cell death. This suggests that MOF may regulate 
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tumorigenesis in a cell- and tissue- dependent manner.
While MOF’s enzymatic activity is druggable by small molecules33 and our RNAi screen 
suggests a crucial role for MOF in MLL-AF9 leukemogenesis, we studied the role of Mof in 
detail using a conditional murine Mof knockout system34. Our current findings indicate a strong 
dependency of MLL-AF9 leukemic cells on Mof. Gene expression and immunofluorescence 
data suggest that the importance of MOF in MLL-AF9 leukemogenesis may be through DNA 
damage repair. Mof knockout in MLL-AF9 transformed cells led to loss of global H4K16ac 
and in line with this finding, rescue experiments with histone acetyltransferase (HAT) domain 
mutated MOF illustrated that the HAT activity of MOF is indispensable for MLL-AF9 leukemia 
maintenance. Finally, experiments with the selective MYST protein HAT inhibitor MG149, 
showed a strong anti-proliferative effect on murine as well as human MLL-AF9 leukemia cell 
lines. MOF HAT activity may be a good target for novel small molecule inhibitor development 
to improve the treatement of patients with MLL-rearranged leukemia.
RESULTS
Chromatin regulator focused RNAi screen in MLL-AF9 leukemia identifies Mof as a key 
regulator
To identify novel druggable targets within epigenetic pathways required for MLL-AF9 (MA9) 
leukemia maintenance, we conducted a customized, chromatin regulator focused RNAi 
screen in murine, MA9 leukemia cells (Figure 1A). An shRNA library containing 2,252 
shRNAs targeting 468 known chromatin regulators was constructed in TRMPV-Neo and 
transduced as one pool into Tet-on-competent, monoclonal mouse MA9 leukemic cells. 
After Neomycin (G418) selection, shRNA expression was induced by Doxycycline treatment. 
shRNA expressing cells were then sorted and changes in shRNA library representation 
after 12 days of culture were assessed by high-throughput sequencing (HiSeq) of shRNA 
guide strands as previously described.16,35 Using the scoring criterion of more than 256-
fold depletion in each of two independent replicates, 20 shRNAs targeting 18 genes were 
strongly depleted (Figure 1B). Only two out of these 18 had two independent shRNAs that 
showed strong depletion, namely Mof and the previously identified target Brd416 (Figure 1B, 
S1A, S1B). This RNAi screen strongly suggests that the acetyltransferase MOF is crucial for 
MA9 leukemic cell growth. 
Mof loss in a murine MLL-AF9 leukemia model leads to impaired colony-forming 
capacity, a phenotype rescued by exogenous full-length Mof
To study the role of MOF in MA9 leukemogenesis and validate the results of our RNAi screen 
we used a well-described conditional Mof knockout (KO) mouse in a C57Bl/6 background.34 
For the initial in vitro experiments, Moff/f, Moff/+ and wild type (Mof+/+) adult mice were 
euthanized and Lin-, SCA1+, cKIT+ cells (LSKs) were harvested from the bone marrow (BM) 
(Figure 2A). These fresh LSKs were infected with MA9 in an MSCV-Migr1 retroviral vector 
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containing the GFP selection marker. Following a few days of liquid culture, cells were sorted 
for GFP positivity. These stable MA9 transformed cells grow indefi nitely and were capable of 
forming dense, round colonies (blast colonies, data not shown). 
For in vitro excision of Mof, MA9 cells were infected with an MSCV-dTomato retrovirus 
containing Cre. 48 hours after infection, Cre positive Moff/f, Moff/+ and Mof+/+ cells were 
sorted, counted and immediately plated in myeloid cytokine supplemented methylcellulose 
for colony-forming unit (CFU) assays. Homozygous Mof loss signifi cantly reduced colony-
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Figure 1. Chromatin regulator focused RNAi screen in MLL-AF9 leukemia identifi es Mof as a key 
regulator
(A) Schematic outline of chromatin regulator focused shRNA library screen coupled with high-throughput 
sequencing (HiSeq) in murine bone marrow (BM) MA9 monoclonal leukemia cells. Dox: Doxycycline.
(B) Volcano plot depicting the changes in representation (x-axis) and signifi cance (y-axis) of each shRNA 
construct in the screen before versus 12 days after hairpin-induced knockdown. One dot represents the 
mean for two independent experiments. The dotted area contains the 20 most signifi cantly depleted 
hairpins in the screen (more than 256-fold depletion, signifi cance (defi ned as -log10 of the p-value) 
≥ 4.5). Total library (gray; 2,252 shRNAs, 468 genes), shMof (red; four shRNAs) and shBRD4 (blue; fi ve 
shRNAs) are highlighted as the only two genes with two hits.
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forming capacity of MA9 cells (Figure 2B and C). No difference in colony morphology was 
observed (Figure 2D). Heterozygous loss of Mof (Moff/+) also led to a reduction of total 
colony number (Figure 2C), albeit less dramatic compared to full Mof deletion, suggesting 
a potential gene dosage effect of Mof on the clonogenic capacity and cell growth of MA9 
cells. However, Mof excision PCR data consistently illustrated that although at time of plating, 
all cells in Moff/f and Moff/+ were completely excised (Figure 2E), all Moff/f colonies that had 
formed at day 7 of the CFU assay were in fact unexcised, whereas the floxed-allele in the 
Moff/+ colonies remained fully excised (Figure 2E). These PCR data indicate strong selective 
pressure against homozygous, but not heterozygous Mof loss in an MA9 leukemic setting. 
To assess specificity of the observed phenotype, a Mof full-length rescue experiment 
was performed. Moff/f, Moff/+ and Mof+/+ MA9 cells were transduced with either an MSCV-
miCD2 retrovirus containing full-length, human influenza hemagglutinin (HA)-tagged Mof or 
the empty vector (Figure 2A). hCD2 positive cells were sorted and subsequent Western blot 
analysis for the HA-tagged MOF indicated that exogenous Mof was expressed (Figure S2A). 
These cells were then transduced with Cre and Cre positive cells were used for CFU assays 
as before. Figure 2F shows full rescue of the phenotype observed in Moff/f, miCD2 cells 
by exogenous expression of full length Mof (Moff/f, miCD2-Mof). Mof excision PCR analysis 
confirms this rescue. While Moff/f, miCD2 cells are fully unexcised 9 days post Cre infection, 
Moff/f, miCD2-Mof cells remain largely excised (Figure 2G). Taken together, these findings 
demonstrate that Mof is required for the colony-forming capacity of MA9 leukemic cells.
Mof loss leads to reduced tumor burden and prolonged survival in an in vivo MLL-AF9 
leukemia model
Mof dependency in MA9 leukemia was further assessed using an in vivo secondary, murine 
leukemia model. Mx1-cre; Moff/f and Mx1-cre mouse BM LSKs were transduced with GFP-
tagged MA9 and 48 hours after infection, GFP+ cells were sorted and injected into sub-
lethally irradiated (600 cGy) C57Bl/6 mice. These mice developed acute myeloid leukemia 
(AML) within 4-8 weeks post transplant (data not shown). Leukemic mice were sacrificed and 
BM cells obtained. 45,000 GFP+ primary leukemic Mx1-cre; Moff/f or Mx1-cre BM cells were 
then injected into sub-lethally irradiated C57Bl/6 mice (Figure 3A). At day 13 post transplant, 
mice were bled to check engraftment (pre pIpC, Figure 3B). That same day, half of the mice 
per group (n = 10 for Mx1-cre, n = 20 for Mx1-cre; Moff/f) were injected with poly(I:C) (pIpC) 
to induce Cre expression. pIpC treated mice received a total of three dosages, one every 
other day and were bled again, 7 days after the last dose. The white blood cell (WBC) count 
(Figure 3C) and GFP% in peripheral blood (PB) (Figure 3B) illustrate the lethality of Mof loss 
to MA9 leukemic cells. Seven days after pIpC treatment Mx1-cre; Moff/f, pIpC+ mice had 
a mean WBC count of 3 K/uL versus 112 K/uL (Mx1-cre; Moff/f, pIpC-) and 104 K/uL (Mx1-
cre, pIpC+), and a significantly lower GFP% of 38% versus 92% (Mx1-cre; Moff/f, pIpC-) 
and 95% (Mx1-cre, pIpC+). Several mice within the Mx1-cre; Moff/f, pIpC+ group had an 
actual reduction of GFP% in the PB after receiving pIpC injections (Figure 3D) indicating a 
reduction of tumor burden upon Mof loss. 
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Figure 2. Mof loss in murine MLL-AF9 leukemia model leads to impaired colony-forming capacity, 
a phenotype rescued by exogenous full-length Mof
(A) Schematic for in vitro Mof knockout and full-length Mof rescue experiments.
(B) Day 7 of methylcellulose colony-forming assay of MA9 in vitro transformed Moff/f, Moff/+ or wild type 
(Mof+/+) LSKs plated immediately upon sorting Cre positive cells. Representative petri dishes are shown.
(C) Bar graph indicating mean number of colonies per 35mm dish after 7 days. 1000 cells were plated 
per dish. Data are representative of four individual experiments.
(D) Colonies at day 7 of CFU assay. Representative images are shown.
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All mice eventually succumbed to AML. At time of death, mice had elevated WBC 
counts (data not shown) and splenomegaly (Figure S3A). FACS analysis showed more than 
90% GFP+ cells in BM (Figure S3B), spleen and PB (data not shown). The majority of GFP+ 
cells in BM, spleen and PB expressed myeloid cell markers MAC1, GR1 and cKIT, indicating 
a myeloid leukemic phenotype (Figure S3C and D). Animals in all three control groups died 
with a median survival of 22 (Mx1-cre, pIpC+), or 24 days (Mx1-cre; Moff/f and Mx1-cre, 
pIpC-). Mx1-cre; Moff/f, pIpC+ mice lived significantly longer with a median survival of 31 
days (p < 0.0001; Figure 3E). At time of death, GFP+ BM cells of Mx1-cre; Moff/f, pIpC+ mice 
showed incomplete excision (Figure S3E), illustrating that Mof-deficient MA9 cells have a 
strong disadvantage of forming leukemia in vivo. When we ended the experiment (day 60), 
the last living mouse in the Mx1-cre; Moff/f, pIpC+ cohort did not have any GFP+ cells in the 
PB or BM. Together these in vivo data demonstrate that Mof is important for maintenance of 
MA9 driven AML.
Homozygous Mof loss in MLL-AF9 transformed mouse LSKs leads to cell death and 
DNA damage
Our CFU assay data show a strong dependence for Mof in MA9 cells. To study the potential 
underlying mechanism, we performed in vitro excision of Mof in MA9 transformed murine 
LSKs as described above. While the strong dependency caused a rapid loss of Mof excision 
(Figure 2E and G), we first had to define the latest time point after Cre infection at which 
MA9 cells are still fully excised. PCR analysis indicated complete Mof excision up to 72 
hours after Cre infection (Figure 4A). We next performed RNA sequencing (RNA-seq) on 
Moff/f and Mof+/+ MA9 cells, harvested 72 hours after Cre infection. Gene ontology (GO) 
analysis comparing MA9 cells with homozygous Mof loss to the wild type control, showed a 
significant enrichment of cell division and DNA damage repair pathways in genes that are 
downregulated in MA9 Mof KO cells. To verify this finding, we stained MA9 transformed LSKs 
at 48 or 72 hours after Cre infection with an immunofluorescent-labeled yH2AX antibody. 
Confocal microscopy revealed significantly more yH2AX foci per cell nucleus in Mof-deficient 
(E) PCR analysis illustrating excision at indicated time points of the 7-day colony-forming experiment. 
Representative gel images are shown.
(F) Day 7 of CFU assay of MA9 in vitro transformed Moff/f, Moff/+ or Mof+/+ LSKs that were infected with full-
length Mof (miCD2-Mof) or empty vector control (miCD2) and selected by sorting hCD2 positive cells. 
Bar graph indicates mean number of colonies per 35mm dish after 7 days. 3000 cells were plated per 
dish. Data are representative of three individual experiments.
(G) PCR analysis illustrates excision throughout the duration of the 7-day colony-forming experiment. 
Representative gel images are shown.
** p < 0.01. Error bars represent SD of mean.
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Figure 3. Mof loss leads to reduced tumor burden and prolonged survival in an in vivo MLL-AF9 
leukemia model
(A) Schematic for in vivo Mof excision experiment. Primary, GFP-tagged MA9 leukemia BM cells in an 
Mx1-cre; Moff/f or Mx1-cre background were injected into sub-lethally irradiated C57Bl/6 mice (n=10 for 
Mx1-cre and n=20 for Mx1-cre; Moff/f). Half of the mice per group were treated with poly(I:C) pIpC at day 
15 post transplant to induce Mof excision.
(B) GFP% of live cells in peripheral blood of mice before and after pIpC treatment. A dot represents a 
single mouse in the experiment.
(C) White blood cell (WBC) counts before and after pIpC treatment.
(D) GFP% of live cells in peripheral blood of mice before and after pIpC treatment. A line connects the 
two values for a single mouse in the experiment.
(E) Survival curve of mice in secondary leukemia experiment. Data are representative of two individual 
experiments. Arrows indicate pIpC treatment.
a. Log-rank test p-value comparing survival of pIpC treated Mx1-cre; Moff/f mice to either of the Mx1-cre control groups.
b. Log-rank test p-value comparing survival of Mx1-cre; Moff/f mice treated with pIpC to the untreated group.
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MA9 cells compared to controls (p < 0.01; Figure 4C), indicative of more DNA damage. This 
increase in DNA damage was largely rescued by overexpression of full-length Mof (Figure 
4C). These experiments demonstrate that there is evidence of cell death and DNA damage 
in MA9 cells upon Mof loss.
Mof histone acetyltransferase activity is required for colony formation of MLL-AF9 
transformed mouse LSKs
MOF has been identified as the major H4K16 acetyltransferase in humans, mice and 
Drosophila.26,34,37-39 MOF contains a HAT domain with a CoA binding site that was found to be 
crucial for its acetyltransferase activity.19,37 While MOF possesses acetyltransferase activity 
on various histones and nucleosomes, depletion of MOF in HeLa cells was shown to lead to a 
dramatic decrease in H4K16ac whereas other acetylation sites appeared to be unaffected.26 
Since our data indicate a strong Mof dependence in MA9 leukemic cells, we set out to 
establish whether this dependence is through MOF HAT activity. When assessing changes 
in global H4K16ac upon Mof loss in MA9 cells, we found a significant decrease of H4K16ac 
(Figure 5A), a decrease that was averted by expression of exogenous Mof (Moff/f, miCD2-
Mof). Next, we designed two HA-tagged, HAT inactivated Mof retroviral constructs (Figure 
5B) in which either the CoA binding site was deleted (Mof-CoAdel) or a HAT inactivating 
point mutation (G327E) was introduced (Mof-G327E). The HAT inactivating point mutation in 
the MOF CoA binding domain was first described in Drosophila37 and later used in a human 
MOF construct where it was also found to diminish H4K16ac40. Alignment of Drosophila, 
murine and human MOF illustrates that the point mutation involves replacement of glycine 
by glutamic acid on position 327 (G327E) in murine, as well as human MOF. The constructs 
were packaged in an miCD2-MSCV retroviral vector with the hCD2 selection marker (miCD2-
Mof-CoAdel and miCD2-Mof-G327E). 
Figure 4. Homozygous Mof loss in MLL-AF9 transformed mouse LSKs leads to cell death and DNA 
damage
(A) MA9 in vitro transformed Moff/f or Mof+/+ LSKs were infected with full-length Mof or empty vector control 
(miCD2) and selected by sorting hCD2 positive cells. Cells were then plated in liquid culture immediately 
upon sorting dTomato positive cells, 48 hours after infection with dTomato-Cre. PCR analysis illustrates 
excision at 48, 72, 96 and 144 hours post Cre infection.
(B) Gene ontology analysis with a differential expression analysis list of significantly (p < 0.05) 
downregulated genes comparing Moff/f cells to Mof+/+ cells at 72 hours post Cre infection.
(C) Number of large yH2AX foci per cell nucleus at 48 or 72 hours post Cre infection. A dot represents 
a single cell.
** p < 0.01. Error bars represent SD of mean.
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Figure 5. Mof histone acetyltransferase activity is required for colony formation of MLL-AF9 
transformed mouse LSKs
(A) MA9 in vitro transformed Moff/f or Mof+/+ LSKs were infected with full-length Mof or empty vector 
control (miCD2) and selected by sorting hCD2 positive cells. Cells were then infected with dTomato-
Cre, 48 hours later sorted and another 24 hours later harvested. Western blot was performed on whole 
protein lysates.
(B) Schematic illustrating full length Mof and two Mof mutants with either a G327E point mutation or a 
CoA binding-site deletion.
(C) MA9 in vitro transformed Moff/f or Mof+/+ LSKs were infected with HA-tagged full-length Mof, CoA 
deleted Mof (CoAdel), Mof with a G327E mutation or empty vector control, and selected by sorting hCD2 
positive cells. Western blot for HA confi rms presence of these exogenous constructs. 
(D) Cells were infected with dTomato-Cre and 48 hours later sorted and harvested. Western blot 
illustrates global H4K16ac and Actin in protein lysates.
(E) Day 7 of CFU assay. Cells were plated immediately upon sorting dTomato positive cells, 48 hours 
after infection with dTomato-Cre. Bar graph indicates mean number of colonies per 35mm dish after 7 
days. Data are representative of three individual experiments.
(F) PCR analysis illustrating excision throughout the duration of the 7-day colony-forming experiment. 
Representative gel images are shown.
(G) MOLM13, NOMO1 and murine polyclonal MA9 cells were plated in liquid culture and treated with 
various concentrations of MG149. Plotted is the IC50 curve for cell viability as a percentage of the 
vehicle (DMSO) control at day 3 of treatment. Numbers indicate the IC50 per cell type (by color).
(H) Western blot showing global H4K16ac and Actin in murine MA9 cells after 3 days of MG149 treatment 
at various concentrations.
** p < 0.01. Error bars represent SD of mean.
We infected unexcised Moff/f and Mof+/+ MA9 cells with either miCD2-Mof, miCD2-
CoAdel, miCD2-G327E or miCD2 and sorted hCD2 positive cells. Western blot analysis for 
HA-tagged MOF indicated that exogenous Mof was expressed at similar levels in miCD2-Mof 
and miCD2-G327E, though Mof expression seemed a little lower with the miCD2-CoAdel 
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construct (Figure 5C). Upon in vitro Mof KO by transduction with retroviral Cre, Western blot 
analysis confirmed that exogenous full-length Mof was capable of restoring H4K16ac levels, 
while both HAT domain mutant Mof constructs were not (Figure 5D). When using these Cre 
transduced MA9 cells for a CFU assay, full-length Mof indeed rescued colony formation 
of Moff/f cells while exogenous, HAT-deficient Mof could not (Figure 5E). Mof excision PCR 
analysis reaffirms these findings where Moff/f miCD2, miCD2-CoAdel and miCD2-G327E cells 
have fully lost excision at day 9 post Cre infection, but miCD2-Mof cells are still largely 
excised (Figure 5F). In summary, we found a loss of global H4K16ac upon Mof KO and in 
line with this finding of H4K16ac loss, rescue experiments with HAT domain mutated MOF 
illustrated that the HAT activity of MOF is indispensable for MA9 colony-forming capacity. 
Our finding that MOF HAT activity is required for MA9 leukemia suggests that targeting 
MOF HAT activity could provide us with a new approach in treating MA9 leukemia patients. 
In 2011 a selective small molecule inhibitor of MYST protein HAT activity, MG149, was 
designed.33 While this small molecule is not particularly potent, we decided to use this inhibitor 
to test its effect on cell viability in the human MA9 AML cell lines NOMO1 and MOLM13 and 
in murine, polyclonal MA9 primary leukemia cells. A dose response curve showed a strong 
anti-proliferative effect on all three MA9 cells with an IC50 of 19.6 uM (murine MA9), 25.4 uM 
(MOLM13) and 50.9 uM (NOMO1). In addition, MG149 inhibition induced global H4K16ac 
loss in murine MA9 cells (Figure 5H). These results suggest that MG149 effectively targets 
MOF HAT activity with an anti-proliferative effect on human as well as murine MA9 leukemia 
cells. 
DISCUSSION
To identify novel druggable targets in MLL-rearranged leukemia, we performed an RNAi 
screen focused on chromatin regulators. This resulted in the identification of Mof as one 
of the most potent suppressors of cell growth in murine MA9 leukemia. We found that 
homozygous Mof loss led to a significant decrease in colony-forming ability, reduced 
tumor burden and prolonged survival in mice. RNA-seq of Mof-deficient MA9 cells showed 
significant downregulation of genes associated with DNA damage repair pathways, and 
upon validation by immunofluorescence we indeed found a significant increase of yH2AX 
foci in Mof-deficient MA9 cells. In addition, we uncovered a loss of global H4K16ac upon Mof 
KO. Rescue experiments with HAT domain mutated MOF illustrated that MOF HAT activity 
is indispensable for MA9 leukemia maintenance. This new insight could be utilized in the 
development of a small molecule inhibitor for the treatment of leukemia patients carrying an 
MLL translocation.
Gene expression analysis in Mof-deficient MA9 cells indicated that MOF loss does 
not lead to clear downregulation of MA9 target genes such as Meis1 and Hoxa cluster 
genes. Our RNA-seq data suggested that MOF loss leads to impairment of more general 
biological processes required for cellular integrity (Figure 4B). This finding implies that MOF 
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may not only be required for MA9 leukemogenesis and not even only for MLL-rearranged 
leukemia, but for a broad range of acute leukemias. We identified DNA damage repair as 
a possible mechanism of cell death in Mof-deficient leukemia cells (Figure 4C). Mof-null 
murine embryonic fibroblasts (MEFs) were previously shown to be deficient in DNA damage 
repair after ionizing radiation.23 In wild type MEFs, radiation induced DNA damage led to an 
increase of global H4K16ac23, suggesting that a MOF-induced increase of H4K16ac may 
be essential for an appropriate DNA damage response. Unacetylated H4K16 is required 
to achieve the maximum tendency of in vitro nucleosome arrays to fold into secondary or 
tertiary chromatin structures.41 In contrast, 30% H4K16 acetylation alleviates compaction 
of the chromatin fiber.42 Therefore it may be that the MOF-loss induced global H4K16ac 
depletion influences the DNA damage response and/or chromatin integrity by increasing 
chromatin compaction.
GO analysis on our RNA-seq data suggested that loss of Mof in MA9 leukemic cells 
may not only lead to DNA damage, but also general chromosomal instability (Figure 4B). 
This could contribute to the rapid cell death we observed in Mof-deficient MA9 cells. Genetic 
and biochemical data underscore the importance of unacetylated acidic histone tails in 
gene silencing.43 Interestingly, the yeast ortholog of MOF, SAS2, was previously shown to 
lead to telomeric silencing44 and it is well established that telomeric dysfunction can lead 
to chromosomal instability45. Future experiments will be required to assess how Mof-loss 
induced H4K16ac depletion may contribute to chromosomal instability in Mof-deficient MA9 
cells, and whether telomeric silencing is involved.
MOF was shown to functionally and physically interact with the histone methyltransferase 
MLL1. The interaction between MOF and MLL1 is important for the chromatin regulatory 
function of both enzymes.46 In normal hematopoiesis, Mll1 is essential for development and 
maintenance of both embryonic and adult progenitors and hematopoietic stem cells (HSCs).47 
In addition, it has been suggested that wild type MLL1 may play a role in MLL-rearranged 
leukemogenesis.48 However, in both normal and malignant hematopoiesis, MLL1s H3K4 
methyltransferase activity is dispensable.49 Given the identified MA9 leukemia dependence 
on the enzymatic activity of MOF (Figure 5E), it may be that, in the setting of MLL-rearranged 
leukemia, it is in fact the HAT activity of MOF that is required for leukemogenesis, and MLL1 
merely functions as a scaffolding protein, recruiting MOF to targets of the oncogenic fusion. 
Over the last decade, many advances have been made in the field of cancer 
epigenomics. Our vastly expanding knowledge on the role of chromatin regulation in cancer 
has led to the development of various drug compounds that target the cancer epigenome, 
several of which are currently in clinical trials.6,50 Here we have established that MOF HAT 
activity is required for MA9 leukemia maintenance and loss of MOF HAT activity leads to 
elevated DNA damage. In addition, we have successfully inhibited cell growth of human 
and murine MA9 leukemia cells by using a first generation small molecule MYST protein 
HAT inhibitor. Based on our findings, we believe that inhibiting MOF HAT activity by small 
molecules may prove to be an effective, novel approach for the treatment of patients with 
MLL-rearranged and perhaps other leukemias.
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RNAi screen
A customized shRNA library (TRMPV-Neo system) focused on mouse chromatin-regulating 
genes, together with control shRNAs, was designed as previously described.16,35 After 
sequence verification the virus library containing 2,252 shRNAs targeting 468 genes (four to 
six shRNAs per gene), was pooled. The virus pool was transduced into monoclonal mouse 
MA9 leukemic cells (two replicates), stably expressing rtTA3 (Tet-on system), at a viral titer 
that on average causes a single viral transduction per cell and at which each shRNA is 
represented in at least 2,000 cells. The infected cells were selected for two days in 1 mg/mL 
Neomycin (G418 sulfate, Corning, NY) and subsequently shRNA expression was induced by 
adding 1 ug/mL Doxycycline (Sigma-Aldrich, St. Louis, MO). The shRNA-expressing cells 
(dsRed and Venus double positive) were sorted (T0) using a FACS ARIA (BD, San Jose, 
CA), and cultured for 12 days (T12).36 The integrated shRNA sequences in T0 and T12 cell 
samples were assessed by HiSeq using the Illumina Next-Gen Sequencing HiSeq platform 
(Illumina, San Diego, CA), as previously described.16,35
Mice
The generation of Mof conditional knockout mouse in a C57Bl/6 background has been 
described.34 To generate Mx1-cre; Moff/f mice, Moff/f mice were crossed to Mx1-cre mice 
and Cre was maintained as a heterozygous allele. Genotyping strategies were previously 
described.34 Wild type C57Bl/6 mice were purchased from Taconic, Hudson, NY. All animal 
experiments in this study were approved by, and adhered to guidelines of the Memorial 
Sloan-Kettering Cancer Center Animal Care and Use Committee.
Isolation of murine LSKs for in vitro MLL-AF9 transformation
Mx1-cre; Moff/f, Moff/f, Moff/+, Mx1-cre and wild type (Mof+/+) adult mice were sacrificed 
and femurs, tibias, fibulas, pelvis and spine were extracted. Single cell suspensions were 
prepared by crushing bones in a mortar after removal of muscle and connective tissues. 
Lineage depletion was performed by labeling BM cells with purified, biotinylated 
monoclonal antibodies to CD3e, CD11b (MAC1), CD45R (B220), Ly-6G (GR1) and TER119 
(Biotin mouse lineage panel, BD, San Jose, CA). Lineage positive (Lin+) cells were in majority 
removed by magnetic bead depletion with streptavidin conjugated MicroBeads over an LD 
column (both Miltenyi Biotech, San Diego, CA). Lin-, SCA1+, cKIT+ cells (LSK) were then 
obtained by staining lineage depleted cells with Streptavidin APC/Cy7, (Biolegend, San 
Diego, CA), CD117 (cKIT) APC and Ly-6A/E (SCA1) PE/Cy7 (both eBioscience, San Diego, 
CA), and sorting the LSK population.
Fresh LSKs were infected with MSCV-MLL-AF9-IRES-GFP retrovirus and GFP positive 
cells sorted on a FACS ARIA cell sorter 48 hours post infection. Cells were then immediately 
used for transplantation or grown out for several weeks to obtain highly proliferative 
transformed cultures for in vitro assays. 
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In vitro colony-forming assays
To study the impact of Mof deletion on the colony-forming capacity of Mof-deficient MA9 
cells, Moff/f, Moff/+ or Mof+/+ MA9 in vitro transformed LSKs were transduced with MSCV-Cre-
IRES-dTomato. After 48 hours, cells were sorted for dTomato positivity, counted and plated 
in methylcellulose M3234 (Stemcell Technologies, Vancouver, BC, Canada), supplemented 
with murine IL3 (10 ng/mL), IL6 (10 ng/mL) and SCF (20 ng/mL) in 35mm culture dishes. 
Colonies were scored after 7 days, using the Eclipse TS100 inverted microscope (Nikon, 
Tokyo, Japan). Since almost all colonies were either compact and hypercellular (blast-like) 
or small and diffuse (consistent with differentiation), colonies were classified into these two 
categories. Cells from pooled colony aggregates were then counted and assessed for Mof 
excision by PCR. 
For Mof rescue experiments, MA9 in vitro transformed LSKs were infected with retrovirus 
containing miCD2, miCD2-Mof, miCD2-Mof-CoAdel or miCD2-Mof-G327E. After 48 hours of 
liquid culture, cells were sorted for hCD2 positivity and expanded to test exogenous Mof 
expression by Western blot. Subsequently, Mof was excised by transduction with Cre and 
CFU assays were performed as described above.
Transplant experiments
For secondary transplant experiments, viable frozen BM cells from primary MA9 leukemic 
mice in an Mx1-cre; Moff/f or Mx1-cre background were thawed and injected into sub-lethally 
irradiated (600cGy) 6-8 week-old C57Bl/6 female recipients (45,000 GFP+ cells per mouse). 
At day 13 post transplant, mice were injected with poly(I:C) (pIpC, Invivogen, San Diego, 
USA) to induce Cre expression. pIpC treated mice received a total of three intraperitoneal 
pIpC injections, each dose 12.5 ug per gram of mouse weight, one every other day. Mice 
were euthanized at time of clinical symptoms of disease, coincided by leukocytosis.
RNA extraction and RNA sequencing 
Trizol (Invitrogen, Carlsbad, CA) was used to extract RNA from viable cells. RNA was QCed 
on the Agilent Bioanalyzer 2100 platform (Agilent, Santa Clara, CA) and Poly-A tail selection 
was performed. Sequencing (RNA-seq) was done using the Illumina Next-Gen Sequencing 
HiSeq platform (Illumina, San Diego, CA) with 30-45 million 50bp, paired-end reads. 
Data Analysis and Statistical Methods
GraphPad Prism software was used for statistical analysis. Statistical significance between 2 
groups was determined by unpaired 2-tailed Student’s t-test. The Kaplan-Meier method was 
applied to plot survival curves for murine leukemic transplant data, and the log-rank test to 
determine statistical significance.
RNA-seq raw reads were aligned to NCBI37/mm9 and normalized using STAR. 
Differential expression data were obtained using the DEseq algorithm. These analyses were 
done through the Basepair platform (New York City, NY). Raw data were deposited in GEO 
(GSE80671). GO analyses were performed using the PANTHER gene analysis tool.
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Figure S1, related to Figure 1. Chromatin regulator focused RNAi screen in MLL-AF9 leukemia 
identifies Mof as a key regulator
(A) A chromatin regulator focused shRNA library screen was performed in murine primary MA9 
monoclonal leukemia cells. Plotted is the high throughput sequencing (HiSeq) normalized read-count 
(RPM) for replicate A (x-axis) versus B (y-axis) at day 0 (before activation of knockdown by doxycycline 
treatment). One dot represents one shRNA (total library 2,252 shRNA, 468 genes). Mof hairpins are 
highlighted in red. All hairpins with less than 600 reads were excluded from the analysis.
(B) Plotted is the Hiseq RPM for replicate A (x-axis) versus B (y-axis) at day 12 after knockdown. Mof 
hairpins are highlighted in red.
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Figure S2, related to Figure 2. Mof loss in a murine MLL-AF9 leukemia model leads to impaired 
colony-forming capacity, a phenotype rescued by exogenous full-length Mof
(A) MA9 in vitro transformed Moff/f, Moff/+ or Mof+/+ LSKs were infected with HA-tagged full-length Mof or 
empty vector control (miCD2), and selected by sorting hCD2 positive cells. Western blot for HA 
confirmed the presence of the exogenous construct.
HA-Mof
f/f f/+ +/+ f/f f/+ +/+
miCD2 miCD2-Mof Rescue:
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Figure S3, related to Figure 3. Mof loss leads to reduced tumor burden and prolonged survival in 
an in vivo MLL-AF9 leukemia model
(A) Primary, GFP-tagged MA9 leukemia BM cells in an Mx1-cre; Moff/f or Mx1-cre background were 
injected into sub-lethally irradiated C57Bl/6 mice (n=10 for Mx1-cre and n=20 for Mx1-cre; Mof f/f ). Half 
of the mice per group were treated with poly-IC (pIpC) at day 15 post transplant to induce Mof excision. 
Plotted is the spleen weight of mice at time of death. A dot represents a single mouse.
(B) Graph illustrating the GFP% of live cells in bone marrow of mice at time of death.
(C) FACS plots illustrating presence of myeloid cell surface markers (MAC1 and GR1) in GFP+ bone 
marrow, spleen and peripheral blood cells at time of death. Representative images are shown. 
(D) FACS plots illustrating presence of myeloid cell surface markers (MAC1 and cKIT) in GFP+ bone 
marrow, spleen and peripheral blood cells at time of death. Representative images are shown. 
(E) PCR analysis illustrating Mof excision at time of death. A representative gel image is shown.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Plasmids and constructs
NH3-terminal HA-tagged WT Mof was amplified by PCR and subcloned into the HpaI site 
of the retroviral vector MSCV-IRES-miCD2 (MSCV-HA-Mof-IRES-miCD2). To generate the 
two Mof HAT domain mutants MSCV-HA-Mof-G327E-IRES-miCD2 and MSCV-HA-Mof-
CoAdel-IRES-miCD2, HA-tagged Mof-G327E (327 glycine to glutamic acid mutation), and 
HA-tagged Mof-CoAdel (deletion of the CoA binding pocket of the MOF HAT domain, 314-
333 residues) were generated using the Q5® Site-Directed Mutagenesis Kit (New England 
BioLabs, Ipswich, MA). The mutant and WT Mof constructs were verified by sequencing. The 
MSCV-MLL-AF9-IRES-GFP and MSCV-Cre-IRES-dTomato plasmid have been previously 
described.1,2 The pCL-Eco plasmid was used for retroviral packaging. 
Transplant experiments
For primary AML experiments, Mx1-cre; Moff/f and Mx1-cre mouse LSKs were harvested 
and infected with MSCV-MLL-AF9-IRES-GFP retrovirus as described. GFP+ cells were sorted 
at 48 hours post infection and 35,000 GFP+ cells injected into sub-lethally irradiated (600 
cGy) 7-week-old C57Bl/6 mice. These mice developed acute myeloid leukemia (AML) within 
4-8 weeks post transplant. Leukemic mice were euthanized and BM cells obtained. For 
secondary transplant experiments, viable frozen BM cells from primary leukemic mice were 
thawed and 45,000 GFP+ cells injected into sub-lethally irradiated (600cGy) 6-8 week-old 
C57Bl/6 female recipients. At day 13 post transplant, mice were bled to check engraftment 
(pre pIpC). That same day, half of the mice per group were injected with pIpC (Invivogen, 
San Diego, USA) to induce Cre expression. pIpC treated mice received a total of three 
intraperitoneal pIpC injections, each dose 12.5 ug per gram of mouse weight, one every 
other day. Mice were euthanized at time of clinical symptoms of disease, coincided by 
leukocytosis. At time of death, bone marrow, spleen and peripheral blood were obtained. The 
Hemavet (Drew Scientific, Waterbury, CT) was used to obtain complete blood counts. Spleen 
cell suspensions were prepared by crushing the tissue through a 0.45 μm mesh filter and 
BM, PB and spleen cells were assessed for GFP and various immunophenotypic markers 
by flow cytometry on a FACS CANTOII (BD, San Jose, CA). FACS cell surface markers used 
were: SCA1 PE-Cy7 (eBioscience, San Diego, CA), MAC1 APC, GR1 PE, cKIT APC, cKIT 
PE-Cy7 and streptavidin APC-Cy7 (all Biolegend, San Diego, CA).
Western blot
Murine, in vitro transformed LSKs with stable expression of the MA9 fusion and miCD2, 
miCD2-Mof, miCD2-Mof-CoAdel or miCD2-Mof-G327E were lysed in 1X lysis buffer (#9803, 
Cell Signaling, Danvers, MA). Samples were heated at 75 °C for 10 minutes, sonicated for 10 
times 30 seconds and analyzed by SDS-PAGE.
Western blotting was done following standard procedures using a 10% Bis-Tris Gel 
(Nupage, Invitrogen, Carlsbad, CA). Proteins were transferred onto PVDF membranes 
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using the iBlot dry transfer system (Invitrogen, Carlsbad, CA). For assessing presence of 
HA-tagged MOF, H4K16ac, H4 and Actin, anti-HA antibody (HA.11, Covance, Dedham, 
MA), anti-H4K16ac antibody (07-329) anti-H4 antibody (07-108) and anti-Actin antibody 
(MAB1501R, all EMD Millipore, Billerica, MA) were used. The secondary antibodies used 
were either sheep anti-mouse IgG (NA931V) or anti-rabbit IgG (NA934V) ECL horseradish 
peroxidase linked whole antibody from GE Healthcare (Little Chalfont Buckinghamshire, UK). 
Liquid cell culture
293T cells used for retroviral production were cultured in DMEM, supplemented with heat 
inactivated 10% fetal bovine serum (FBS) and 50 U/mL penicillin/streptomycin (all Thermo 
Fisher Scientific, Waltham, MA). In vitro transformed MA9 mouse LSKs and MA9 primary 
leukemia cells were cultured in IMDM, supplemented with heat inactivated 10% FBS, 50 U/
mL penicillin/streptomycin (all Thermo Fisher Scientific, Waltham, MA) and murine IL3 (10 
ng/mL), IL6 (10 ng/mL) and SCF (20 ng/mL)(all PeproTech, Rocky Hill, NJ). MOLM13 and 
NOMO1 cells were culture in RPMI, supplemented with heat inactivated 10% fetal bovine 
serum (FBS) and 50 U/mL penicillin/streptomycin (all Thermo Fisher Scientific, Waltham, MA).
yH2AX immunofluorescence staining
Cytospins were fixed using a 4% PFA/PBS mix and cells perforated with 50ug/mL Digitonin 
in PBS. Cells were incubated at 4 °C overnight with yH2A.X p-S139 (Abcam, Cambridge, 
MA) and 30 minutes at room temperature with the secondary antibody anti-rabbit Alexa488 
(Molecular Probes, Thermo Fisher Scientific, Waltham, MA). Then cells were stained with DAPI 
and mounted using Prolong Gold Antifade Reagent (both Thermo Fisher Scientific, Waltham, 
MA). The number of yH2AX foci was determined using ImageJ software on representative 
confocal microscopy images.
MG149 treatment experiment
MG149 was dissolved in dimethyl sulfoxide (DMSO, Thermo Fisher Scientific, Waltham, MA). 
For MG149 treatment experiments, MOLM13, NOMO1 and murine, polyclonal primary MA9 
leukemia BM cells were plated in triplicate in a 96-well flat bottom non-treated cell culture 
plate (Falcon, Corning Life Sciences, Corning, NY). Cells were counted at day 3 and day 5 on 
a FACS CANTOII with DAPI viability stain (Thermo Fisher Scientific, Waltham, MA).
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HISTONE ACETYLTRANSFERASE ACTIVITY OF 
MOF IS REQUIRED FOR ADULT, BUT NOT 
EARLY FETAL HEMATOPOIESIS IN MICE
Daria G. Valerio & Haiming Xu, Meghan E. Eisold, Carolien M. Woolthuis, 
Tej K. Pandita, Scott A. Armstrong
Blood. 2016; in press
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KEY POINT
MOF acetyltransferase activity is essential for adult, but not early and mid- gestational murine 
hematopoietic maintenance.
ABSTRACT
K(Lysine) Acetyltransferase 8 (KAT8, also known as MOF) is a histone 4 lysine 16 (H4K16) 
acetyltransferase and crucial for murine embryogenesis. Lysine acetyltransferases have been 
shown to regulate various stages of normal hematopoiesis. However, the function of Mof in 
hematopoietic stem cell (HSC) development has not yet been elucidated. We set out to study 
the role of MOF in general hematopoiesis by using a Vav1-cre induced conditional murine 
Mof knockout system, and found that MOF is critical for hematopoietic cell maintenance and 
HSC engraftment capacity in adult hematopoiesis. Rescue experiments with a Mof histone 
acetyltransferase domain mutant illustrated the requirement for Mof acetyltransferase activity 
in the clonogenic capacity of HSCs and progenitors. In stark contrast, fetal steady-state 
hematopoiesis at embryonic day 14.5 was not affected by homozygous Mof deletion despite 
dramatic loss of global H4K16ac. Hematopoietic defects start manifesting in late gestation 
at E17.5. The discovery that Mof and its H4K16 acetyltransferase activity are required for 
adult, but not early and mid- gestational hematopoiesis, supports the notion that multiple 
chromatin regulators may be crucial for hematopoiesis at varying stages of development. 
Mof is therefore a developmental-stage-specific chromatin regulator found to be essential for 
adult, but not early fetal hematopoiesis.
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INTRODUCTION
Histone acetylation was first reported in 1964.1 More recently, histone acetyltransferases 
(HATs) have been shown to acetylate various non-histone substrates, thus HATs are now 
categorized as lysine acetyltransferases (KATs).2 KATs play key roles in normal and malignant 
hematopoiesis.3 Acetyltransferases such as p300, CBP, MOZ GCN5 and HBO1 were shown 
to regulate various stages of normal blood cell development including hematopoietic stem 
cell (HSC) maintenance, myeloid proliferation, B-cell apoptosis and erythropoiesis.4-8 
KATs are divided into five families according to their homology and mechanism of 
acetylation, among which the MYST family is the largest.9 All members of the MYST family 
(named for its founding members MOZ, YBF2, SAS2 and TIP60) contain a MYST region with 
a canonical acetyl coenzyme A (CoA) binding site and C2HC-type zinc finger motif.10 One 
of the best-characterized MYST-family proteins is K(Lysine) Acetyltransferase 8 (KAT8, also 
known as MOF). MOF is a histone 4 lysine 16 (H4K16) acetyltransferase11-13 and is crucial for 
murine embryogenesis13,14. Murine embryos with homozygous, constitutional loss of Mof do 
not develop past the blastocyst stage. MOF is a cell type-dependent regulator of chromatin 
state and controls various essential cellular processes such as DNA damage response15-19, 
cell cycle progression15,20 and embryonic stem cell self-renewal and pluripotency21. 
MOF was shown to functionally and physically interact with the histone methyltransferase 
Mixed-Lineage Leukemia 1 (MLL1).22 In hematopoiesis, Mll1 is essential for development 
and maintenance of both embryonic and adult progenitors and HSCs.23,24 However, it’s 
methyltransferase activity was recently shown to be dispensable for HSC maintenance and 
functionality.25 These findings prompt the question whether MOF and its HAT activity are 
required for hematopoiesis. In 2013, Gupta et al. have shown that T-cell specific deletion 
of Mof blocks differentiation and reduces T-cell numbers.26 To assess the role of MOF in 
hematopoietic development and HSC maintenance and differentiation, we used a conditional 
murine system14 in which the Vav1 promoter drives early embryonic hematopoietic 
expression of Cre recombinase27 (Vav1-cre; Moff/f mice). We found that MOF is critical for 
hematopoiesis in newborn and adult mice. In addition, we show that MOF acetyltransferase 
activity is required for hematopoietic stem cell and progenitor maintenance and colony-
forming capacity. However, MOF and H4K16ac seem dispensable for maintenance of the 
highly proliferative E14.5 fetal hematopoietic system. Together our findings illustrate that 
MOF-controlled chromatin regulation is a developmental-stage-specific mechanism for 
hematopoietic maintenance. 
RESULTS
Homozygous Mof loss leads to lethal hematopoietic failure in mice shortly after birth
To examine the function of Mof in hematopoiesis, we used a conditional murine system14 in 
which the Vav1 promoter drives hematopoietic expression of Cre recombinase27. Moff/f mice 
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were backcrossed to C57Bl/6 mice.14 Mice with homozygous Mof loss in the hematopoietic 
compartment (Vav1-cre; Moff/f) were carried to term and born with Mendelian frequencies, 
but died 8 to 11 days after birth (P8-P11) whereas heterozygous Mof loss (Vav1-cre; Moff/+) 
did not affect survival (Figure 1A). At time of death, Vav1-cre; Moff/f P9 pups were smaller than 
both the heterozygous and wild type (Moff/f) control (Figure 1B), had a smaller spleen and 
thymus (Figure 1C and S1A), were pancytopenic (Figure 1D) and had low bone marrow (BM) 
cellularity (Figure 1E). Flow cytometry (FACS) analysis of BM and spleen indicated that the 
absolute number of mature myeloid, lymphoid and erythroid cells was significantly reduced 
in Vav1-cre; Moff/f P9 pups (Figure 1F, S1B and S1C). A similar pattern was found in the 
T-cell lineage in thymoid tissue (Figure S1D and S1E). Total number of myeloid progenitors 
(MPs, Lin-SCA1-cKIT+) and Lin-SCA1+cKIT+ (LSK) cells in Vav1-cre; Moff/f P9 BM were also 
significantly lower (Figure 1G). Within the BM compartment the relative number of mature 
myeloid and lymphoid cells (Figure S1F), and erythroid cells (data not shown) remained 
similar, while the percentage of LSKs and MPs was significantly reduced in Vav1-cre; Moff/f 
P9 pups (Figure S2A and S2B). FACS analysis indicated a reduction of cKIT+ cells within the 
Lin- BM population of Vav1-cre; Moff/f pups (Figure S2A). These FACS analyses indicate that 
in steady state hematopoiesis, while absolute numbers of all hematopoietic populations are 
down, LSKs and MPs are also reduced in percentage relative to total hematopoietic cells. 
Together, these data show that homozygous Mof loss leads to lethal hematopoietic failure 
in mice shortly after birth, and that while cell numbers in all lineages are affected, HSC-
enriched populations may suffer the greatest losses.
Vav1-cre-Moff/f P9 hematopoietic bone marrow cells are functionally impaired
To test the functionality of P9 Vav1-cre; Moff/f BM MPs and HSCs, colony-forming capacity was 
tested in a colony-forming unit (CFU) assay. Figure 2A illustrates a significant but variable 
reduction in colony count and total number of live cells in Vav1-cre; Moff/f BM cells compared 
to Vav1-cre; Moff/+ or Moff/f BM cells. The type of colonies generated by Vav1-cre; Moff/f BM 
cells did not differ significantly (Figure 2B). Next, we performed non-competitive transplant 
experiments where 633,000 Vav1-cre; Moff/f, Vav1-cre; Moff/+ or Moff/f CD45.2+ BM cells were 
Figure 1. Vav1-cre induced homozygous Mof loss leads to lethal hematopoietic failure in pups
(A) Survival curve of Vav1-cre-Moff/f and Vav1-cre-Moff/+ mice represented as days after birth (x-axis).
(B) Representative photographs of 9-day-old Vav1-cre-Moff/f, Vav1-cre-Moff/+ and Moff/f pups.
(C) Representative photographs of spleen, thymus and liver of 9-day-old Vav1-cre-Moff/f, Vav1-cre-Moff/+ 
and Moff/f pups. Colors of arrows correlate to mouse genotype (Vav1-cre-Moff/f orange, Vav1-cre-Moff/+ 
mustard green, Moff/f blue).
(D) White blood cell (WBC) count, hemoglobin (Hb) and platelet count at time of sacrifice.
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(E) Bone marrow (BM) cell count after CD45.2 selection.
(F) Bar graphs representing the total number of mature B-cells (B220+), myeloid cells (GR1+/MAC1+), and 
T-cells (CD3+) in BM (harvested from femurs, pelvic bones, tibias and spine) and spleen as measured 
by FACS.
(G) Bar graph representing the total number of myeloid progenitor (MP) and Lin-SCA1+cKIT+ LSKs in BM 
as measured by FACS.
* p < 0.05, ** p < 0.01. Error bars show SD of mean. Significance compared to Moff/f.
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injected into lethally irradiated B6.SJL (CD45.1+) mice (Figure 2C). Two out of four Vav1-cre; 
Moff/f recipients had to be sacrificed within 12 days post transplant (Figure 2D) due to failure 
of donor cells to give rise to the minimally required hematopoiesis to survive lethal irradiation 
(data not shown). Figure 2E illustrates the low percentage of donor cells (CD45.2+) present 
in the recipient BM of the Vav1-cre; Moff/f recipient mice that failed to engraft, compared 
to a properly engrafted Vav1-cre; Moff/+ recipient mouse (8.8% versus 96.5%). CD45.2 
percentages of all surviving recipients were monitored every 4 weeks (Figure 2F) and mice 
were sacrificed 16 weeks post transplant, at which time BM engraftment was around 90% in 
all groups (data not shown). PCR analysis of Mof excision demonstrated incomplete excision 
in CD45.2+ BM cells derived from Vav1-cre; Moff/f recipients whereas the floxed allele was 
completely excised in CD45.2+ BM cells from heterozygous recipients (Figure 2G), indicating 
that complete homozygous deletion of Mof is not compatible with engraftment. Overall these 
functional experiments showed a variable phenotype of hematopoietic Vav1-cre; Moff/f cells. 
However, excision PCR data (Figure 2G) suggest that this variability is due to a high selection 
pressure against complete excision of Mof, indicating that complete homozygous excision 
is not compatible with functional engraftment of post-natal hematopoietic cells in a non-
competitive transplant setting.
Mx1-cre induced homozygous Mof loss in adult mice results in dramatic hematopoietic 
failure
Since Vav1-cre; Moff/f mice did not live past the first 2 weeks of life, we utilized the Mx1-cre 
system to assess the effect of Mof loss on adult hematopoiesis. In Mx1-cre mice, the Mx1 
promoter drives expression of Cre and can be induced by synthetic double-stranded RNA 
such as poly I:C (pIpC). In adult Mx1-cre; Moff/f and Mx1-cre; Moff/+ mice, induction of Cre 
by pIpC injections resulted in a rapid and lethal pancytopenia in Mx1-cre; Moff/f mice (data 
not shown). While Mx1 is not only expressed in hematopoietic tissue, but in various organs, 
we used a competitive transplant model to better assess the fate of adult hematopoietic 
Figure 2. Vav1-cre-Moff/f P9 hematopoietic bone marrow cells are functionally impaired
(A) Day 10 of CFU assay of fresh, CD45.2+ Vav1-cre-Moff/f, Vav1-cre-Moff/+ and Moff/f P9 bone marrow 
(BM) cells. Bar graphs indicate mean number of colonies after 10 days (left) and number of live cells 
(right) per plating. 20,000 cells were plated per dish. Data are representative of 3 experiments with 
multiple donor mice per experiment.
(B) Mean percentage of the various colony types relative to all colonies counted per dish per genotype.
(C) Schematic for transplant experiment with CD45.2+ Vav1-cre-Moff/f, Vav1-cre-Moff/+ and Moff/f P9 BM 
cells. B6.SJL recipient mice were injected with BM cells shortly after lethal irradiation (2 x 5Gy). The 
experiment was repeated three times with multiple donor mice per genotype, per experiment.
(D) Survival curve of recipient mice. Mice were all sacrificed 16 weeks (wks) post transplant. Vav1-cre-
Moff/f n=4, Vav1-cre-Moff/+ n=8, Moff/f n=9.
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(E) Bar graph illustrating the percentage of donor cells (CD45.2+) present in recipient BM comparing the 
failed Vav1-cre; Moff/f recipient mice to a properly engrafted Vav1-cre; Moff/+ recipient mouse.
(F) CD45.2% of live cells in peripheral blood (PB) over the time-course of the transplant experiments.
(G) PCR analysis illustrating Mof excision in CD45.2+ BM cells at time of sacrifi ce. A representative 
image is shown.
* p < 0.05. Error bars show SD of mean. Signifi cance compared to Moff/f.
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cells upon MOF loss. Whole BM cells derived from an Mx1-cre; Moff/f, Mx1-cre or Moff/f 
mouse were mixed at a 1:1 ratio with whole BM cells from a wild type (WT) B6.SJL mouse 
and injected into lethally irradiated B6.SJL recipients (Figure 3A). After 16 weeks the mean 
CD45.2 percentage in the peripheral blood (PB) was 26% in Mx1-cre; Moff/f recipients, 37% 
in Mx1-cre recipients and 44% in Moff/f recipients (data not shown). Per genotype, mice were 
split in two even groups with a similar mean CD45.2 percentage and Cre expression was 
induced in one group each, by pIpC injections. Two weeks after the last dose, mice were 
euthanized and processed. Figure 3B, C and D show the CD45.2 percentage of live cells in 
PB, BM and spleen respectively, illustrating that homozygous Mof loss leads to a rapid and 
nearly complete loss of adult hematopoietic cells. While mature myeloid cells are relatively 
more depleted in Mx1-cre; Moff/f pIpC+ CD45.2+ BM cells than mature lymphoid cells 
(Figure 3E), it becomes evident from the absolute cell counts (Figure 3F) that all lineages 
within the CD45.2+ compartment are dramatically depleted. A similar pattern was observed 
for the few residual CD45.2+ cells that remained in PB and spleen (Figure S3A and S3B). 
FACS analysis for progenitors and HSCs showed a significant depletion of MPs, LSKs and 
LT-HSCs relative to the total number of CD45.2+ cells in Mof-deficient BM cells (Figure 3G, 
S3C and S3D). Our findings indicate that Mof is not only required to maintain postnatal, 
but also adult hematopoiesis. Similar to what was found in postnatal hematopoiesis, cell 
numbers in all lineages are strongly affected by Mof loss in an adult transplant setting, but 
HSCs and progenitors suffer the greatest losses. 
Figure 3. Mx1-cre induced homozygous Mof loss in adult mice results in dramatic hematopoietic 
failure
(A) Schematic for competitive transplant experiment with whole bone marrow (BM) cells derived from 
adult Mx1-cre-Moff/f, Mx1-cre and Moff/f mice and BM cells from a B6.SJL mouse. B6.SJL recipient mice 
were injected with fresh BM cells shortly after lethal irradiation. After 16 weeks, half of the mice per 
genotype were injected with pIpC and 2 weeks after the 5th dose of pIpC, mice were euthanized and 
processed. The experiment was performed with 2 donors per genotype and 16-18 recipients per group.
(B) CD45.2% of live cells in peripheral blood (PB) of mice at time of sacrifice, post pIpC treatment. Each 
dot represents a single mouse in the experiment.
(C) CD45.2% of live cells in bone marrow (BM) of mice at time of sacrifice, post pIpC treatment.
(D) CD45.2% of live cells in spleen of mice at time of sacrifice, post pIpC treatment.
(E) Percentages of mature B-cells (B220+), myeloid cells (GR1+/MAC1+), and T-cells (CD3+) in live, 
CD45.2+ BM cells as measured by FACS at time of sacrifice.
(F) The total number of CD45.2+ mature B-cells, myeloid cells, and T-cells as measured by FACS at time 
of sacrifice.
(G) Percentages of LT-HSCs (CD150+/CD48-) within the live, CD45.2+, LSK BM population as measured 
by FACS at time of sacrifice.
* p = 0.0006, ** p = 0.0001, **** p < 0.000006. Error bars show SD of mean.
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Homozygous Mof loss does not affect fetal hematopoiesis at E14.5
Essentially all definitive blood cells and a significant proportion of yolk sac derived primitive 
blood cells express Vav1.27 In the embryo, Vav1 expression appears first in the liver, where 
it becomes just detectable at E9.5 and stronger at E12.5. At that stage, the liver has begun 
to replace the yolk sac and Aorta-Gonad-Mesonephros system as the major hematopoietic 
organ.28 At E14.5, fetal hematopoiesis is at its peak in the liver after which it starts to divert to 
the BM. At E18 most of the hematopoietic progenitors are still located in the liver, but gradually 
decrease through postnatal day 14 (P14) and already at P4, the majority of hematopoietic 
progenitors are found in the BM compartment.29 
Since Vav1-cre; Moff/f pups were delivered to term but displayed lethal hematopoietic 
defects about a week after birth, we set out to study the effects of Mof loss on hematopoiesis 
in murine embryos at E14.5 when fetal liver (FL) hematopoiesis is at its peak. The appearance 
of Vav1-cre; Moff/f embryos did not differ from their heterozygous and WT siblings (Figure 4A) 
and FL cellularity was consistent over all three genotypes (Figure 4B). PCR analysis on fresh, 
CD45.2+ FL cells illustrated complete Mof excision of the floxed alleles in Vav1-cre; Moff/f 
and Vav1-cre; Moff/+ (Figure 4C) and RT-qPCR data show substantial downregulation of Mof 
in the homozygous knockout cells (Figure S4A). Consistent with homozygous Mof deletion, 
Western blot analysis showed loss of global H4K16ac in CD45.2+ Vav1-cre; Moff/f FL cells 
(Figure 4D). Despite this significant loss of H4K16ac in Mof-deficient FL cells, FACS analysis 
showed no change in lymphoid, myeloid and erythroid lineages (Figure 4E and 4F), and also 
MP, LSK and HSC populations were preserved (Figure 4G). These data indicate that Mof and 
subsequent H4K16ac loss does not affect steady state fetal hematopoiesis at E14.5. 
Figure 4. Vav1-cre induced homozygous Mof loss does not affect fetal hematopoiesis at E14.5
(A) Representative photographs of Vav1-cre-Moff/f, Vav1-cre-Moff/+ and Moff/f embryos at E14.5.
(B) Total live fetal liver (FL) cell count.
(C) PCR analysis illustrating Mof excision in fresh CD45.2+ FL cells. A representative image is shown.
(D) Western blot showing global H4K16ac, H4 and Actin in fresh CD45.2+ FL cells.
(E) Percentages of mature B-cells (B220+), myeloid cells (GR1+), and T-cells (CD3+) in live FL cells as 
measured by FACS.
(F) Percentages of cells at various stages of differentiation within the erythroid lineage in live FL cells as 
measured by FACS.
(G) Percentages of MPs and LSKs in live, Lin- FL cells, and HSCs (CD150+/CD48-) as a percentage of 
LSKs, all measured by FACS.
Error bars show SD of mean.
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Vav1-cre-Moff/f hematopoietic E14.5 fetal liver cells are functionally impaired
CFU assays were performed to assess the functional capacity of E14.5 Vav1-cre; Moff/f FL 
HSCs and myeloid progenitors. The colony-forming capacity of Vav1-cre; Moff/f FL cells was 
greatly diminished (Figure 5A). The few colonies that formed were more mature (CFU-M 
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and CFU-G, Figure 5B), suggesting that HSCs or early progenitors may be affected by Mof 
loss to a greater extent than the more mature populations. Next, we performed two non-
competitive transplant experiments where 2,000,000 Vav1-cre; Moff/f, Vav1-cre; Moff/+ or Moff/f 
unselected FL cells were injected into lethally irradiated B6.SJL mice (Figure 5C). All six 
Vav1-cre; Moff/f recipients had to be sacrifi ced within 12 days post transplant (Figure 5D) 
due to failure of donor cells to give rise to the minimally required hematopoiesis to survive 
lethal irradiation (CBC data not shown). Figure 5E shows the percentage of donor cells 
(CD45.2+) present in the recipient PB. This shows that Mof-defi cient E14.5 FL cells were 
unable to reconstitute hematopoiesis in adult mice, whereas heterozygous Mof loss did not 
affect reconstitution. These fi ndings are suggestive of a possible homing defect of FL cells 
to the BM and indeed, we found Vav1-cre; Moff/f cells to exhibit impaired homing capacity in 
a transplant setting (Figure S4B and S4C).
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Figure 5. Vav1-cre-Moff/f hematopoietic E14.5 fetal liver cells are functionally impaired
(A) Day 10 of CFU assay of fresh fetal liver (FL) cells derived from E14.5 Vav1-cre-Moff/f, Vav1-cre-Moff/+ 
and Moff/f embryos. Bar graph indicates mean number of colonies per dish after 10 days. 20,000 cells 
were plated per dish. Data are representative of 3 experiments with multiple embryos per experiment.
(B) Mean percentage of the various colony types relative to all colonies counted per dish per genotype.
(C) Schematic for transplant experiment with FL cells derived from E14.5 Vav1-cre-Moff/f, Vav1-cre-Moff/+ 
and Moff/f embryos. B6.SJL recipient mice were injected with FL cells shortly after lethal irradiation (2 x 
5Gy). The experiment was repeated 2 times with multiple donor embryos per genotype, per experiment.
(D) Survival curve of recipient mice. Mice were all sacrifi ced 16 weeks post transplant. Vav1-cre-Moff/f 
n=6, Vav1-cre-Moff/+ n=6, Moff/f n=7.
(E) CD45.2% of live cells in peripheral blood (PB) over the time-course of the transplant experiments.
(F) Schematic for transplant experiment with FL cells derived from E14.5 Vav1-cre-Moff/f, Vav1-cre-Moff/+ 
and Moff/f embryos and 250,000 whole BM helper cells. B6.SJL recipient mice were injected with cells 
shortly after lethal irradiation. The experiment was repeated two times with multiple donor embryos per 
genotype, per experiment.
(G) CD45.2% of live cells in the peripheral blood over the time-course of the transplant experiments. 
Vav1-cre-Moff/f n=6, Vav1-cre-Moff/+ n=5, Moff/f n=5.
(H) CD45.2% of live cells in BM of recipient mice at week 16.
(I) PCR analysis illustrating Mof excision in CD45.2+ BM cells at time of sacrifi ce. 
** p < 0.01. Error bars show SD of mean. Signifi cance compared to Moff/f.
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To determine short- and long-term engraftment potential of Mof-deficient E14.5 FL 
cells, the rapid death of recipient mice due to lethal irradiation had to be circumvented. 
Therefore, we repeated the FL transplants, but now co-injected 250,000 whole BM, CD45.1+ 
WT helper cells (Figure 5F). These helper cells were capable of rescuing Vav1-cre; Moff/f 
recipient mice from lethal irradiation death. Over the entire time course of the experiment, 
CD45.2 percentages did not rise above 2% in the PB of Vav1-cre; Moff/f FL recipients 
while Vav1-cre; Moff/+ and Moff/f recipients demonstrated stable engraftment with CD45.2 
percentages around 75% (Figure 5G). At time of sacrifice (week 16 post transplant), the 
mean CD45.2 percentage in BM of Mof-deficient FL recipients was 1.8%; significantly lower 
than the CD45.2 percentage in Vav1-cre; Moff/+ (69.2%) or Moff/f (93.2%) FL recipients (Figure 
5H). The few FL cells that did engraft in the Vav1-cre; Moff/f group were only partially excised, 
unlike the engrafted Vav1-cre; Moff/+ FL cells in which the one allele was completely excised 
(Figure 5I). FACS analysis of the CD45.2+ BM cells revealed no significant differences 
between the three groups with regard to the percentage of mature lymphocytes, myeloid 
cells (Figure S4D), LSKs and LT-HSCs (Figure S4E). 
In contrast to the presumably normal hematopoiesis in Vav1-cre; Moff/f embryos, 
these experiments demonstrated significant functional impairment of Mof-deficient E14.5 
FL cells. However, these experiments address fetal HSC functionality outside of the fetal 
microenvironment and therefore suggest an important role of the fetal microenvironment in 
maintaining normal hematopoiesis in Vav1-cre; Moff/f embryos.
Mof-deficient embryos start manifesting hematopoietic defects at E17.5
We wished to further narrow down the time frame in which murine hematopoiesis starts 
to derail due to Mof deficiency. Given the lack of phenotype in Mof-deficient E14.5 
hematopoiesis, we chose to assess FL hematopoiesis at E17.5, a late gestational age, only 
a day or two before birth. Gross morphology of Vav1-cre; Moff/f embryos appeared normal 
(Figure 6A) and the Mof allele was largely excised in hematopoietic Vav1-cre; Moff/f FL 
cells (Figure 6B), consistent with a loss of global H4K16ac (Figure 6C). Total FL cell counts 
were comparable between all three groups (Figure 6D) and erythroid populations did not 
appear affected by loss of Mof (Figure 6E), fitting with the normal appearance of Mof-null 
embryos. However, the CD45.2+ cell number was significantly decreased in E17.5 Vav1-cre; 
Moff/f livers (Figure 6F). FACS analysis of these Mof-deficient CD45.2+ FL cells indicated that 
the absolute number of mature myeloid and lymphoid cells (Figure 6G), and the number of 
MPs, LSKs and HSCs (Figure 6H), was significantly reduced in Vav1-cre; Moff/f embryos. 
These Mof-deficient FL cells were also functionally impaired, whereas they formed fewer 
colonies than the heterozygous and WT control (Figure 6I). The type of colonies did not differ 
significantly (Figure 6J). Together these findings suggest that the hematopoietic defects 
resulting from Mof and subsequent H4K16ac loss start manifesting in late gestation, though 
at E17.5 the phenotype is still quite modest compared to the phenotype in pups and adult 
mice. Interestingly, at E17.5 the erythroid lineage seems intact, which could explain why Mof-
deficient embryos are born at normal ratios. 
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Figure 6. Mof-deficient embryos start manifesting hematopoietic defects at E17.5
(A) Representative photographs of Vav1-cre-Moff/f, Vav1-cre-Moff/+ and Moff/f embryos at E17.5. 
(B) PCR analysis illustrating Mof excision in fresh CD45.2+ FL cells. A representative image is shown.
(C) Western blot showing global H4K16ac, H4 and Actin in fresh CD45.2+ FL cells.
(D) Total live fetal liver (FL) cell count.
(E) The absolute number of cells at various stages of differentiation within the erythroid lineage in E17.5 
FLs as measured by FACS.
(F) Total number of live, CD45.2+ FL cells.
(G) The absolute number of mature B-cells (B220+), myeloid cells (GR1+), and T-cells (CD3+) in E17.5 
FLs as measured by FACS.
(H) The absolute number of MPs, LSKs and HSCs (CD150+/CD48-) as measured by FACS.
(I) Day 10 of CFU assay of fresh FL cells derived from E17.5 Vav1-cre-Moff/f, Vav1-cre-Moff/+ and Moff/f 
embryos. Bar graph indicates mean number of colonies per dish after 10 days. 20,000 cells were plated 
per dish. Each groups contains three biological replicates.
(J) Mean percentage of the various colony types relative to all colonies counted per dish per genotype.
* p < 0.05, ** p < 0.01. Error bars show SD of mean. Significance compared to Moff/f.
Mof histone acetyltransferase activity is required for adult hematopoietic cell survival
MOF has been identified as the major H4K16 acetyltransferase in humans, mice and 
Drosophila.11-14,20 MOF contains a MYST family HAT domain with a CoA binding site (Figure 7A) 
that was shown to be crucial for its acetyltransferase activity.10,12 While MOF possesses 
acetyltransferase activity on various histones and nucleosomes, depletion of MOF in HeLa 
cells was shown to lead to a dramatic decrease in H4K16ac, whereas other acetylation sites 
appeared to be unaffected.20 
Since our data indicate a pivotal role for Mof in adult hematopoiesis, we set out to 
establish the specificity of our model for Mof loss and determine whether MOF HAT activity 
is dispensable. We designed a full-length, Human influenza hemagglutinin (HA)-tagged Mof 
and two HAT inactivated Mof retroviral constructs (Figure 7A) in which either the Coenzyme 
A (CoA) binding site was deleted (Mof-CoAdel) or a HAT inactivating point mutation (G327E) 
was introduced (Mof-G327E). The HAT inactivating point mutation in the MOF CoA binding 
domain was first described in Drosophila12 and later used in a human MOF construct where 
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Figure 7. Mof histone acetyltransferase activity is required for adult hematopoietic cell survival
(A) Schematic of full-length Mof, CoA binding domain deleted Mof or G327E mutant Mof.
(B) Schematic for in vitro rescue experiment. BM LSKs derived from four Moff/f or four WT mice were 
pooled by genotype and retrovirally transduced with full-length Mof (miCD2-Mof), a Mof mutant (miCD2-
CoAdel or miCD2-G327E) or empty vector (miCD2) and hCD2+ cells were sorted after 48 hours. These 
cells were then infected with dTomato-Cre, sorted another 48 hour (hr) later and used for CFU assays.
(C) Western blot showing global H4K16ac, H4 and Actin in Moff/f and wild type (WT) miCD2, miCD2-Mof, 
miCD2-Mof-CoAdel and miCD2-Mof-G327E cells at 48 hours post Cre transduction.
(D) Day 10 of CFU assay. 7000 cells were plated per dish. Representative petri dishes are shown.
(E) Day 10 of CFU assay. Bar graph indicates mean number of colonies per dish after 10 days (left) or 
mean number of live cells (right) per dish. Data are representative of two individual experiments.
(F) Mean percentage of the various colony types relative to all colonies counted per dish per genotype.
(G) PCR analysis illustrating Mof excision in hCD2+, dTomato+ LSKs, 48 hours post Cre infection and at 
day 10 of the colony-forming assay. A representative image is shown.
** p < 0.01. Error bars show SD of mean.
it was also found to diminish H4K16ac30. Alignment of Drosophila, murine and human MOF 
illustrates that the point mutation involves replacement of glycine by glutamic acid on position 
327 (G327E) in murine, as well as human MOF (Figure S5A). The constructs were packaged 
in an miCD2-MSCV retroviral vector with the hCD2 selection marker (miCD2-Mof, miCD2-
Mof-CoAdel and miCD2-Mof-G327E). Our data on Mof loss in the postnatal stage indicate 
variability in the phenotype, most likely due to leakage of the Cre system and high selection 
pressure against excised cells (Figure 2G). We therefore set-up an in vitro Cre transduction 
experiment using adult Moff/f or WT BM-derived LSKs. In order to assess expression of 
the exogenous Mof constructs we performed Western blot analysis for HA-tagged MOF in 
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transformed mouse BM LSKs. Figure S5B illustrates that exogenous Mof was consistently 
expressed by miCD2-Mof, miCD2-Mof-G327E and miCD2-Mof-CoAdel.
For the adult BM-derived LSK rescue experiment we transduced Moff/f or WT LSKs 
with miCD2, miCD2-Mof, miCD2-Mof-G327E or miCD2-Mof-CoAdel. After 48 hours, cells 
were sorted and then infected with dTomato-Cre. After another 48 hours of culture, dTomato 
positive cells were sorted, harvested for extraction of gDNA and protein and plated in 
methylcellulose for CFU assays (Figure 7B). Western blot analysis confirmed that exogenous 
full-length Mof was capable of restoring H4K16ac levels upon genetic Mof loss, while both 
HAT domain mutant Mof constructs were not (Figure 7C). CFU assays showed that exogenous 
expression of full-length Mof could indeed rescue hematopoietic Cre positive Moff/f cells from 
their detrimental fate, indicating the specificity of Mof loss in the observed phenotype (Figure 
7D and 7E). However, HAT-deficient Mof was incapable of rescuing Cre+ Moff/f cells (Figure 
7D and 7E). The one or two colonies that did form in Mof-deficient or Mof HAT-deficient 
cells were differentiated (CFU-G or CFU-M, Figure 7F). These colony-forming capacity and 
proliferation findings are supported by Mof excision PCR data where consistent and strong 
excision was observed in Cre+ Moff/f miCD2-Mof cells throughout the experiment, while the 
few cells that did grow in the Cre+ Moff/f miCD2, miCD2-Mof-CoAdel and miCD2-Mof-G327E 
setting lost Mof excision and were largely unexcised by day 10 of the CFU assay (Figure 7G). 
Interestingly, we found that Mof-deficient LSKs had significantly more yH2AX foci per 
cell nucleus compared to the WT control (p < 0.0001; Figure S5C and S5D), indicative of more 
DNA damage. All together these data indicate that the observed phenotype of homozygous 
Mof deletion in hematopoietic adult cells is specific to the loss of Mof. In addition, we have 
demonstrated that the HAT activity of Mof is crucial for survival of adult hematopoietic cells 
and that it may be required for genomic stability or adequate DNA damage response in adult 
HSCs.
DISCUSSION
The discovery that Mof is required for adult, but not early fetal hematopoiesis sheds new 
light on our understanding of regulation of hematopoietic development. We demonstrate that 
Mof is critical for hematopoietic cell maintenance and reconstitution in adult hematopoiesis. 
Rescue experiments with Mof HAT domain mutants illustrated the requirement for Mof 
acetyltransferase activity in the clonogenic capacity of HSCs and progenitors. In stark contrast, 
fetal steady-state hematopoiesis at E14.5 did not seem to be affected by homozygous Mof 
deletion despite dramatic loss of global H4K16ac. Given that previously published work 
using the Vav1-cre system has generated defects in fetal HSCs at E14.531, we conclude that 
Mof plays a critical role in adult, but not early fetal HSC maintenance.
HSCs undergo discrete developmental changes throughout life, the biggest being 
the transition from fetal to adult hematopoiesis.32 Early and mid- gestational hematopoiesis 
is characterized by rapid proliferation of undifferentiated HSCs to supply the developing 
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hematopoietic system.33 In adult hematopoiesis, lifelong blood cell production depends 
on the delicate balance between HSC self-renewal and differentiation34, so in contrast to 
fetal hematopoiesis, most adult HSCs turn quiescent35 to ensure HSC pool maintenance. 
This switch sets in at E16.5 and is complete at around 3 weeks after birth.32 As fetal HSCs 
markedly differ from adult HSCs with respect to cell cycle status35, proliferative capacity33 
and differentiation potential36, it is not surprising that they also differ in gene expression31,37 
and regulation31,38. While some genes39-44 regulate HSC maintenance throughout fetal 
and adult life, the transcription factor Sox1731 was found to be essential for fetal but not 
adult hematopoiesis. Similar to the observed phenotype in hematopoietic Mof loss, the 
transcriptional regulator Bmi1 has been shown to maintain adult, but not early fetal HSCs.38 
While pluripotency and lineage differentiation depend on establishing and maintaining 
gene expression programs that are largely regulated by chromatin organization45, it seems 
likely that multiple chromatin regulators are crucial for hematopoiesis at varying stages of 
development. Consistent with this notion is the finding that the chromatin regulator Ezh2 is 
required for fetal but not adult hematopoiesis.46 Our findings also support this concept that 
chromatin regulators are differentially involved in hematopoietic development, whereas we 
have shown that MOF HAT activity is a crucial regulator of post-natal and adult hematopoiesis, 
but not of the highly proliferative early and mid- gestational hematopoietic compartment. The 
fact that we can isolate fetal, phenotypically defined HSCs that are completely devoid of 
H4K16ac is quite remarkable and suggests a dramatic difference in chromatin structure 
between fetal and adult HSCs.
Further highlighting the importance of H4K16 acetylation, we have shown that the 
enzymatic activity of MOF is crucial for adult HSC maintenance and functionality (Figure 
7E). In addition we found an increase in DNA damage in Mof-deficient adult HSCs (Figure 
S5C and S5D). Further studies will be required to test why fetal hematopoietic cells can exist 
despite the dramatic, MOF-loss-induced H4K16ac deficiency (Figure 4D). H4K16 acetylation 
was found to have a limited role in transcriptional regulation of HEK293 cells47, as opposed 
to its activity in mouse embryonic stem cells21. While most studies on Mof depletion report 
adverse outcomes in various cell types, a recent study found that Mof deficiency in quiescent 
glomerular podocytes had no effect on kidney function in mice.48 These findings suggest 
that H4K16ac requirement may indeed be cell type specific, though it remains surprising 
that a highly proliferative hematopoietic system such as found in an E14.5 embryo, can be 
maintained, despite lack of H4K16ac. This is particularly interesting, as H4K16ac is believed 
to be one of the most important histone modifications to maintain euchromatin in mammalian 
cells.49 Previous data from murine embryonic fibroblasts (MEFs) suggest that a MOF-induced 
increase of H4K16ac is essential for an appropriate DNA damage response.17 Our finding 
of an increase in DNA damage in Mof-deficient LSKs, leads us to speculate that the MOF-
loss induced global H4K16ac depletion in adult HSCs potentially reduces accessibility of 
nucleosomes to repair proteins, by increasing chromatin compaction at the DNA damage 
foci, leading to gross genomic instability. Possibly other chromatin marks compensate for this 
lack of H4K16ac in fetal HSCs. Another possibility is that the regulation of chromatin structure 
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is dramatically different between fetal and adult HSCs. Future studies using quantitative mass 
spectrometry to define global epigenomic changes50 could yield significant mechanistic 
insight into the role of altered epigenomic states throughout hematopoietic development.
The observed hematopoietic defects found in the liver of E17.5 Mof-deficient 
embryos (Figure 6), though more moderate than in pups and adults, make it unlikely 
that the phenotype in post-natal and adult Mof-null mice is solely caused by an impaired 
seeding capacity or engraftment of FL cells to the BM niche. Previous work has shown that 
distinct microenvironmental regulatory mechanisms exist between the fetal and adult HSC 
niche.32,33,51,52 It is, however, conceivable that the FL microenvironment itself is also modified 
during fetal development in order to meet the changing needs of lineage differentiation and 
HSC expansion.32 Our data suggest that earlier embryonic, Mof-deficient HSCs (<E15.5) are 
capable of proliferation and differentiation (Figure 4). However, over the next few days of 
gestation, intrinsic cellular requirements and microenvironmental stimuli change and it may 
be that Mof-null, H4K16ac-deficient HSCs are incapable of adapting to these changes due 
to significant abnormalities in chromatin structure. 
As previously mentioned, MOF and MLL1 complexes interact and this interaction was 
shown to be important for the chromatin regulatory function of both enzymes.22 Apart from 
its role in normal hematopoiesis, wild type MLL1 has been shown to play a role in MLL-
rearranged leukemogenesis.53,54 However, in both normal and malignant hematopoiesis, the 
H3K4 methyltransferase activity of MLL1 is dispensable.25 Given the interaction of MLL1 and 
MOF, and the necessity of MOFs HAT activity in adult hematopoiesis, it will be interesting 
to determine leukemia dependence on the enzymatic activity of MOF. It may be that in the 
setting of MLL-rearranged leukemia, it is in fact the HAT activity of MOF that is required for 
leukemogenesis. Future experiments assessing the role of MOF HAT activity in MLL1 fusion 
leukemogenesis should shed light on this hypothesis.
In conclusion, our study shows that Mof is a critical regulator of adult, but not early fetal 
hematopoiesis, thereby supporting the notion that chromatin regulation of hematopoiesis 
changes over time. We have identified MOF-controlled chromatin regulation as a 
developmental-stage-specific mechanism for adult hematopoietic maintenance. 
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EXPERIMENTAL PROCEDURES
Mice
The generation of Mof conditional knockout mouse in a C57Bl/6 (CD45.2+) background has 
been described previously.14 Moff/f mice were crossed to Vav1-cre or Mx1-cre mice and 
Cre was maintained as a heterozygous allele to generate Vav1-cre; Moff/f or Mx1-cre; Moff/f 
mice. Genotyping strategies were described previously.14 WT B6.SJL (CD45.1+) mice were 
purchased from Taconic, Hudson, NY. All animal experiments in this study were approved 
by and adhered to guidelines of the Memorial Sloan-Kettering Cancer Center Animal Care 
and Use Committee.
Isolation of murine hematopoietic cells
Vav1-cre; Moff/f, Vav1-cre; Moff/+, Moff/f, Mx1-cre; Moff/f, Mx1-cre and WT adult mice or 8-9 
day-old pups were sacrificed and peripheral blood, spleen, thymus, liver and bones (femurs, 
tibias, fibulas, pelvis and spine) were extracted. BM cell suspensions were prepared by 
crushing bones after removal of muscle and connective tissue. Spleen and thymus cell 
suspensions were prepared by crushing the tissue through a 0.45 μm nylon mesh filter. 
Vav1-cre; Moff/f, Vav1-cre; Moff/+ and Moff/f FL cells were obtained by timed breeding 
of a Vav1-cre; Moff/+and Moff/f couple during the course of 3 days and daily checking the 
females for a vaginal plug. Fourteen or seventeen days after a vaginal plug was observed, 
pregnant females were euthanized (E14.5 or E17.5 respectively). Fetuses were extracted 
from the euthanized mother and kept in PBS (Thermo Fisher Scientific, Waltham, MA) for 
further processing. FL cell suspensions were prepared by extracting the liver from the 
embryo and flushing it through a 23G needle in a tube containing PBS supplemented with 
2.5% fetal bovine serum (FBS, Thermo Fisher Scientific, Waltham, MA).
Transplant experiments
All transplant experiments were performed by retro-orbitally injecting freshly isolated BM 
or FL cells into lethally irradiated (2 x 5Gy), 6-8 week-old B6.SJL female recipient mice. 
Mice were euthanized at or after 16 weeks or sacrificed sooner when severely anemic. Mice 
were bled every 4 weeks to monitor complete blood count (CBC), CD45.2% and mature 
hematopoietic populations. Further details on transplant experiments can be found in the 
Supplemental data.
Obtaining CD45.2+, Lineage depleted or LSKs
CD45.2+ cells were obtained by labeling BM or FL cells with a CD45.2 APC antibody 
(Biolegend, San Diego, CA) and sorting positive cells on an ARIA cell sorter (BD, San Jose, 
CA). Lineage depletion was performed by labeling BM or FL cells with purified, biotinylated 
monoclonal antibodies to CD3e, CD11b (MAC1), CD45R (B220), Ly-6G (GR1) and TER119 
(Biotin mouse lineage panel, BD). Lin+ cells were in majority removed by magnetic bead 
depletion with streptavidin conjugated MicroBeads over an LD column (both Miltenyi Biotech, 
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San Diego, CA). If required, Lin-, SCA1+, cKIT+ (LSK) cells were then obtained by staining 
lineage depleted cells with Streptavidin APC/Cy7, (Biolegend, San Diego, CA), CD117 (cKIT) 
APC and Ly-6A/E (SCA1) PE/Cy7 (both eBioscience, San Diego, CA), and sorting the LSK 
population.
In vitro colony-forming assays
To study the impact of Mof deletion on colony-forming capacity, fresh CD45.2+ sorted BM 
cells or whole FL cells (both 20,000 cells per dish) were plated in methylcellulose M3434 
(Stemcell Technologies, Vancouver, BC, Canada) in 35mm culture dishes. Colonies were 
scored after 10 days, using the Eclipse TS100 inverted microscope (Nikon, Tokyo, Japan). 
Cells from pooled colony aggregates were then assessed for Mof excision. 
In case of the Mof LSK rescue experiments, fresh LSKs from four Moff/f and four WT 
mice were pooled by genotype, split into four and infected with retrovirus containing miCD2, 
miCD2-Mof, miCD2-Mof-CoAdel or miCD2-Mof-G327E. After 48 hours of liquid culture, cells 
were sorted for hCD2 positivity and immediately infected with dTomato-Cre. Another 48 
hours later, dTomato positive cells were sorted, counted and plated (7000 cells per dish) in 
M3434 methylcellulose as described. 
Data Analysis and Statistical Methods
GraphPad Prism software was used for statistical analysis. Statistical significance between 2 
groups was determined by unpaired 2-tailed Student’s t-test. The Kaplan-Meier method was 
used to plot survival curves for murine leukemic transplant data.
See Supplemental Experimental Procedures for more details. 
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Figure S1, related to Figure 1. Vav1-cre induced homozygous Mof loss leads to lethal                       
hematopoietic failure in mouse pups
(A) Spleen and thymus cell count of 9-day-old Vav1-cre-Moff/f, Vav1-cre-Moff/+ and Moff/f pups.
(B) FACS gating strategy for measuring differentiation within the erythrocyte lineage in bone marrow 
(BM) and spleen. Live cells were selected prior to CD71/TER119 gating. P1 through P4 defines erythroid 
cell maturity where P1 consists of erythroid progenitors and P4 of mature erythrocytes. Representative 
images of a Moff/f mouse are shown.
(C) Total number of cells at various stages of differentiation within the erythroid lineage in BM (harvested 
from femurs, pelvic bones, tibias and spine) and spleen as measured by FACS.
(D) FACS gating strategy for measuring various stages of differentiation within the T-cell lineage in the 
thymus. Live cells were selected prior to CD4/CD8 gating. CD4+ or CD8+ cells are most mature and 
CD4-/CD8- (double negative or DN) cells most immature. Within DN cells, maturity is defined by CD44 
and CD25 cell surface markers where P1 is most immature and P4 most mature. Representative images 
of a Moff/f mouse are shown. DP = double positive.
(E) Total number of cells at various stages of differentiation within the T-cell lineage in the thymus as 
measured by FACS.
(F) Percentages of mature B-cells (B220+), myeloid cells (GR1+/MAC1+), and T-cells (CD3+) out of live, 
CD45.2+ PB, BM and spleen cells as measured by FACS.
* p < 0.05, ** p < 0.01. Error bars represent SD of mean. Significance compared to Moff/f.
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Figure S2, related to Figure 1. Vav1-cre induced homozygous Mof loss leads to depletion of 
myeloid progenitors and LSKs in mouse pups
(A) FACS gating strategy for measuring MP and LSK percentages in bone marrow (BM) derived from 
9-day-old Vav1-cre-Moff/f and Moff/f pups. After CD45.2+ live cell selection, Lin- cells are gated and the 
Lin- population is divided into MPs and the HSC enriched LSK population by cKIT and SCA1 staining. 
Representative images are shown. 
(B) Percentages of MP and LSK cells in Lin- BM as measured by FACS.
** p < 0.01. Error bars represent SD of mean. Significance compared to Moff/f.
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Figure S3, related to Figure 3. Mx1-cre induced homozygous Mof loss in adult mice results in 
dramatic hematopoietic failure
(A) A competitive transplant was performed with 1,000,000 whole bone marrow (BM) cells derived from 
adult Mx1-cre-Moff/f, Mx1-cre and Moff/f mice and 1,000,000 BM cells from a B6.SJL mouse. B6.SJL 
recipient mice were injected with the fresh BM cells shortly after lethal irradiation. After 16 weeks, half of 
the mice per genotype were injected with pIpC and 2 weeks after the 5th dose of pIpC, mice were 
euthanized and processed. Shown is the percentage of mature B-cells (B220+), myeloid cells           
(GR1+/MAC1+), and T-cells (CD3+) in live, CD45.2+ PB cells as measured by FACS at time of sacrifice.
(B) Percentages of mature B-, myeloid and T-cells in live, CD45.2+ spleen cells as measured by FACS 
at time of sacrifice.
(C) Percentages of MPs in live, CD45.2+, Lin- BM cells as measured by FACS at time of sacrifice.
(D) Percentages of LSKs in live, CD45.2+, Lin- BM cells as measured by FACS at time of sacrifice.
** p < 0.01. Error bars represent SD of mean.
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Figure S4, related to Figure 4 and 5. Vav1-cre-Moff/f hematopoietic E14.5 fetal liver cells have 
reduced Mof expression and are functionally impaired
(A) Bar graph illustrates relative expression levels (RT-qPCR) as mean log fold change in E14.5 
Vav1-cre-Moff/f  FL cells compared to Moff/f control cells.  
(B) Schematic for homing experiment. CD45.2+ FL cells derived from E14.5 Vav1-cre-Moff/f, 
Vav1-cre-Moff/+ or Moff/f embryos (n=5 per genotype) were pooled per genotype and 1,500,000 cells 
injected per lethally irradiated B6.SJL recipient mouse. Mice were euthanized 24 hours after transplant 
to assess donor cell homing to the BM.
(C) Graph represents the absolute number of CD45.2+ cells detected in the BM of recipient mice, 24 
hours post transplant. Each dot represents a single recipient mouse in the experiment.
(D) Transplant experiment with 2,000,000 FL cells derived from E14.5 Vav1-cre-Moff/f, Vav1-cre-Moff/+ 
and Moff/f embryos and 250,000 whole bone marrow (BM) helper cells. B6.SJL recipient mice were 
injected with cells shortly after lethal irradiation. Percentages of mature B-cells (B220+), myeloid cells 
(GR1+/MAC1+), and T-cells (CD3+) in live, CD45.2+ BM cells are shown as measured by FACS at time of 
sacrifice (week 16).
(E) Percentages of LSKs and LT-HSCs (CD150+/CD48-) out of live, CD45.2+ BM cells as measured by 
FACS at time of sacrifice.
** p < 0.01. Error bars represent SD of mean.
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Figure S5, related to Figure 7. Mof loss in LSKs leads to DNA damage
(A) Aligned HAT domains (underlined residues) from Drosophila, human and murine MOF. The 
Acetyl-CoA binding pocket is highlighted in purple and the position of the G327E point mutation is 
marked in green.
(B) While Mof deficient cells in pups were not fully Mof deficient and Mof deficient FL cells quickly died 
after putting them in culture, the functionality of these constructs had to be tested in a different murine 
cell type. Murine MLL-AF9 leukemia cells in a Moff/f background were infected with HA-tagged 
full-length Mof (miCD2-Mof), CoA deleted Mof (miCD2-CoAdel), G327E mutated Mof (miCD2-G327E) or 
empty vector control (miCD2) in an MSCV-miCD2 retroviral vector, and selected by sorting hCD2+ cells. 
Western blotting for HA confirms presence of these exogenous constructs.
(C) Moff/f or wild type (WT) LSKs were harvested from adult mice, in vitro transduced with Cre, sorted 48 
hours post Cre infection and fixed. DNA damage was assesed by immunofluorescence of yH2AX. 
Representative images are shown.
(D) Graph illustrates the number of large yH2AX foci per cell nucleus, where a dot represents a single 
cell. Shown are two biological replicates per genotype. There is no significant difference between 
biological replicates.
** p < 0.01. Error bars represent SD of mean.
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Plasmids and constructs
NH3-terminal HA-tagged WT Mof was amplified by PCR and subcloned into the HpaI site of 
the retroviral vector MSCV-IRES-miCD2 (MSCV-HA-Mof-IRES-miCD2). To generate the two 
Mof HAT domain mutants MSCV-HA-Mof-G327E-IRES-miCD2 and MSCV-HA-Mof-CoAdel-
IRES-miCD2, HA-tagged Mof-G327E (327 glycine to glutamic acid mutation, a point mutation 
in the highly conserved CoA binding pocket of the MOF HAT domain), and HA-tagged Mof-
CoAdel (deletion of the CoA binding pocket of the MOF HAT domain, 314-333 residues) were 
generated using the Q5® Site-Directed Mutagenesis Kit (New England BioLabs, Ipswich, 
MA). The mutant and WT Mof constructs were verified by sequencing. The MSCV-MLL-AF9-
IRES-GFP and MSCV-Cre-IRES-dTomato plasmid have been previously described.1,2 The 
pCL-Eco plasmid was used for retroviral packaging. 
Liquid cell culture
293T cells used for ecotropic retroviral production were cultured in DMEM, supplemented 
with heat inactivated 10% fetal bovine serum (FBS) and 50 U/mL penicillin/streptomycin (all 
Thermo Fisher Scientific, Waltham, MA).
In vitro transformed MA9  mouse LSKs and fresh FL cells were cultured in IMDM, 
supplemented with heat inactivated 10% FBS, 50 U/mL penicillin/streptomycin (all Thermo 
Fisher Scientific) and murine IL3 (10 ng/mL), IL6 (10 ng/mL) and SCF (20 ng/mL)(all 
PeproTech, Rocky Hill, NJ). 
Fresh BM LSKs or hematopoietic progenitors were cultured in Stemspan (Stemcell 
Technologies, Vancouver, BC, Canada), supplemented with 100ng/mL SCF, 100ng/mL TPO, 
50ng/mL FLT3, 10ng/mL IL3 and 10ng/mL IL6 (all PeproTech).
Transplant experiments
Transplant experiments with P9 Vav1-cre; Moff/f, Vav1-cre; Moff/+ and Moff/f BM cells 
were performed by isolating CD45.2+ BM cells and injecting 633,000 cells per recipient. 
Depending on the donor cell number, 2-3 recipients per donor were used. Transplant 
experiments with Vav1-cre; Moff/f, Vav1-cre; Moff/+ and Moff/f E14.5 FL cells were performed 
by injecting 2,000,000 unselected FL cells per recipient (2-3 recipients per donor). For the 
FL co-transplant experiments, 2,000,000 unselected FL cells and 250,000 whole BM helper 
cells from a B6.SJL mouse were injected per recipient. FL and P9 transplant experiments 
were repeated at least two times with multiple donors per genotype per experiment.
Mx1-cre; Moff/f, Mx1-cre and Moff/f BM transplant experiments were conducted by 
isolating whole BM cells from two 20-week-old donor mice per genotype and from one B6.SJL 
mouse. Per recipient, 1,000,000 unselected BM cells from both the Mx1-cre; Moff/f, Mx1-cre 
or Moff/f mouse and from the B6.SJL WT mouse were injected. 16 weeks post transplant, 
mice were split in even groups with a similar mean CD45.2 percentage after which one of 
the groups received five poly I:C (pIpC, Invivogen, San Diego, CA) injections every other 
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day (12.5 μg per gram of mouse body weight). Two weeks after the last dose, mice were 
euthanized and processed. We observed some depletion of CD45.2+ cells in the BM of Moff/f 
recipients though this difference was much more dramatic in the Mx1-cre; Moff/f recipients. 
Homing experiments
Homing experiments were performed by venous injection of CD45.2+ E14.5 Vav1-cre; Moff/f, 
Vav1-cre; Moff/+ or Moff/f FL cells into lethally (5 x Gy) irradiated B6.SJL recipients. Five 
mice were pooled per genotype and 1,500,000 cells injected per recipient mouse. Mice 
were euthanized exactly 24 hours after transplant and bones harvested to assess CD45.2 
frequency by FACS. 
FACS analysis
Mof-loss induced changes in hematopoietic populations were identified by staining cells for 
various surface markers and subsequent FACS analysis on a CANTO II (BD, San Jose, CA). 
The following FACS antibodies were used in various combinations: CD44 APC, CD25 PE, 
SCA1 PE-Cy7, SCA1 PerCP-Cy5.5, CD48 FITC and CD45.2 PerCP-Cy5.5 (all eBioscience, 
San Diego, CA), CD4 PerCP-Cy5.5, TER119 APC, B220 APC-Cy7, CD3 PB, MAC1 APC, 
MAC1 PerCP-Cy5.5, GR1 PE, GR1 PECy7, cKIT APC, cKIT PE-Cy7, streptavidin APC-Cy7, 
CD150 PE, CD45.2 APC and CD45.1 PE (all Biolegend, San Diego, CA), CD8a PB, CD71 PE 
and CD45.2 FITC (all BD). 
Western blot
Murine, in vitro transformed LSKs with stable expression of the MA9 fusion and miCD2, miCD2-
Mof, miCD2-Mof-CoAdel or miCD2-Mof-G327E were lysed in 1X cell lysis buffer (#9803, Cell 
Signaling, Danvers, MA). Samples were heated at 75 °C for 10 minutes, sonicated for 10 
times 30 seconds and analyzed by SDS-PAGE by loading a total of 2 million cells per lane. All 
H4K16ac and H4 Western blots were performed using either murine E14.5 or E17.5 CD45.2+ 
FL cells or Cre-transduced LSKs that were lysed in an LDS lysis buffer (4X LDS sample buffer 
from NuPage, H2O and 0.5M DTT, all Thermo Fisher Scientific). Samples were heated at 95 
°C for 10 minutes, sonicated for 10 times 30 seconds and analyzed by SDS-PAGE by loading 
100,000 cells per lane.
Western blotting was done following standard procedures using a 10% Bis-Tris Gel 
(Nupage, Invitrogen, Carlsbad, CA) and transferred onto PVDF membranes using the iBlot dry 
transfer system (Invitrogen). For assessment of HA-tagged proteins, global H4K16ac, global 
H4, Actin and GAPDH, anti-HA antibody (HA.11, Covance, Dedham, MA), anti-H4K16ac 
antibody (07-329, EMD Millipore, Billerica, MA), anti-H4 antibody (07-108, EMD Millipore, 
Billerica, MA), anti-Actin antibody (MAB1501R, EMD Millipore) and anti-GAPDH antibody 
(FL-335, Santa Cruz) were used. Secondary antibodies were either sheep anti-mouse IgG 
(NA931V) or anti-rabbit IgG (NA934V) ECL horseradish peroxidase linked antibody from GE 
Healthcare (Little Chalfont Buckinghamshire, UK). 
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yH2AX immunofluorescence staining
Cytospins were generated using the Shandon Cytospin 4 cytofuge (Thermo Fisher Scientific, 
Waltham, MA) by spinning 70,000-90,000 cells onto glass slides (500 rpm for 10 minutes). 
Cytospins were fixed using a 4% PFA/PBS mix and cells perforated with 50ug/mL Digitonin 
in PBS. Cells were incubated at 4 °C overnight with yH2A.X p-S139 (Abcam, Cambridge, 
MA) and 30 minutes at room temperature with the secondary anti-rabbit Alexa488 antibody 
(Molecular Probes, Thermo Fisher Scientific, Waltham, MA). Then cells were stained with 
DAPI and mounted using Prolong Gold Antifade Reagent (both Thermo Fisher Scientific, 
Waltham, MA). Nuclear immunofluorescence microscopy was done using a Leica SP5 
upright confocal microscope (Leica, Wetzlar, Germany). The number of yH2AX foci was 
determined using ImageJ software on representative microscopy images.
REFERENCES
1. Bernt KM, Zhu N, Sinha AU, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 
methylation by DOT1L. Cancer Cell. 2011;20(1):66-78.
2. Deshpande AJ, Deshpande A, Sinha AU, et al. AF10 regulates progressive H3K79 methylation and 
HOX gene expression in diverse AML subtypes. Cancer Cell. 2014;26(6):896-908.
Thesis_DG.Valerio_v3_homecomputer.indb   184 10/17/16   12:08 AM
185MOF in Normal Hematopoiesis
CH
AP
TE
R 
5
Thesis_DG.Valerio_v3_homecomputer.indb   185 10/17/16   12:08 AM
Thesis_DG.Valerio_v3_homecomputer.indb   186 10/17/16   12:08 AM
6
SUMMARY AND GENERAL DISCUSSION
Thesis_DG.Valerio_v3_homecomputer.indb   187 10/17/16   12:08 AM
188 Chapter 6
Thesis_DG.Valerio_v3_homecomputer.indb   188 10/17/16   12:08 AM
189Summary and General Discussion
CH
AP
TE
R 
6
In this thesis we have explored chromatin regulation in acute leukemia and normal 
hematopoiesis. In doing so, we have focused on the H3K4 methyltransferase MLL1 and the 
H4K16 acetyltransferase MOF. Here we will summarize the major findings of our experimental 
studies reported in Chapters 3, 4 and 5 and discuss their relevance for our understanding of 
the biology of leukemia as well as their potential therapeutic implications.
NUP98 FUSION PROTEINS INTERACT WITH THE NSL AND MLL1 
COMPLEXES TO DRIVE LEUKEMOGENESIS
In Chapter 3 we showed that NUP98 fusion proteins encoded by NUP98 fusion genes such as 
NUP98-HOXA9, NUP98-HOXD13, NUP98-TOP1 and NUP98-NSD1, physically interact with 
MLL1 and the NSL histone modifying complexes. Using ChIP-seq, we identified significant 
overlap in binding targets between NUP98 fusions and MLL1 (Figure 1, top panel). Further 
functional assays illustrated that Mll1 is required for the colony formation of various NUP98-
fusion driven leukemias in vitro and for maintenance of NUP98-HOXA9 (NHA9) leukemia 
in vivo. Mll1 loss leads to terminal differentiation of leukemic blasts through decreased 
expression of genes where NUP98 fusions and MLL1 colocalize, such as Meis1 and Hox 
cluster genes (Figure 1, bottom panel). This relation between MLL1 and NUP98 fusion target 
gene expression was confirmed by rescue experiments with exogenous expression of these 
shared target genes, which leads to rescue of the Mll1-loss-induced phenotype. Thus these 
findings indicate that MLL1 is crucial for NUP98 fusion leukemogenesis, likely by recruiting 
the NUP98 fusion protein to its target gene loci.
One of the next questions is: which are the critical protein(s) that interact with the 
NUP98 fusion and the MLL1 and NSL complexes? Based on previous Drosophila data1 it is 
likely that the interaction is through PHF20, which is a component of both the MLL1 and NSL 
complex. It is also possible that the NUP98 fusion protein interacts with the MLL1 complex 
through menin, similar to what has been found for the MLL-AF9 fusion protein2, and that MOF 
directly binds to MLL1 as was described by Dou et al3. Knockdown experiments followed by 
IP of the various proteins involved, could shed light on this question.
With regard to the specific domain of interaction, our data demonstrate that MLL1 and 
NSL protein complexes interact with the NUP98 N-terminus, but only in case of a truncated 
NUP98 as found in the fusion protein; wild type NUP98 does not interact. As was previously 
shown in Drosophila4, our findings confirm that, while wild type NUP98 is localized in the 
nuclear membrane as part of the nuclear pore complexes, the NUP98 N-terminus only 
localizes in the nucleoplasm. We found that the same nucleoplasmic localization holds true for 
NUP98 fusion proteins. Therefore we hypothesize that, due to this nucleoplasmic localization, 
MLL1 and NSL complexes can interact with the NUP98 fusion protein and that this interaction 
allows for the NUP98 fusion to be recruited to the DNA target loci. Based on our findings, this 
mechanism of oncogenicity may apply to all various NUP98 translocations.
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Figure 1. NUP98 fusion proteins interact with the NSL and MLL1 complexes to drive leukemogenesis 
The top panel illustrates that NUP98 fusion proteins were found to physically interact with the MLL1 
(turquoise colored) and NSL (yellow/orange colored) complexes. The dark blue proteins are shared 
between both the MLL1 and NSL complex. Based on Drosophila data, this interaction may be through 
PHF20, a protein present in both complexes. NUP98 fusion proteins bind DNA at various target genes 
such as Meis1 and Hoxa and b cluster loci where they upregulate expression of these genes. The 
bottom panel indicates that upon MLL1 loss, expression of the target genes diminishes, possibly while 
NUP98 fusions are no longer able to bind the DNA loci. The decreased expression of these target genes 
leads to terminal differentiation of the leukemic blasts.
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HISTONE ACETYLTRANSFERASE ACTIVITY OF MOF IS REQUIRED 
FOR MLL-AF9 LEUKEMOGENESIS
In Chapter 4 we identified Mof knockdown as one of the most potent suppressors of MLL-AF9 
(MA9) leukemic cell growth in a chromatin regulator focused RNAi screen. Further experiments 
using a murine conditional Mof knockout (KO) model illustrated that homozygous Mof deletion 
in MA9 leukemic cells leads to reduced tumor burden and prolonged survival in mice. RNA 
sequencing and immunofluorescence experiments indicate defective DNA damage repair 
as one of the mechanisms of cell death in Mof-deficient MA9 cells. In addition, we uncovered 
a loss of global H4K16ac upon Mof KO. Rescue experiments with histone acetyltransferase 
(HAT) domain mutated MOF illustrated that MOF HAT activity is indispensable for MA9 
leukemia maintenance (Figure 2).
Though we have established the importance of MOF HAT activity for MA9 
leukemogenesis, we have not yet elucidated the mechanism by which H4K16ac loss leads 
to cell death. Based on our data and previous studies in murine embryonic fibroblasts 
(MEFs), impaired DNA damage and possibly chromosomal instability are involved. Li et 
al. showed that radiation induced DNA damage in wild type MEFs leads to an increase of 
global H4K16ac5, suggesting that a MOF-induced increase of H4K16ac may be essential 
for an appropriate DNA damage response. Unacetylated H4K16 is required to achieve the 
maximum tendency of in vitro nucleosome arrays to fold into secondary or tertiary chromatin 
structures.6 In contrast, 30% H4K16 acetylation alleviates compaction of the chromatin fiber.7 
Therefore it may be that global H4K16ac depletion upon loss of MOF reduces accessibility 
of nucleosomes to repair proteins, by increasing chromatin compaction at the DNA 
damage foci. Future experiments assessing chromatin accessibility in MA9 Mof-null cells 
by assay for transposase-accessible chromatin with high throughput sequencing (ATAC-
seq) and micrococcal nuclease digestion assays should provide data on general chromatin 
compaction and may help elucidate the connection between H4K16ac and accessibility of 
genes involved in DNA damage repair.
HISTONE ACETYLTRANSFERASE ACTIVITY OF MOF IS REQUIRED 
FOR ADULT, BUT NOT EARLY FETAL HEMATOPOIESIS IN MICE
In Chapter 5 we have demonstrated that Mof expression is critical for hematopoietic cell 
maintenance and hematopoietic reconstitution in adult hematopoiesis. Rescue experiments 
with Mof HAT domain mutants illustrated the requirement for MOF acetyltransferase activity 
in HSC and progenitor maintenance and colony-forming capacity. In contrast, E14.5 fetal 
hematopoiesis did not seem affected by homozygous Mof deletion despite dramatic loss of 
global H4K16ac. Hematopoietic defects start manifesting late gestation at E17.5 (Figure 3).
Thesis_DG.Valerio_v3_homecomputer.indb   191 10/17/16   12:08 AM
192 Chapter 6
HAT
histone acetyl
histone methyl
H3K4 H4K16
RBBP5
ASH2L
DPY30
MLL1
MOF
WDR5
N
C
MENIN
© DARIA VALERIO
MLL1 AF9
Figure 2. Histone acetyltransferase activity of MOF is required for MLL-AF9 leukemogenesis
The physical interaction between wild type MLL1 and the MLL-AF9 fusion protein through menin has 
previously been established. In addition, it was shown that MOF and MLL1 not only share several 
proteins in their respective complexes, but also directly interact. MLL1 is an H3K4 methyltransferase, 
but this enzymatic function is not required for MLL-AF9 leukemogenesis. We found that MOF and it’s 
histone acetyltransferase (HAT) activity are required for MLL-AF9 leukemia maintenance and that loss of 
MOF HAT activity leads to global loss of H4K16ac and thereby leukemic blast cell death.
It has been well established that the hematopoietic system undergoes discrete 
developmental changes in the transition from fetal to adult hematopoiesis. Where earlier fetal 
hematopoiesis demands rapid expansion of undifferentiated HSCs to supply the developing 
hematopoietic system8, lifelong blood cell production in adult hematopoiesis depends on 
the delicate balance between HSC self-renewal and differentiation9. While pluripotency 
and lineage differentiation require the establishment and maintenance of gene expression 
programs that are largely regulated by chromatin organization10, it seems likely that multiple 
chromatin regulators are crucial for hematopoiesis at varying stages of development. 
Consistent with this notion is the fi nding that the chromatin regulator Ezh2 is required for fetal 
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but not adult hematopoiesis.11 Our findings also support this idea of chromatin regulators 
being differentially involved in hematopoietic development, since we have shown that MOF 
HAT activity is a crucial regulator of post-natal and adult hematopoiesis, but not of the highly 
proliferative early and mid- gestational hematopoietic compartment. 
Although many common signals may be present in both the fetal and adult HSC niche, 
distinct regulatory mechanisms exist to promote de novo generation or expansion of HSCs 
in the fetus, as compared to the mechanisms governing the balance of HSC differentiation 
and quiescence in the adult.8 Significant progress has been made in understanding the adult 
hematopoietic microenvironment, but only little is known about the fetal niche. Hackney et al. 
have made a first step in defining key components of the fetal liver (FL) microenvironment that 
support HSC expansion.12,13 By generating and comparing FL derived stromal cell lines with 
varying abilities to support HSC expansion, they identified multiple differentially expressed 
genes that play an important role in the in vivo FL HSC niche. It is, however, conceivable that 
the FL microenvironment itself is also modified during fetal development in order to meet 
the changing needs of lineage differentiation and HSC expansion in the embryo.12 Our data 
suggest that earlier embryonic, Mof-deficient HSCs (<E15.5) are capable of proliferation and 
differentiation. However, over the next few days of gestation, intrinsic cellular requirements 
and microenvironmental stimuli change and it may be that Mof-null, H4K16ac-deficient HSCs 
are incapable of adapting to these changes due to significant abnormalities in chromatin 
structure.
Another interesting question that remains to be addressed is why E14.5 fetal 
hematopoietic cells can exist despite the dramatic, MOF-loss-induced H4K16ac deficiency. 
Most studies on Mof depletion report adverse outcomes in a wide array of cell types 
and H4K16ac has been shown to play a critical role in regulating transcription in mouse 
embryonic stem cells.14 However, a recent study found that Mof deficiency and concurrent 
H4K16ac loss in quiescent glomerular podocytes had no effect on kidney function in mice.15 
These findings suggest that H4K16ac requirement may indeed be cell type or tissue specific, 
though it remains surprising that highly proliferative and immature fetal HSCs can function 
despite lack of H4K16ac. It may be that, in the earlier fetal HSC, other chromatin marks such 
as H3K27ac compensate for this lack of H4K16ac and thereby can maintain accessible 
chromatin. Future studies using quantitative mass spectrometry to define global epigenomic 
changes16 could yield significant mechanistic insight into the role of altered epigenomic 
states throughout hematopoietic development.
ARE MOF AND MLL1 GOOD SMALL MOLECULE INHIBITOR 
TARGETS IN ACUTE LEUKEMIA?
In Chapter 4 we have shown that MOF HAT activity is required for MA9 leukemogenesis and 
that loss inhibits leukemic cell maintenance. These findings suggest that inhibiting MOF HAT 
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activity with a small molecule might offer an effective approach in treating patients with MLL-
rearranged leukemia. As a matter of fact, there already is a compound available (MG149) 
that effectively targets MOF HAT activity, implying that developing a more potent MOF HAT 
inhibitor would be technically feasible. However, our data and previous fi ndings suggest 
that MOF loss rapidly kills cells, including normal adult hematopoietic cells, and, though 
we have identifi ed E14.5 fetal HSCs not to be affected by MOF loss (Chapter 5), in general 
the effect of MOF HAT loss may not be suffi ciently selective. On the other hand, this does 
not automatically mean that there is no therapeutic window in which a MOF HAT inhibitor 
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Figure 3. Histone acetyltransferase activity of MOF is required for adult, but not E14.5 fetal 
hematopoiesis
MOF and MLL1 physically interact. MLL1 H3K4 methyltransferase activity is not required for normal 
murine hematopoiesis. However, loss of MOF histone acetyltransferase (HAT) activity in murine, adult 
hematopoietic cells leads to global loss of H4K16ac and rapid hematopoietic cell death. The same 
global loss of H4K16ac is observed in fetal hematopoietic Mof-null cells, but despite this dramatic 
change, early and mid- gestational hematopoiesis does not appear to be affected.
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would kill leukemic cells very effectively without too much toxicity for normal cells. Evidence 
suggests that cancer cells are more sensitive to inhibition of enzymatic activity of certain 
proteins than normal tissue, in those instances indeed allowing for a therapeutic window. 
Examples of epigenetic modifiers that would fall in this category are DOT1L, BRD4 and 
LSD1. DOT1L loss has been shown to severely impair normal hematopoiesis17, sustained 
BRD4 inhibition demonstrates dramatic toxicity in most tissues18 and LSD1 inhibition leads 
to severe hematopoietic toxicity19. However, small molecule inhibitors targeting enzymatic 
activity for all three of these proteins are currently in clinical trials.20 We therefore believe it 
is worth further exploring MOF HAT activity as a candidate drug target in MLL-rearranged 
acute leukemia and we feel that developing potent small molecules targeting MOF activity 
is warranted. 
In this thesis we have demonstrated that the MLL1 core complex physically interacts with 
oncogenic NUP98 fusion proteins and that MLL1 is required for the leukemogenic potential of 
NUP98 translocations (Chapter 3). Unlike Mof KO, Mll1 deficiency does not cause rapid cell 
death, but leads to differentiation of leukemic blasts, suggesting that, much like in Dot1l KO 
models17, the leukemic cell resumes a more normal hematopoietic maturation program and 
eventually dies. However, it is as of yet unclear what part of MLL1 to target. The MLL1 SET 
domain has histone methyltransferase activity, methylating H3K4. We considered that it may 
be this histone methyltransferase activity that is required for NUP98 fusion leukemogenesis. 
Yet, our unpublished data suggest that MLL1 loss in NHA9 leukemic cells does not change 
global H3K4me3. In addition, we found that MLL1 SET-domain deleted hematopoietic stem- 
and progenitor cells are still capable of leukemic transformation upon introduction of the 
NHA9 fusion (unpublished data), much like what was previously found for MA9 21. These data 
point toward the dispensability of MLL1 histone methyltransferase activity in NUP98 fusion 
leukemogenesis. We have, however, shown the colocalization of NUP98 fusion proteins and 
MLL1 at NUP98 fusion target loci by ChIP-seq. This finding indicates that NUP98 fusions may 
utilize their interaction with the MLL1 complex to be recruited to chromatin, specifically at 
NUP98 fusion target loci such as Hox cluster genes and Meis1. In MLL-rearranged leukemia, 
genetic deletion of Menin reverses aberrant Hox gene expression, mediated by MLL1-
menin promoter-associated complexes.22 Following the latter gene expression reversal, the 
differentiation arrest and oncogenic properties of MLL1 fusion transformed leukemic blasts 
are abrogated. Inhibitors blocking the interaction between MLL1 and menin were shown to 
reverse aberrant Hoxa9, Flt3 and Meis1 expression and prolong survival of MA9 leukemic 
mice.23 It might be that, similar to what has been observed in MLL-rearranged leukemia, 
NUP98 fusion proteins require not only MLL1, but also the interaction between MLL1 and 
menin in order to bind target gene loci. This hypothesis requires further investigation, but if 
correct, would offer an interesting therapeutic opportunity for leukemia patients carrying a 
NUP98 translocation.
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BLOEDFUNCTIE EN -PRODUCTIE
Bloed bestaat uit meerdere type cellen die allen essentieel zijn voor ons bestaan. Het grootste 
volume van bloed wordt ingenomen door bloedplasma. In dat plasma bevinden zich rode 
bloedcellen (erytrocyten) die zorgen voor zuurstoftransport, witte bloedcellen (leukocyten) 
die dienen als afweer tegen infecties en bloedplaatjes (trombocyten) die belangrijk zijn voor 
de bloedstolling. Omdat de meeste bloedcellen een beperkte levensduur hebben, vindt er 
continu nieuwe aanmaak plaats. De productie van bloedcellen (hematopoëse) speelt zich 
af in het beenmerg. Aan de basis van dit systeem staan hematopoietische stamcellen. Deze 
stamcellen hebben de unieke eigenschap dat ze bij de celdeling zowel een nieuwe stamcel 
als een dochtercel kunnen produceren. De dochtercel van een stamcel noemt men een 
voorlopercel en deze kunnen via een stapsgewijs en complex proces uitrijpen (differentiëren) 
tot een van de drie verschillende soorten bloedcellen (Figuur 1 van Introductie). “Volwassen” 
of uitgerijpte bloedcellen komen terecht in het perifere bloed en worden dan door het hart 
via de circulatie rondgepompt naar de verschillende organen en weefsels om hun eerder 
genoemde functies uit te oefenen. In het perifere bloed zijn normaal gesproken geen 
hematopoietische stamcellen of voorlopercellen aanwezig. 
ACUTE LEUKEMIE
Acute leukemie is bloedkanker, een ziekte waarbij onrijpe hematopoietische cellen (stamcellen 
of voorlopercellen) ontsporen, met een woekering (ongeremde celdeling, oftewel proliferatie) 
van deze cellen tot gevolg. Deze cellen (leukemische blasten) hebben tevens het vermogen 
tot normale differentiatie verloren. In het geval van acute leukemie ontstaat hierdoor een 
ophoping van leukemische blasten in het beenmerg. Zij verdringen het normale, gezonde 
bloedsysteem waardoor er te weinig nieuwe erytrocyten, leukocyten en trombocyten worden 
aangemaakt. Dit geeft klachten zoals vermoeidheid, een bleke huid, verhoogde kans op 
infecties en een verhoogde bloedingsneiging. Tevens lekken leukemische blasten op enig 
moment uit het beenmerg naar het perifere bloed, waardoor er een sterk verhoogd aantal in 
het perifere bloed en soms ook in andere organen te vinden kan zijn. 
In algemene zin wordt in het hematopoietisch systeem onderscheid gemaakt tussen 
myeloïde cellen (myeloïde leukocyten, erytrocyten, trombocyten en hun voorlopercellen) en 
lymfoïde cellen (lymfoïde leukocyten en hun voorlopercellen). Bij acute myeloïde leukemie 
(AML) is sprake van afwijkingen in myeloïde voorlopercellen en bij acute lymfoïde leukemie 
(ALL) ontstaat de fout in lymfoïde voorlopercellen.
Hematopoietische stam- of voorlopercellen worden leukemische cellen doordat er 
fouten optreden in het DNA. Het DNA in onze cellen bestaat uit een zeer lange streng aan 
code die is opgedeeld in genen. Eén gen kan een gen-specifiek eiwit produceren. Al deze 
diverse eiwitten reguleren de biologische functies binnen het menselijk lichaam. Er zijn 
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grofweg twee soorten genetische fouten die ten grondslag kunnen liggen aan het ontstaan 
van leukemie doordat er geen of verkeerde eiwitten worden geproduceerd:  relatief kleine 
fouten in de DNA-code genaamd mutaties en grotere chromosomale afwijkingen zoals 
translocaties waarbij een deel van het ene chromosoom wordt verwisseld met een deel van 
een ander chromosoom waardoor er een nieuw fusie-gen ontstaat.
Er zijn een groot aantal verschillende translocaties die leukemie kunnen veroorzaken. 
In dit proefschrift hebben we ons gericht op translocaties van het MLL1-gen en van het 
NUP98-gen. Deze translocaties, waarbij een stuk van MLL1 of NUP98 naar een ander 
chromosoom verhuist en daar fuseert met een stuk van een ander gen (bijvoorbeeld AF9 
of HOXA9), produceren een fusie-eiwit. Deze fusie-eiwitten verstoren belangrijke functies 
van de hematopoietische cellen en veranderen een normale hematopoietische cel in een 
leukemische cel. Hoe deze fusie-eiwitten de cellen in hun groei ontregelen en daarmee 
leukemie veroorzaken is echter nog grotendeels onopgehelderd. Door deze ziekte-
mechanismen te doorgronden kunnen er nieuwe medicijnen worden ontwikkeld die zich 
specifiek richten op de kankercel. Op dit moment bestaat de behandeling van patiënten met 
acute leukemie overwegend uit de toepassing van chemotherapie, hetgeen succesvol is bij 
een gedeelte van de patiënten. Een substantieel aantal patiënten reageert uiteindelijk echter 
onvoldoende op chemotherapie of ervaart dusdanige bijwerkingen dat zij vroeger of later 
komen te overlijden. Er is dan ook dringend behoefte aan nieuwe behandelingen voor deze 
patiëntengroep. Door kennis te vergaren over de biologie van leukemie kunnen er specifieke 
medicijnen ontwikkeld worden die de leukemie gerichter aanvallen op hun kwetsbare plek. 
Dergelijke gerichte behandeling (targeted therapy) zou in theorie kunnen zorgen voor een 
groter effect en minder bijwerkingen.
EPIGENETICA; MEER DAN DNA
De code van al het DNA in onze cellen is exact hetzelfde. Zelfs tussen mens en muis is 
92% van de DNA-code gelijk. Er moeten dus mechanismen bestaan die er voor zorgen 
dat huidcellen, spiercellen, bloedcellen, etc. allemaal andere functies uitoefenen. Deze 
mechanismen scharen we onder het kopje “epigenetica”. “Epi” komt van het Griekse woord 
“έπι” wat “bovenop” betekent; dat wat zich bovenop de genetica afspeelt. Omdat er veel 
DNA is en dat allemaal in een zeer kleine celkern wordt opgeborgen moet het DNA slim 
worden opgerold. Zoals al eerder genoemd zit DNA opgerold in chromosomen. Deze 
chromosomen bestaan uit DNA wat rondom een eiwitcomplex gerold zit en daarmee een 
soort kralenkoord vormt. Dit “kralenkoord” kan strak of wat losser opgevouwen zijn en alleen 
als het losser gevouwen is kunnen de genen worden afgelezen en daarmee eiwitten worden 
geproduceerd. Zodoende worden er dus grote stukken DNA nooit of minder vaak afgelezen 
terwijl ander delen continu open en daarmee “aan” zijn. Dit proces wordt gereguleerd door 
chemische verbindingen die zich koppelen aan DNA of de eiwitten waarom het DNA zich 
Thesis_DG.Valerio_v3_homecomputer.indb   202 10/17/16   12:08 AM
203Nederlandse Samenvatting
CH
AP
TE
R 
7
wikkelt (Figuur 3 van Introductie). Sommige van deze verbindingen zorgen voor gesloten en 
andere juist voor geopend DNA. De eiwitten die deze processen regelen en de chemische 
verbinding plaatsen of juist verwijderen noemen we epigenetische regulator-eiwitten.
EPIGENETISCHE DISREGULATIE IN LEUKEMIE
Epigenetische regulatie is van groot belang voor ons bestaan. Als hier fouten optreden kan 
dat drastische gevolgen hebben voor het functioneren van een cel. De afgelopen jaren is 
duidelijk geworden dat epigenetische disregulatie een belangrijke rol speelt bij het ontstaan 
van kanker. Veel onderzoekers hebben zich gericht op het bestuderen van epigenetische 
disregulatie in kankercellen, in de hoop daarmee nieuwe therapeutische aangrijpingspunten 
te vinden. Dat werk vordert gestaag en er zijn inmiddels diverse medicijnen op de markt 
of in ontwikkeling (Hoofdstuk 2). Er kan echter resistentie optreden tegen deze nieuwe 
medicijnen waardoor het medicijn zijn werkzaamheid verliest; uit kankercellen die resistent 
worden en daarmee ontsnappen aan de werking van het geneesmiddel kunnen zich weer 
nieuwe kankercellen ontwikkelen. De gedachte is daarom dat je meer ziekte-mechanismen 
tegelijk moet aanpakken om de verschillende ontsnappingsroutes te blokkeren en zodoende 
alle kankercellen uit te roeien. Het doel van ons onderzoek was om een deel van het 
epigenetische regulator-mechanisme bij acute leukemie op te helderen en daarmee een 
basis te leggen voor de ontwikkeling van een dergelijk nieuw medicijn. 
In dit proefschrift hebben we onderzoek gedaan naar twee eiwitten die beide 
epigenetische regulator-eiwitten zijn: MOF en MLL1. In eerste instantie vonden we dat deze 
eiwitten beide binden aan het NUP98-fusie-eiwit (Hoofdstuk 3). In muismodellen bleek dat 
acute leukemie die aangedreven wordt door deze NUP98-translocaties niet kan bestaan 
zonder MLL1; de leukemische blasten die geblokkeerd zijn in hun uitrijping gaan weer 
differentiëren doordat de door NUP98-fusie-eiwit gedreven genexpressie programma’s 
worden uitgezet. Binnen circa twee weken zijn alle leukemische blasten dood. Van MLL1 
was reeds bekend dat het een rol speelt bij leukemie die wordt aangedreven door MLL-
AF9 translocaties. Wij vroegen ons vervolgens af of ook MOF belangrijk is voor het ontstaan 
en het in stand houden van MLL-AF9 leukemie (Hoofdstuk 4). Wederom met behulp van 
muismodellen bleek dat MOF een cruciaal eiwit is voor MLL-AF9 leukemie en dat muizen 
geen leukemie ontwikkelen als de pre-leukemische cellen MOF verliezen. Eiwitten hebben 
meestal meerdere functies, maar uit ons onderzoek blijkt dat specifiek de epigenetische 
regulator functie van MOF essentieel is voor MLL-AF9 leukemie. 
Bij het onderzoek naar de rol van bepaalde eiwitten in het ontstaan van ziekten is het ook 
belangrijk om te weten wat de rol van deze eiwitten is in het normale weefsel. Het was reeds 
bekend dat de normale hematopoëse in muizen onmogelijk is zonder MLL1. Muis-embryo’s 
sterven vroeg in de zwangerschap doordat de vorming van hematopoietische stamcellen 
en voorlopercellen ontbreekt. De rol van MOF bij de normale hematopoëse was echter nog 
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onbekend. Wij hebben dit onderzocht door gebruik te maken van genetisch gemodificeerde 
muismodellen waarbij MOF al gedurende de embryonale ontwikkeling afwezig is in alle 
hematopoietische cellen (Hoofdstuk 5). Het blijkt dat MOF expressie essentieel is voor de 
aanmaak en overleving van volwassen hematopoietische cellen. Bovendien blijkt wederom 
de epigenetische regulator functie van MOF onmisbaar te zijn. Uit ons onderzoek blijkt echter 
ook dat muizen-embryo’s zonder MOF expressie een normaal functionerend hematopoietisch 
systeem hebben, ondanks de afwezigheid van de epigenetische regulator activiteit van MOF. 
MOF is daarmee momenteel een van de weinige epigenetische regulator-eiwitten waarvan 
bekend is dat de expressie en activiteit essentieel zijn voor de volwassen hematopoëse, 
maar overbodig voor vroege foetale hematopoëse. Deze bevindingen benadrukken het 
belang van epigenetische regulatie bij de ontwikkeling van het hematopoietisch systeem in 
zoogdieren.
De resultaten in dit proefschrift bieden een aanzet tot het doorontwikkelen van 
reeds bestaande moleculen die de epigenetische activiteit van MLL1 en MOF remmen. 
De ontwikkeling van op deze inzichten gebaseerde medicijnen biedt perspectief voor het 
doelgericht behandelen van patiënten met acute leukemie. 
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LIST OF ABBREVIATIONS
4-OHT  4-Hydroxytamoxifen
AGM  Aorta-Gonad-Mesonephros
ALL  Acute Lymphoid Leukemia
AML  Acute Myeloid Leukemia
AR  Androgen Receptor 
ATAC-seq Assay for Transposase-Accessible Chromatin with high-throughput          
  sequencing
B6.SJL  C57 black 6 mice, but hematopoietic cells express CD45.1 rather than   
    CD45.2
BET  Bromodomain and Extra Terminal 
BM  Bone Marrow
C-terminal COOH-terminal
C57Bl/6  C57 black 6 mice with hematopoietic cells expressing CD45.2
CBC  Complete Blood Count
CFU  Colony-forming Unit
ChIP  Chromatin Immunoprecipitation 
ChIP-seq Chromatin Immunoprecipitation with high throughput sequencing
CML  Chronic Myeloid Leukemia
Co-IP  Co-Immunopreciptation
CoA  Canonical acetyl coenzyme A
CoAdel  CoA binding site deletion
Cryo-EM  Cryogenic-electron microscopy
E14.5  Embryonic age 14.5
ETOH  Ethanol
FBS  Fetal Bovine Serum
FDR  False Discovery Rate
FG  Phenylalanine, Leucine
FL  Fetal Liver
G327E  Point mutation: replacement of glycine by glutamic acid on position 327
gDNA  Genomic DNA
GLEBS  Gle2-Binding Sequence
GLFG  Glycine, Leucine, Phenylalanine, Glycine
GSEA  Gene Set Enrichment Analysis
GSI  Gamma-Secretase Inhibitors
H3K27  Histone 3, Lysine 27
H3K36  Histone 3, Lysine 36
H3K4  Histone 3, Lysine 4
H3K79  Histone 3, Lysine 79
H3K9  Histone 3, Lysine 9
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H4K16  Histone 4, Lysine 16
HA  Human influenza hemagglutinin
HAT  Histone acetyltransferase
Hb  Hemoglobin
HDAC  Histone deacetylase 
HMT  Histone methyltransferase
HSC  Hematopoietic Stem Cell
IC50  Half maximal inhibitory concentration 
KAT  (K) Lysine acetyltransferase
KO  Knockout
Lin  Lineage (in hematopoiesis, refers to differentiated cells of all lineages)
lncRNAs  Long non-coding RNAs  
LSK  Lineage-negative (Lin-), SCA1+, cKIT+
LT-HSC  Long-term Hematopoietic Stem Cell
MA9  MLL-AF9
MDS  Myelodysplastic Syndrome
MEF  Murine Embryonic Fibroblast
MLL1  Mixed-Lineage Leukemia 1, also known as KMT2A
Mll1-/-NHA9 NHA9 transformed ERT2-cre;Mll1f/f
Mll1+/-NHA9 NHA9 transformed ERT2-cre;Mll1f/+
Mll1+/+NHA9 NHA9 transformed Mll1f/f 
MM  Multiple Myeloma
MOF  Ortholog of Drosophila Males absent on the First, also known as KAT8
MP  Myeloid Progenitor
MPNST  Malignant Peripheral Nerve Sheath Tumor
MYST  Moz-Ybf2/Sas3-Sas2-Tip60
N-terminal NH3-terminal
NES  Normalized Enrichment Score
NHA9  NUP98-HOXA9
NHD13  NUP98-HOXD13
NLS  Nuclear Localization Signal 
NMC  NUT Midline Carcinoma
NPC  Nuclear Pore Complexes
NSC  Non-Specific Lethal Complex
P9  Postnatal day 9
PB   Peripheral blood
PHD-finger Plant Homeodomain finger
pIpC  poly(I:C)
PTM  Post-Translational Modification 
qRT-PCR Quantitative Real-Time PCR
RBD  RNA Binding Domain 
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RNAi  RNA interference
RNAPII  RNA Polymerase II 
RNA-seq RNA high-throughput sequencing
RTK  Receptor Tyrosine Kinase
SCLC  Small Cell Lung Cancer
SD  Stand Deviation
SET  Su(var)3-9, Enhancer of zeste, Trithorax
shRNA  short hairpin RNA
T-ALL  T-cell Acute Lymphoid Leukemia
Trx  Trithorax 
WBC  White Blood Cell
WT  Wild Type
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